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Abstract 
Extracorporeal membrane oxygenation (ECMO) is the final option for patients with acute 
severe cardiac and/or respiratory failure that is unresponsive to conventional 
management. ECMO plays a supportive role and its success relies on optimal drug 
therapy to reverse the underlying disease process and to prevent or treat complications. 
Vital drugs may be sequestered and/or degraded in the ECMO circuit resulting in altered 
pharmacokinetics (PK). This may be further complicated by the PK changes that occur in 
the presence of critical illness and may lead to therapeutic failure and/or drug toxicity.  
However, much of the currently available PK data is from neonates receiving ECMO and 
may not be extrapolated to adult patients given the developmental and physiologic 
differences. Equally, such PK alterations are complex and are challenging to investigate in 
a critically ill patient on ECMO. The aim of this research was to investigate each of the 
circuit, drug and critical illness factors affecting PK during ECMO in adult patients. A 
combination of linear and non-linear mixed effects modelling, compartmental and 
population methods and dosing simulations was utilised to characterise antibiotic, sedative 
and analgesic PK. The incremental research plan comprised of; 
(i) ex vivo experiments for drug stability testing in human blood;  
(ii) ex vivo drug disposition studies in ECMO circuits primed with fresh whole 
human blood;  
(iii) PK studies in healthy and critically ill ovine models of ECMO with appropriate 
non-ECMO controls and;  
(iv) an international multi-centre clinical population PK study in critically ill adults on 
ECMO.  
The introductory chapter (Chapter 1) outlines the origins of this research based on clinical 
observations, hypothesis generating preliminary data (Chapter 1.1), summarises the 
available extracorporeal life support therapies (Chapter 1.2) and provides a clinical context 
to PK alterations induced by ECMO (Chapter 1.3). This is followed by a literature review on 
PK alterations during ECMO (Chapter 2). Thus, an understanding of the clinical problem, 
available extracorporeal therapies, and identifying the gaps in literature (Chapter 3) 
facilitated the development of a comprehensive research plan (Chapter 4.1). Chapter 4.2 
describes the methodology for the development of ex vivo and ovine models of ECMO. The 
protocol for the international multi-centre population PK study that aims to develop dosing 
guidelines for 18 key antibiotic, sedative and analgesic drugs is presented in Chapter 4.3.  
Ex vivo studies identified drug stability, lipophilicity (Chapter 5.1) and protein binding 
(Chapter 5.2) as the key drug factors determining their sequestration and /or degradation in 
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ECMO circuits. An increase in peripheral volume of distribution (Vd) of the highly protein-
bound, lipophilic drug midazolam was identified in both healthy and critically ill sheep on 
ECMO (Chapter 6.1) providing further in vivo evidence of circuit drug sequestration. PK of 
eight antibiotic drugs that exhibited a wide range of lipophilicity and protein binding was 
characterised in healthy sheep controls and healthy and critically ill sheep on ECMO 
(Chapter 6.2). This experiment identified that ECMO may variably influence Vd and 
decrease clearance (CL) in the presence of critical illness, based on lipophilicity and protein 
binding characteristics and these properties may be used to predict their PK during ECMO.  
Population PK modelling of meropenem in critically ill patients on ECMO (with or without 
renal replacement therapy) was performed and compared with data from non ECMO 
controls in a matched-cohort study (Chapter 7). This study provided preliminary evidence 
that in the absence of significant circuit sequestration for hydrophilic and less protein-bound  
drugs such as meropenem, an increased Vd (critical illness and ECMO factors) may be to 
an extent countered by a decreased CL (from ECMO and kidney injury) minimising the net 
influence ECMO has on PK. The closing chapter (Chapter 8) discusses key findings of this 
research and lays a roadmap for future work.  
The overarching finding of this research is that drug factors lipophilicity and protein binding 
play a significant role in altering PK during ECMO and drug factors may be used to predict 
PK of antibiotic and sedative drugs. The combined effect of critical illness and ECMO may 
be limited for hydrophilic and less protein-bound drugs compared with lipophilic and more 
protein-bound drugs. The ongoing clinical population PK study will provide robust dosing 
guidelines for prescription of commonly used antibiotics, sedative and analgesic drugs 
during ECMO. 
Future research should focus on optimising the interactions between drug, device and the 
disease. While it may be challenging to alter drug physicochemistry, whilst maintaining 
safety and efficacy, further refinements to ECMO circuitry may be considered. Equally, the 
impact of ECMO on pathophysiology, especially on hepatic and renal organ systems which 
are responsible for metabolism and excretion of most drugs need to be better understood. 
Building pharmacodynamic (PD) models based on animal and clinical studies will add 
another dimension of PK/PD during ECMO as the PD alterations induced by ECMO, if at 
all, are yet to be investigated.  
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CHAPTER 1  
INTRODUCTION 
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1.1 ORIGINS OF THIS RESEARCH 
 
The Adult Intensive Care Unit at TPCH in Brisbane, Queensland, Australia officially 
commenced its extracorporeal membrane oxygenation (ECMO) service in 2009 at the 
height of the H1N1 pandemic. The service was modelled on The Alfred, a high volume, 
experienced ECMO centre in Melbourne, Australia. Under the strong leadership of Dr Dan 
Mullany, TPCH has now evolved to become an ECMO centre with world class outcomes. 
In the early days of ECMO at TPCH, clinicians and nurses at the bedside made some 
observations in ECMO patients that were not typical of a critically ill patient not supported 
with ECMO. One such observation that triggered this research was the unusually high 
sedation requirement in ECMO patients. “It doesn’t seem to touch them “, remarked a 
senior clinician after his desperate attempts to sedate his ECMO patient with high doses of 
multiple sedative agents. Another nurse tired of giving sedative boluses to keep her patient 
safe in bed noted “looks like all the drugs we give are sucked up by this hungry machine”. 
Puzzled by the unusual sedative requirements, another clinician wondered “what was 
happening to all the antibiotics we are giving these ECMO patients, at least with sedation 
we know when it’s not working”. Based on such clinical observations, Professor Fraser 
suggested that “drugs and ECMO” would be very relevant topic for my PhD studies and 
thus the “ECMO Pharmacokinetic (PK) Project” was born. 
In 2010, under the leadership of Professor Fraser and Associate Professor Lin Fung, the 
Critical Care Research Group at the Prince Charles Hospital secured a 3 year National 
Health and Medical Research Council Project Grant to examine inflammation and 
coagulation effects of ECMO in ovine models. A team of experienced clinicians, scientists, 
perfusionists, cardiologists, cardiac surgeons and research assistants was assembled for 
the ovine ECMO study. Although not originally intended, the ovine experiments provided a 
perfect opportunity to mechanistically investigate PK of drugs during ECMO.  
Encouraged by the NHMRC grant success, an ECMO Special Interest Group Meeting 
which was attended by clinicians and researchers across Australasia was held at TPCH in 
December 2010.  This meeting facilitated collaboration with Professor Jason Roberts, a 
well-known PK expert, clinicians and pharmacists from other ECMO centres to form the 
multi-centre clinical PK study collaborative that helped the translation side of this research.  
The PK work was well supported by the two state of the art analytical laboratories at the 
University of Queensland in Brisbane. The Burns Trauma and Critical Care Research 
Centre developed and performed PK assays for antibiotic study drugs and the Centre for 
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Integrated preclinical Drug Development assisted with sedative and analgesic drug 
assays.   
This research represents an attempt to further the field of ECMO, a life saving technique. 
Since the 2009 H1N1 pandemic, there has been a significant surge in the use of ECMO 
globally. This has occurred despite the lack of definitive evidence for the use of ECMO. 
Undoubtedly, ECMO is an invasive therapy with risks. Encouraged by excellent results 
reported especially in centres with higher case volumes (even when used as a salvage 
therapy) many clinicians believe that significant refinements in ECMO technology, its 
clinical application and service delivery are possible and may shift the risk: benefit ratio in 
favour of ECMO. Thus the H1N1 pandemic was the perfect trigger not only for increased 
ECMO up take in the clinical arena, but also for research aimed at improving all aspects of 
ECMO. To witness many young patients survive a potentially ‘unsurvivable” illness with 
“salvage ECMO” provided necessary motivation and impetus for this translational 
research.  
The remaining sections in this chapter provide a context for this research and also present 
some preliminary hypothesis generating work that was performed prior to embarking on a 
comprehensive research plan which was both labour and resource intensive. This pilot 
work was approved by the Institutional Human Ethics and Research Committee and 
informed consent was obtained from patients and/or surrogate decision makers as 
applicable.  
 
1.1.1. ECMO: a life saving therapy 
ECMO is a final treatment option for patients who are at a high risk of death from acute 
cardiorespiratory failure that is unresponsive to maximal conventional therapy1,2. 
Conventional modern intensive care management, although extra-ordinary, is usually 
limited to mechanical ventilation with adjuncts3, high dose pharmacological cardiovascular 
support, renal dialysis and other supportive measures. This is partly due to lack of viable, 
less invasive mechanical options to acutely support cardiopulmonary function4. With 
refinements in technology, ECMO has emerged to fill this void. ECMO is among the most 
rapidly increasing life support techniques used in intensive care. Its use in the United 
States has increased more than 433% in a space of only 5 years5. ECMO is highly 
versatile and not only provides temporary cardiorespiratory support in the acute setting, 
but it also effectively complements cardiac surgical and interventional cardiology 
procedures, timely implantation of long-term cardiac assist devices, heart and lung 
transplantation programmes and cardiopulmonary resuscitation4,6.  
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1.1.2 ECMO circuits are not passive conduits for blood 
ECMO is considered a supportive therapy whilst drug therapy is used to treat the 
underlying disease and minimise complications 8. In a manner analogous to the lung it 
attempts to mimic, ECMO is critically dependent upon the large surface area of the 
oxygenator and associated tubing to ensure adequate blood flows through the circuit to 
facilitate gas transfer. This bio-synthetic interface results in significant sequestration of the 
administered drugs making it difficult to provide optimal drug therapy to reverse the 
underlying disease7. For many important drugs, available data from neonates illustrates an 
interaction between the drug and the artificial surfaces of the ECMO device8-15. This 
results in significantly altered drug concentrations in the most severely ill patients who 
already have profound PK changes. Given the morbidity and mortality associated with 
suboptimal antibiotic and sedative therapy in ICU patients, altered PK of these drugs 8-12 is 
of high clinical relevance. Published data from neonates demonstrate that ECMO 
dramatically affects PK in the most severely ill patients who already have significant PK 
changes9,11,16,17. However, there is a significant paucity of PK data in adult patients on 
ECMO.  
In critically ill patients not receiving ECMO, it has been shown PK changes can result in 
highly significant changes to drug exposure through interactions between the patient, 
pathology and the drug18-21. The ECMO system introduces additional variables - the circuit 
itself, and the effects of systemic inflammation due to the prolonged use of an 
extracorporeal circuit. Sequestration of drugs in the circuit, increased Vd and CL are the 
major PK changes associated with ECMO17, although the extent of these changes remains 
poorly characterised. Previous studies in the neonatal circuit highlight the influence that 
drug properties such as molecular size, degree of ionization at physiological pH, 
lipophilicity and plasma protein binding have on drug disposition during ECMO22,23.  
Drug sequestration may be further influenced by the age of circuit components, type of the 
pump, oxygenator and tubing as well as the variety of fluids that can be used for circuit 
priming24-27. Patient factors such as systemic inflammation, haemodilution, bleeding and 
transfusion, organ dysfunction and renal replacement therapy all add to the clinical 
challenges of drug dosing during ECMO17.  
 
1.1.3 Defining the burden of altered PK during ECMO 
Given that most neonatal PK data originates from older generation of ECMO circuits and 
the paucity of PK data from adult patients on ECMO, preliminary data was obtained from 
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retrospective data base analysis and prospective PK sampling in adult patients receiving 
ECMO to further inform hypothesis development.  
 
1.1.3.1 Risks of suboptimal antimicrobial therapy:  
Plasma meropenem concentrations were measured in patients receiving the drug in 
standard doses (1g/8h) based on standard regimes. Standard dosing resulted in 
suboptimal plasma meropenem concentrations raising concerns of therapeutic failure in 
these complex patients (Figure 1).  Administering higher doses of antibiotics to account for 
the PK alterations is not viable solution during ECMO as this may lead to potential toxicity 
from some drugs and their active metabolites28 (e.g. oseltamivir and oseltamivir 
carboxylate).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Plasma meropenem concentrations over time with conventional 
meropenem dosing (1g/8h). In this patient who developed enterobacter sepsis on 
venovenous ECMO, whilst a minimum target of 40% time that the meropenem 
concentration was maintained above the MIC (40% T>MIC) was achieved with standard 
dosing the more aggressive target of 4 x MIC used locally, 8 µg/mL, was only achieved for 
30% of the dosing interval8. 
 
1.1.3.2 Escalating sedation requirements during ECMO: 
A retrospective review of sedation requirements in 30 consecutive ECMO patients11 was 
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performed to evaluate sedation practices on ECMO. Sedation in these patients was titrated 
by a senior bedside nurse.  The average 24-hourly dose increased by 18mg per day for 
midazolam (95% CI: 8, 29mg, p=0.001) and 29mg per day for morphine (95% CI: 4, 53 mg, 
p=0.021) from the first day of ECMO. The venovenous group required a daily midazolam 
dose that was 157 mg higher on average than the venoarterial group (95% CI: 53, 261 mg, 
p=0.005). Patients often received up to 1500mg of morphine and midazolam per day 
despite supplemental sedation with propofol, dexmedetomidine and thiopentone. 
Extubation or tracheotomy was not possible in all patients and this heightened sedation 
requirement raised concerns of increased morbidity due to excessive sedation in the ICU29. 
 
1.1.3.3 Is escalating sedation requirement associated with a decrement in sedative drug 
concentration? 
To further investigate this clinical problem, opportunistic PK sampling was performed in a 
patient prior to and after commencement of ECMO. Sedation prior to after commencement 
of ECMO was titrated to a Richmond Agitation Sedation Scale of -3 to -4 and a bispectral 
index (BIS) of 40-45. The patient also received neuromuscular paralysis with vecuronium 
(0-5mg/h, titrated to 1-2 twitches on train-of-four monitoring) to optimise ECMO flows and 
ventilation. Pre- ECMO sedation comprised of propofol (100mg/h), morphine and 
midazolam (20mg/h of each). In the first 3 hours after commencement of ECMO, the 
propofol infusion regimen was increased to 200mg/h (p=0.4) and the morphine and 
midazolam infusion regimens were each increased to 50mg/h (p< 0.001) to achieve pre-
ECMO sedation levels (Fig 2a). In addition, propofol was also administered as repeated 
boluses (30-50mg, up to total of 300mg in the first hour).  
The escalation in morphine and midazolam doses correlated with a decrement in plasma 
concentrations of these drugs and their active metabolites. There was a significant 
reduction in the plasma morphine (20%), midazolam (11%), 1-hydroxy midazolam (17%), 
morphine-3-glucuronide (36%) and morphine-6-glucuronide (35%) concentrations upon 
commencement of ECMO as compared to pre-ECMO levels, which then increased 
consistent with the marked increase in administered drug doses (Fig 2b, 2c). The increased 
requirement for sedation persisted for the entire duration of ECMO (19 days). Tracheotomy 
performed on day 7 did not lead to a significant reduction in sedative doses. 
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Figure 2. Increased sedation during ECMO. Escalating sedative drug doses (a) upon 
commencement of ECMO correlated with a decrement in plasma concentrations (b, c) of these 
drugs and their active metabolites9. 
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1.1.4 Morbidity from altered PK during ECMO 
There is increasing awareness of the implications of altered PK and its impact during 
critical illness30-32. The success of ECMO, especially in critically ill patients with severe 
pneumonia or a pandemic viral respiratory illness relies heavily on the success of antibiotic 
therapy. Optimal antibiotic therapy in these patients is a balance between potency and 
exposure21,33-36. A recent review of Extracorporeal Life Support Organization (ELSO) data37 
revealed a total of 2,418 infections during 20,741 (12%) ECMO cases. Infections increased 
the duration of ECMO, post-ECMO ventilator support and were associated with an 
increased risk of death. Neonatal studies have reported severe PK variations, however 
limited data is available to guide antibiotic therapy in adults22,25,38-42. Sub-optimal 
prescription of antibiotics in patients on ECMO can worsen the problem by selecting for 
resistant microorganisms34.  
By default, clinicians prescribe standard doses to these complicated patients, thereby 
risking therapeutic failure or toxicity. Neonatal studies also consistently demonstrate the 
need to escalate sedative doses during ECMO22,43-45. By acting as a reservoir, ECMO may 
also prolong the pharmacological effect of sedatives even after drugs have been ceased. 
Sedation practices in the ICU are changing and emerging data supports its judicious 
use46,47. This is concerning as it is now well established that excessive sedation in critically 
ill patients is associated with increased mortality and morbidity29. However, unlike sedation, 
there are no real-time PD end-points for antibiotic therapy and therapeutic drug monitoring 
48
 is available for only a handful of antibiotics. 
 
1.1.5 Why study PK during ECMO in adult patients? 
There are no other reliable techniques currently available to provide flexible and tailored 
extracorporeal support to adult patients with acute cardiorespiratory failure that is 
unresponsive to maximal conventional treatment49,50. ECMO certainly has shown promise 
and future research is vital not just in area of PK but many other areas of ECMO therapy to 
improve patient outcomes. 
i) Generate new knowledge of the interaction between ECMO and drugs:  
Population PK modelling is crucial to ensure drug safety and efficacy. The success of 
ECMO is dependent on optimal disease modifying drug delivery. This research will not only 
identify the drugs that are more suitable for use during ECMO but the findings may also 
inform the development of strategies for drug dosing using PK/ PD principles in critically ill 
9 
 
patients receiving ECMO. Such PK modelling may likely be able to translate the 
physicochemical / PK correlations from adults to children. 
ii) Developing adequate antimicrobial drug dosing regimens:  
Optimal antimicrobial prescription has significant implications not only for the patients on 
ECMO but also for other ICU patients and the community in general. Optimal dosing of an 
antimicrobial agent will not only lead to improved microbiological and clinical cure rates in 
an individual patient, but also will reduce the emergence of resistant organisms. 
iii) Improving sedation practices during ECMO:  
Using sedative agents at an appropriate dose may minimise ICU morbidity47 related to risk 
of infections, duration of mechanical ventilation, inotrope and vasopressor requirements, 
drug withdrawal and post traumatic stress and length of hospital stay. This not only has 
resource implications but significantly affects patient outcomes. This research also 
evaluates existing ICU sedation protocols as compared with BIS monitoring. 
iv) Recognising potential and refining ECMO: 
It is foreseeable that with further refinements in technology, ECMO will not only establish 
itself as a viable option for management of severe acute cardiorespiratory failure but also 
its role is likely to expand further to benefit a wide range of critically unwell patients 2,5. 
Technological improvements need to be complimented by research directed at its judicious 
clinical application and this research is one critical step in this direction. 
As highlighted in the literature review in subsequent chapters, drugs are variably affected 
by the presence of ECMO and meaningful recommendations for antibiotic, sedative and 
analgesic drug dosing can only be developed after systematic investigation of this complex 
problem. Thus, the above preliminary data underpins the importance of a comprehensive 
research plan that addresses the key determinants of altered PK during ECMO and 
development of dosing guidelines for key drugs used during ECMO. 
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1.2 EXTRACORPOREAL LIFE SUPPORT DEVICES AND STRATEGIES FOR 
MANAGEMENT OF ACUTE CARDIORESPIRATORY FAILURE IN ADULT PATIENTS: 
A COMPREHENSIVE REVIEW 
 
1.2.1. Introduction to publication 
This chapter provides an overview of available extracorporeal life support therapies and 
strategies for management of acute cardiorespiratory failure in adult patients. 
Extracorporeal membrane oxygenation (ECMO) is one of the most common applications of 
extracorporeal life support and is used to support heart and/or lungs in patients who fail 
conventional treatment. Equally, the ECMO circuit may be used in many different 
configurations (e.g. use without the artificial oxygenator and with a pump just to provide 
circulatory support).This chapter emphasises that the success of extracorporeal therapies 
relies not only on the individually tailored application of the devices but also on the 
optimisation of pharmacotherapy directed at underlying disease and at minimising 
complications. Deeper understanding of extracorporeal life support therapy being applied 
is critical to choose an optimal phamacotherapeutic strategy in these complex patients. 
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Evolution of extracorporeal life support (ECLS) technology has added a new dimension to the intensive care
management of acute cardiac and/or respiratory failure in adult patients who fail conventional treatment. ECLS also
complements cardiac surgical and cardiology procedures, implantation of long-term mechanical cardiac assist
devices, heart and lung transplantation and cardiopulmonary resuscitation. Available ECLS therapies provide a range
of options to the multidisciplinary teams who are involved in the time-critical care of these complex patients. While
venovenous extracorporeal membrane oxygenation (ECMO) can provide complete respiratory support,
extracorporeal carbon dioxide removal facilitates protective lung ventilation and provides only partial respiratory
support. Mechanical circulatory support with venoarterial (VA) ECMO employed in a traditional central/peripheral
fashion or in a temporary ventricular assist device configuration may stabilise patients with decompensated cardiac
failure who have evidence of end-organ dysfunction, allowing time for recovery, decision-making, and bridging to
implantation of a long-term mechanical circulatory support device and occasionally heart transplantation. In highly
selected patients with combined severe cardiac and respiratory failure, advanced ECLS can be provided with central
VA ECMO, peripheral VA ECMO with timely transition to venovenous ECMO or VA-venous ECMO upon myocardial
recovery to avoid upper body hypoxia or by addition of an oxygenator to the temporary ventricular assist device
circuit. This article summarises the available ECLS options and provides insights into the principles and practice of
these techniques. One should emphasise that, as is common with many emerging therapies, their optimal use is
currently not backed by quality evidence. This deficiency needs to be addressed to ensure that the full potential of
ECLS can be achieved.Review
Introduction
Extracorporeal life support (ECLS) is a therapeutic op-
tion increasingly used in the management of patients
with cardiorespiratory failure that is refractory to max-
imal conventional treatment [1,2]. This support may fa-
cilitate therapeutic intervention, bridge to recovery,
bridge to a long-term support device, heart or lung
transplantation, or bridge to palliation. Despite the
renewed interest in ECLS technology following the 2009
H1N1 influenza pandemic [3], there is a lack of* Correspondence: kiran_shekar@health.qld.gov.au
1Critical Care Research Group, Adult Intensive Care Services, The Prince
Charles Hospital and The University of Queensland, Rode Road, Chermside,
Brisbane, Queensland 4032, Australia
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12 months following its publication. After this
Attribution License (http://creativecommons.o
reproduction in any medium, provided the or
2014definitive evidence regarding its routine application.
Current ECLS equipment has evolved to allow a pleth-
ora of perfusion strategies enabling tailored temporary
support for patients and the ability to transition between
configurations. A number of factors limit more frequent
utilisation. These factors include challenges in patient
selection, choice of an appropriate strategy, technical as-
pects of initiation and maintenance, and minimising
complications [4].
This review provides a summary of the available ECLS
options and cannulation techniques for short-term sup-
port of adult patients with cardiorespiratory failure that
is refractory to conventional treatment.Ltd. The licensee has exclusive rights to distribute this article, in any medium, for
time, the article is available under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Extracorporeal membrane oxygenation
Details about the technology, principles and practice of
extracorporeal membrane oxygenation (ECMO) can be
found elsewhere [5,6]. Venovenous (VV) ECMO is pre-
dominantly used as a rescue therapy for selected patients
with acute respiratory distress syndrome (ARDS) and re-
fractory hypoxia [1,7,8]. Patients with refractory hypoxia
due to ARDS continue to have a high mortality, in the
order of 70 to 90%. Whether VV ECMO further improves
survival in this group of patients when compared with
lung-protective ventilation (LPV) and adjuncts such as
neuromuscular blockade [9] and prone ventilation [10] is
yet to be established. Recent studies demonstrating harm
or no benefit with the use of high-frequency oscillation in
patients with moderate to severe ARDS exclude this tech-
nique as a routine rescue option for refractory hypoxia and
may further expand the scope of VV ECMO [11,12]. Des-
pite unfavourable results in the early studies, the CESAR
trial showed improved disability-free survival at 6 months
in 90 patients who were randomised to receive ECMO
(37% vs. 53% on LPV, P = 0.03) [13]. However, 22 of these
patients did not receive ECMO and a majority of them im-
proved with LPV. The study was criticised for lack of
standardisation of LPV in the control group. This may not
be seen as definitive evidence supporting the use of VV
ECMO. However, the CESAR trial and the UK data from
patients with H1N1-related ARDS do confirm that referral
to an ECMO centre may lower hospital mortality com-
pared with matched non-ECMO-referred patients [14].
Analysis of 2009 H1N1 pandemic data [3,15-18] dem-
onstrates that while VV ECMO may be in equipoise with
LPV, it may play a vital role in younger patients withTable 1 Available extracorporeal respiratory support devices
ECLS strategy Principle i
VV ECMO standard (femoral vein–femoral vein) Default stra
VV ECMO (dual-lumen cannula) Complete o
Bridge to lu
VV ECMO high flow (SVC and IVC access) Complete re
VV ECMO high flow with two oxygenators in parallel Complete r
Femoral VV with pump
(iLA™Activve; Novalung GmbH, Hechingen, Germany)
Complete o
Pulmonary artery–left atrium pumpless with oxygenator
(iLA™; Novalung GmbH)
Bridge to lu
Salvage for
Salvage for
Femoral arterio-venous pumpless (iLA™; Novalung GmbH) Partial resp
VV ECCOR (Hemolung™; Alung Technologies, Pittsburgh, PA, USA) Partial resp
Complete respiratory support, oxygenation and carbon dioxide removal; partial resp
extracorporeal carbon dioxide removal; ECLS, extracorporeal life support; ECMO, ext
lung assist; SVC, superior vena cava; VV, venovenous.critical oxygenation who have fewer failed organ systems
and fail LPV [8]. Although VV ECMO is relatively easy to
institute technically, the complexities relate more to the
availability of the service, practicalities of transfer to an
ECLS centre, timing and patient selection, care of the pa-
tient on ECMO and minimising complications [4]. Pa-
tients often need to be retrieved whilst supported by
ECMO, and data suggest that this can be undertaken
safely in trained hands with an appropriate system [19].
VV ECMO and the more portable proprietary extracor-
poreal respiratory support devices such as Cardiohelp™
(Maquet Cardiopulmonary AG, Hirrlingen, Germany) can
be utilised for transport [20].
A number of configurations of VV ECMO can be applied
based on individual patient requirements (Table 1).
Although there are many other factors, patient arterial oxy-
genation is critically dependent on the fraction of total car-
diac output passing through the oxygenator while adequate
carbon dioxide (CO2) clearance can still occur with lower
blood flows [21]. The bicaval dual-lumen Avalon™ cannula
(Avalon Laboratory, Los Angeles, CA, USA) inserted
through the internal jugular vein allows single-site cannula-
tion for VV ECMO [22], but flows are unlikely to be as high
compared with the use of two large venous drainage cannu-
lae positioned in the venae cavae via internal jugular and
femoral veins. Additionally, meticulous positioning is re-
quired, usually with transoesophageal echocardiography.
Use of a dual-lumen cannula in the neck may facilitate mo-
bilisation in bed, extubation and rehabilitation in patients
who receive prolonged ECMO support [22].
Extracorporeal carbon dioxide removal
Hypercapnia and respiratory acidosis, although usually
well tolerated, is a barrier to implementing ultra-and strategies
ndication(s)
tegy for complete extracorporeal respiratory support
r partial respiratory support predominantly
ng transplant
spiratory support for larger patients; for example, male weight >90 kg
espiratory support for very large patients; for example, male weight >120 kg
r partial respiratory support
ng transplant
refractory hypoxia during complete respiratory support on VV ECMO
severe pulmonary hypertension with normal left heart
iratory support only in a very haemodynamically stable patient
iratory support
iratory support, carbon dioxide removal and some or no oxygenation. ECCOR,
racorporeal membrane oxygenation; IVC, inferior vena cava, iLA, interventional
Figure 1 Interventional lung assist device (iLA™; NovaLung
GmbH, Talheim, Germany) for pumpless arterio-venous carbon
dioxide removal. Reproduced with permission from [27].
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interest in extracorporeal technologies that facilitate
extracorporeal CO2 removal (ECCOR). Refinements in
technology [21,23] have resulted in fewer complications
when used as adjuncts to LPV [24], but definitive evi-
dence is lacking [25].
ECCOR requires an arterial or venous access cannula,
a pump to drain blood during venous access, a mem-
brane lung and a return venous cannula. Heparin-coated
wire-reinforced cannulae may be placed percutaneously
in a femoral–femoral or a femoral–jugular orientation.
Alternatively, a wire-reinforced double-lumen catheter
may be inserted under ultrasound guidance via the right
internal jugular vein with the drainage port positioned
in the intra-hepatic inferior vena cava and the return
port in the right atrium [21,26]. A flow of fresh gas con-
taining little or no CO2 is utilised to create a diffusion
gradient across the membrane and allows CO2 removal.
While ECMO necessitates high blood flow rates (5 to
7 l/minute) to ensure optimal oxygenation, ECCOR al-
lows CO2 removal at much lower blood flow rates (<1 l/
minute) due to significant differences in CO2 and oxygen
kinetics [21,23]. Although lower blood flows can be
achieved with smaller cannulae with greater ease, vascu-
lar complications may still occur especially with arterial
cannulation.
Various novel ECCOR devices are currently available
to facilitate LPV and are reviewed in detail elsewhere
[21,23]. The available and emerging devices are sum-
marised in Table 1. The pumpless interventional lung as-
sist iLA™ membrane ventilator marketed by Novalung
GmbH (Hechingen, Germany) is a low-gradient device
(Figure 1) that can be employed peripherally (femoral ar-
tery access and femoral vein return) and allows complete
CO2 removal in patients with adequate oxygenation and
robust haemodynamics. There have been reports of its
successful use in patients with ARDS [28] and severe
asthma [29] and as a bridge to lung transplantation [30].
However, the risks of arterial access have to be carefully
considered in these patients. The pulmonary artery–left
atrial configuration of the same device has been used as
a bridge to lung transplantation particularly in those
who have significant pulmonary hypertension [31]. A VV
configuration of the membrane oxygenator with a pump
(iLA™ Activve; Novalung GmbH) is also available for
partial or complete respiratory support [32].
Devices such as the Decap™ system (Hemodec, Sal-
erno, Italy) that serve the dual purpose of renal replace-
ment therapy and ECCOR are also available [33]. By
combining the membrane lung and the pump into a sin-
gle unit, the Hemolung™ (Alung Technologies, Pitts-
burgh, PA, USA) achieves efficient CO2 removal at flows
between 400 and 600 ml/minute [21] using dual-lumen
catheters similar to those used for renal replacementtherapy. These low-flow systems provide partial CO2 re-
moval only and do not provide any oxygenation benefit.
Even though modern low-flow VV ECCOR devices re-
portedly require a lower degree of anticoagulation, con-
cerns remain over risks of circuit thrombosis. Other
emerging technologies such as intravascular gas ex-
change and respiratory dialysis [21] are beyond the scope
of this article. Similarly, bridging the acutely ill patients
to lung transplantation [34,35] with ECLS is a highly
specialised service beyond the scope of this review.
Extracorporeal respiratory support can thus be pro-
vided with ECCOR or ECMO depending on the lung
pathology, pulmonary compliance and oxygenation and
decarboxylation requirements of an individual patient.
ECMO and ECCOR can also bridge highly selected pa-
tients to lung transplantation.
Extracorporeal life support in acute cardiac failure
Providing temporary mechanical circulatory support
(MCS) support to patients with acute refractory cardiac
failure using ECLS techniques is a rapidly evolving area;
intervention may be time critical and mortality is higher
than ECLS for isolated respiratory failure [36,37]. The
use of ECLS in the setting of cardiopulmonary resuscita-
tion is discussed elsewhere [38,39]. Patient outcomes
with the use of long-term ventricular assist devices
(VADs) in cardiogenic shock (INTERMACS class 1) are
poor [40,41]. Recently published International Society
for Heart and Lung Transplantation Guidelines for MCS
a b c
Figure 2 Venoarterial extracorporeal membrane oxygenation. Venoarterial extracorporeal membrane oxygenation can be instituted: (a)
centrally by cannulating the right atrium/inferior venacava and the aorta; (b) peripherally using the femoral vein and femoral artery (solid arrow,
arterial return cannula; hollow arrow, back-flow cannula for distal limb perfusion); or (c) peripherally using the axillary/subclavian artery. The choice
is often guided by the clinical setting, the expected duration of support and pulmonary function.
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for patients with cardiac failure [42], and these are not
discussed in this article. These guidelines strongly rec-
ommend consideration of the use of temporary MCS in
patients with multiorgan failure, with sepsis or on mech-
anical ventilation to allow successful optimisation of
their clinical status and neurologic assessment prior to
placement of a long-term MCS device [42].
The severity of noncardiac organ system failures can be
defined using scoring systems such as the Sequential
Organ Failure Assessment score. Severe multiorgan failure
(for example, Sequential Organ Failure Assessment score
>15) has been considered a contraindication to VV ECMO
[43] and similar criteria may be applicable for venoarterial
(VA) ECMO or for the use of an ECMO circuit as a tem-
porary VAD. Factors considered in the initial cannulation
strategy include: the underlying cause of cardiac dysfunc-
tion and projected time course of recovery; the severity ofTable 2 Extracorporeal life support strategies for mechanical
ECLS strategy Principle in
VA ECMO (return femoral artery) Default strat
Central VA ECMO (return aorta) Failure to we
Salvage for s
VA ECMO (return axillary artery) Reversible c
Reversible c
Centrimag™ (Levitronix LLC, Waltham, MA, USA) LVAD
(access left atrium/left ventricle, return aorta)
Isolated LV
Centrimag™ (Levitronix LLC) RVAD
(access right atrium, return pulmonary artery)
Isolated RV
Centrimag™ (Levitronix LLC) BiVAD Biventricular
TandemHeart (CardiacAssist, Inc., Pittsburgh, PA, USA)
percutaneous LVAD (access left atrium via femoral vein,
return femoral artery
Isolated LV
Impella™ (Abiomed, Aachen, Germany) percutaneous LVAD
(access femoral artery)
Isolated LV
Peripheral VA ECMO + Impella™ (Abiomed) percutaneous LVAD Isolated LV
Implantable LVAD + temporary RVAD (±oxygenator) Met criteria
BiVAD, biventricular assist device; ECLS, extracorporeal life support; ECMO, extracorp
device; RV, right ventricular; RVAD, right ventricular assist device; VA, venoarterial.pulmonary dysfunction and projected time course of
recovery; the functional reserve of each ventricle; the pres-
ence and severity of valvular pathology; risk of arterial ac-
cess and size of vessels; the severity of coagulopathy and
risk of sternotomy; and planned future surgery, such as
long-term VAD or transplant.
For patients with predominant cardiac failure with
preserved pulmonary function, the available MCS de-
vices provide several options (Table 2). Central VA
ECMO has been traditionally applied as a bridge to re-
covery in patients who fail to wean from cardiopulmo-
nary bypass after cardiac surgery (Figure 2). Central VA
ECMO outside this setting in adults is uncommon. Fem-
oral VA ECMO (Figure 2) is more commonly used in
adults requiring urgent cardiac support because it can
be achieved rapidly and a sternotomy is avoided. One of
the major limitations of peripheral femoro-femoral VA
ECMO is left ventricular (LV) afterload mismatch andcirculatory support in isolated cardiac failure
dication(s)
egy for potentially reversible cardiogenic shock of any cause
an from cardiopulmonary bypass where recovery expected within 7 days
mall patients with cardiogenic shock where femoral arterial access inadequate
ardiogenic shock where high flows not required
ardiogenic shock with lower-limb vascular disease
support where recovery is expected in 8 weeks
support where recovery is expected in 8 weeks
support where recovery is expected in 8 weeks
support
support
support with better LV decompression
for LVAD but unexpected reversible RV dysfunction occurred
oreal membrane oxygenation; LV, left ventricular; LVAD, left ventricular assist
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particularly so in patients with very low native cardiac
output states and severe mitral valve regurgitation, and
may result in severe hydrostatic pulmonary oedema in
some patients. Although some centres use an intra-
aortic balloon pump in conjunction with peripheral VA
ECMO to reduce LV afterload and pulmonary conges-
tion, no definitive data exist to support routine use.
LV and aortic root stasis from lack of cardiac ejection
and failure of aortic valve opening may result in cata-
strophic intracardiac and aortic root thrombosis. In-
creased anticoagulation to minimise this risk may
heighten the risk of significant bleeding. Minimally inva-
sive strategies such as percutaneous transseptal left atrial
decompression [44] and subxiphoid surgical approaches
to drain the left ventricle [45] have been described to re-
duce LV distension. The residual atrial defect may re-
quire correction once the patient has been weaned from
mechanical support. Use of a percutaneously inserted
VAD (Impella™; Abiomed, Aachen, Germany) to decom-
press the left ventricle has also been reported in this set-
ting [46], alleviating the need for a high-risk septostomy
or surgical venting.
Femoral VA ECMO is also limited by femoral arterial
size, and thus cannula size and the requirement for distal
limb perfusion. Given its less invasive nature (comparedFigure 3 Biventricular assist device along with respiratory support pr
(Levitronix LLC, Waltham, MA, USA) extracorporeal membrane oxygenation
respiratory support provided by the oxygenator in the circuit. Reproduced
right atrium.with thoracic access), peripheral VA ECMO – with atten-
tion to optimal LV afterload, minimising LV distension
with optimal fluid and inotrope therapy, anticoagulation
and pulmonary management – is a viable first-line option
for patients with isolated acute cardiac failure refractory
to conventional management.
The limitations of peripheral VA ECMO have
prompted the use of ECMO devices [47] to facilitate
ventricular unloading by changing to a temporary left
ventricular assist device (LVAD) or a biventricular assist
device configuration (Figure 3). Any perfusion strategy
that creates a right to left shunt requires an oxygenator
in the circuit. Oxygenators may additionally provide
temperature control. This strategy effectively provides
biventricular support and gas exchange through a single
pump configuration with the ability to cease right
ventricular (RV) support when not required. However,
this configuration requires sternotomy and cannulation
of the left ventricle (or left atrium) and aorta. A reopera-
tion (sternotomy or thoracotomy) is then required for
explantation of the cannulae upon cardiac recovery or
for implantation of a long-term mechanical assist device.
Less invasive techniques for temporary cardiorespira-
tory support including a transition strategy to an
intermediate-term support configuration [48] allowing
mobilisation have been described (Figure 4). Althoughovided by the oxygenator in the circuit. The hybrid Centrimag™
system can be used as a biventricular assist device along with
with permission from [47]. LVAD, left ventricular assist device; RA,
Figure 4 From venoarterial extracorporeal membrane oxygenation (ECMO) to use of ECMO as a temporary ventricular assist device.
(A) Emergent femoro-femoral venoarterial extracorporeal membrane oxygenation. (B) Left ventricular apical cannulation and decompression. (C)
Right ventricular recovery and isolated temporary left ventricular support. (D) Axillary artery cannulation to facilitate mobilisation. Reproduced with
permission from [48].
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omy is avoided, potentially reducing risk for subsequent
surgery in the absence of cardiac recovery (long-term
VAD implantation as a bridge to destination or heart
transplantation).
Temporary RV support can be provided with the Cen-
trimag™ ECMO system (Levitronix LLC, Waltham, MA,
USA) through percutaneous femoral venous access to
the right atrium and return to the pulmonary artery via
a cannulated exteriorised Dacron graft. This strategy is
described for temporary support of the RV with inser-
tion of a long-term LVAD but is applicable to other
causes of severe isolated RV dysfunction. An oxygenator
can be included in the circuit to ensure adequate oxy-
genation, CO2 removal and temperature regulation.
Upon RV recovery, the graft can be ligated and buried
upon decannulation without re-sternotomy.
Percutaneously inserted LVADs such as TandemHeart™
(CardiacAssist, Inc., Pittsburgh, PA, USA) and Impella™
(Abiomed) [49] are potential options for MCS in the
acute setting. However, there is a paucity of supportive
evidence for their use and the complications with arter-
ial access such as bleeding and limb ischemia cannot be
understated. TandemHeart™ utilises a centrifugal pump
to drain the left atrial blood from a catheter placed
transeptally via the femoral vein and returns it to thefemoral artery. The Impella™ device uses an axial pump
that is inserted retrogradely across the aortic valve via
the femoral artery. These devices provide LV support
and lack the ability to provide extracorporeal respiratory
support if required. However, there are case reports per-
taining to their successful use as RV assist devices and/
or biventricular assist devices [50,51].
Even though the third-generation, implantable LVADs
designed for long-term MCS are a significant improve-
ment on earlier devices [52], their use in a deteriorating
patient with multiorgan dysfunction is associated with
poor outcomes and is not currently recommended.
Advanced extracorporeal life support in severe
cardiorespiratory failure
The number of patients with severe combined cardiac
and respiratory failure who fail conventional treatment
is very small and ECLS in this group is controversial, be-
ing considered either heroic or futile. In the setting of
pneumonia or sepsis and severe cardiac dysfunction,
where feasible, VV ECMO with inotropic support should
be the initial perfusion strategy [53]. Septic myocardial
depression may improve with management of the sepsis,
improved oxygenation and normalisation of respiratory
acidosis [54]. Peripheral femoral VA ECMO (Figure 2)
may be considered a rescue option for these patients if
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sis is uncertain and conditions such as myocarditis are
considered likely. Use of this strategy in septic patients
with multiple organ failure who may have severe coagu-
lation and hepatic dysfunction may be futile. However,
heroic measures can result in good outcomes [56].
Upper body hypoxia can occur if myocardial recovery
occurs and lung function remains poor. This may be over-
come by transition to VV ECMO if myocardial recovery is
satisfactory or with the use of VA–venous ECMO, which
allows return of oxygenated blood to both arterial and
venous sides of the circulation, thereby minimising the
risk of upper-body hypoxia. Although peripheral arterial
cannulation for VA–venous ECMO is less invasive and is
an attractive option, balancing the oxygenation and perfu-
sion needs of an individual patient by regulating the return
of oxygenated blood to the underperfused coronary and
cerebral circulation may be challenging, and a central con-
figuration may be preferred in this setting. Returning the
oxygenated blood in the ascending aorta by cannulating
the axillary [57,58] or subclavian artery cannulation has
also been described (Figure 2) in this setting. However, ax-
illary artery side graft cannulation may be complicated by
ipsilateral upper-limb hyperperfusion and bleeding from
the arterial graft [59].
A more invasive, high-risk option in this setting in-
cludes use of the Centrimag™ ECMO system (Levitronix
LLC) as a temporary LVAD/biventricular assist deviceTable 3 Advanced extracorporeal life support strategies for c
or long-term support may be required
ECLS strategy Principle indic
VA ECMO (return femoral artery) Default strateg
VA ECMO (return axillary artery) Reversible card
Reversible card
Reversible card
VA ECMO (return ascending aorta) Failure to wean
Salvage for sm
inadequate
Salvage for sev
VA–venous ECMO Patients develo
Salvage for sev
Venous–pulmonary artery ECMO Reversible RV d
Centrimag™ (Levitronix LLC, Waltham, MA, USA) RVAD
(femoral access + oxygenator)
Reversible RV d
Centrimag™ (Levitronix LLC) RVAD (right atrium access +
oxygenator)
Reversible isola
remove oxyge
Centrimag™ (Levitronix LLC) hybrid (requires oxygenator) Severe LV after
Severe combin
before interme
Implantable LVAD + temporary RVAD (±oxygenator) Met criteria for
ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation; LV
right ventricular assist device; VA, venoarterial.with an oxygenator in the circuit. The device can be
employed in several configurations (Table 3) to support
both the left and/or right ventricles and the oxygenator
can be removed from the circuit when pulmonary func-
tion stabilises. This strategy can support patients for a
longer period of time, allowing more time to recover,
and minimises the risks of LV distension and throm-
bosis. This is ideally suited to patients with suspected
acute myocarditis in whom myocardial recovery is pos-
sible but prolonged support may be required. Alterna-
tively, central VA ECMO may be used in a patient in
extremis [60,61] when femoral cannulation is expected
to be difficult. Regardless of the initial strategy used,
transition to VV ECMO (Figure 5) should be considered
as soon as adequate cardiac function returns and is
pragmatically possible. Continued vigilance as well as
prospective risk management of the potential for LV
and/or aortic root thrombosis must be considered when
exploring specific potential configurations, and must be
assessed prior to implantation.
By providing a range of support options based on the de-
gree of cardiac and respiratory failure (Table 3), ECLS thus
redefines the contemporary management of this condition.
Experimental extracorporeal life support therapies
Several other ECLS cannulation strategies merit consid-
eration and further investigation. These strategies are
necessitated by inherent limitations of ECLS therapiesardiac and respiratory support: bridging to intermediate
ation(s)
y for potentially reversible cardiogenic shock of any cause
iogenic shock where high flows are not required
iogenic shock with lower-limb vascular disease
iogenic shock with poor gas exchange
from cardiopulmonary bypass where recovery expected within 7 days
all patients with cardiogenic shock where femoral arterial access
ere combined cardiac and respiratory failure
ping circulatory instability on venovenous ECMO
ere combined cardiac and respiratory failure
ysfunction expected duration up to 2 weeks
ysfunction expected duration up to 2 weeks
ted RV dysfunction expected duration up to 8 weeks with plan to
nator and convert to RVAD
load mismatch on VA ECMO
ed cardiac and respiratory failure where early RV recovery is expected
diate term LV recovery
LVAD but unexpected reversible RV dysfunction occurred
, left ventricular; LVAD, left ventricular assist device; RV, right ventricular; RVAD,
RA 
a b 
access 
RA 
return
IVC
access 
Figure 5 Patient in extremis initially receiving femoro-femoral venoarterial extracorporeal membrane oxygenation (ECMO) with transition
to venovenous ECMO. Patient in extremis initially received femoro-femoral venoarterial (VA) ECMO for severe cardiorespiratory failure with transition
to venovenous (VV) ECMO on day 4 following satisfactory cardiac recovery. (a) Chest X-ray scan shows multistage access cannula in the right atrium
(RA) during VA ECMO, (b) which was later withdrawn into the inferior vena cava (IVC) during VV ECMO. (b) A venous return cannula can also be seen
in the right atrium.
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some of the support options less invasive. A summary of
these therapies is presented in Table 4.
Refractory hypoxia and severe pulmonary hypertension
may be encountered on VV ECMO and is often terminal.
Percutaneous transeptal cannulation of the left atrium to
return the oxygenated blood has been proposed as an op-
tion to avoid a sternotomy, which needs to be further in-
vestigated. Similarly, percutaneous transeptal cannulation
of the left atrium for access along with percutaneous right
atrial cannulation may assist in venting the left ventricle
during VA ECMO. Other emerging less invasive ECLS op-
tions include hybrid systems that can provide renal re-
placement therapy and CO2 removal.
Limitations of extracorporeal life support
therapies
ECLS therapies are high-risk invasive interventions under-
taken in a few specialised centres. Despite the advance-
ments in ECLS technology, the associated complications
such as bleeding, thrombosis and infections cannot be
underestimated. Apart from the risk profile, the success ofTable 4 Experimental extracorporeal life support options
ECLS strategy Possibl
VV ECMO + atrial septostomy Refracto
sternoto
VV ECMO + transeptal return to left atrium Refracto
sternoto
Venoarterial ECMO + transeptal access from left atrium and right
atrium
Refracto
ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation; VVECLS relies heavily on its clinical application. Careful se-
lection of both patients and the ECLS perfusion strategy is
the key and not all centres may have the experience or the
resources to provide the full complement of ECLS therap-
ies discussed in this paper.
The lack of robust evidence is a significant limitation.
The complexities in delivering ECLS include resources and
cost-effectiveness, staff training, governance and availability
of funding for other programmes such as cardiothoracic
surgery, long-term mechanical assist devices, and heart and
lung transplantation. Such undertaking may be feasible in
resource-rich settings, but significant innovation and refine-
ment is required prior to its widespread use. With minimal
improvement in outcomes in ARDS over the years, wide-
spread use of VV ECMO and ECCOR may be a reality in
years to come. VA ECMO and its use as a temporary VAD
for MCS is a complex undertaking and its use will probably
be limited to specialised centres.
Conclusion
ECLS therapies hold promise and further research is in-
dicated to explore their full potential. Given the smalle indication(s)
ry hypoxia and/or pulmonary hypertension on VV ECMO avoiding
my
ry hypoxia and/or pulmonary hypertension on VV ECMO avoiding
my
ry left ventricular distension on venoarterial ECMO
, venovenous.
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respiratory support globally, it may not be feasible to
generate evidence-based guidelines for all available ther-
apies. However, ongoing refinements in technology, de-
velopment of minimally invasive techniques, better
understanding of the physiological impact of the ECLS
circuit (for example, altered pharmacokinetics of vital
drugs [62]) and improved clinical delivery may improve
patient outcomes. ECLS therapies will probably play a
vital future role in the management of adult patients
with acute cardiorespiratory failure. Collaboration be-
tween global ECLS centres is the key in designing and
conducting high-quality clinical trials that will hopefully
provide more clarity in patient selection, choice of ECLS
device and the appropriate perfusion strategy to be used.
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1.3 INCREASED SEDATION REQUIREMENTS IN PATIENTS RECEIVING 
EXTRACORPOREAL MEMBRANE OXYGENATION FOR RESPIRATORY AND 
CARDIORESPIRATORY FAILURE.  
 
1.3.1. Introduction to this publication 
This analysis of sedation data from patients receiving ECMO was the first report of altered 
sedative PK in adult patients. Patients on ECMO required much more sedation (often 
greater than 4 fold) when compared with critically ill patients not on ECMO. Sedative drugs 
have clinically titrable endpoints where as this is not the case for antibiotic drugs for many 
of which even therapeutic drug monitoring is not readily available. Thus this paper serves 
not only as a hypothesis generator but makes the case for further systematic research. 
Anaesthesia and Intensive Care, Vol. 40, No. 4, July 2012
Extracorporeal membrane oxygenation (ECMO) 
temporarily supports patients with severe cardiac 
and/or respiratory failure that is not responsive to 
maximal conventional treatment1. It is usually a 
bridge to organ recovery, but can also be used as 
a bridge to long-term mechanical assist devices 
or transplantation2,3. Its role extends even further as an 
adjunct to cardiopulmonary resuscitation (CPR)4, as 
well as high risk percutaneous cardiac interventions5. 
Improvements in equipment, patient selection and 
a better understanding of extracorporeal circuit 
technology have resulted in some centres reporting 
significantly improved outcomes6-8. The Conventional 
Ventilation or ECMO for Severe Adult Respiratory 
Failure (CESAR) trial9, and the Australian and New 
Zealand Intensive Care Society ECMO investigator 
study into Influenza A (H1N1)10, support its role in 
the advanced management of respiratory failure 
unresponsive to maximal conventional therapy11-14. 
Data from the Extracorporeal Life Support Organ-
ization registry15 suggest an increasing use of 
ECMO in adults with refractory respiratory and/or 
cardiac failure, with a reported survival of 63% for 
venovenous (VV) ECMO and 53% for venoarterial 
(VA) ECMO.
ECMO is a highly invasive treatment in a 
group of patients who have failed conventional 
treatment and optimal sedation for this complex 
group of patients is not clearly defined. Sedative 
and analgesic medications promote patient 
* MB, BS, FCICM, Staff Specialist, Adult Intensive Care Unit, Critical 
Care Research Group and University of Queensland.
† BAppSc, BPharm, PhD, Senior Clinical Pharamcist, Royal Brisbane 
and Women’s Hospital and Burns Trauma and Critical Care Research 
Centre, University of Queensland.
‡ MB, BS, FFICANZCA, Senior Staff Specialist, Adult Intensive Care 
Unit, Critical Care Research Group and University of Queensland.
§ Nurse Researcher, Adult Intensive Care Unit; Critical Care Research 
Group and Griffith University.
** BPharm, Senior Clinical Pharmacist, Critical Care Research Group.
†† Clinical Research Nurse, Adult Intenisve Care Unit and Critical Care 
Research Group.
‡‡ PhD, Associate Professor, Institute of Health and Biomedical 
Innovation and School of Public Health, Queensland University of 
Technology and Critical Care Research Group.
§§ MB, ChB, PhD, MRCP, FRCA, FFARCSI, FCICM, Senior Staff 
Specialist, Adult Intensive Care Unit and Director, Critical Care 
Research Group.
Address for correspondence: Dr K. Shekar, Prince Charles Hospital, 
Rode Road, Chermside, Qld 4032. Email: kiran_shekar@health.qld.gov.au
Accepted for publication on March 6, 2012.
Increased sedation requirements in patients receiving 
extracorporeal membrane oxygenation for respiratory and 
cardio-respiratory failure
K. SHeKAR*, J. A. RoBeRTS†, D. V. MUllANy‡, A. CoRley§, S. FISQUeT**, T. BUll††, 
A. G. BARNeTT‡‡, J. F. FRASeR§§
Adult Intensive Care Unit, Prince Charles Hospital, Brisbane, Queensland, Australia
SUMMARy
Critically ill patients receiving extracorporeal membrane oxygenation (ECMO) are often noted to have 
increased sedation requirements. However, data related to sedation in this complex group of patients is limited. 
The aim of our study was to characterise the sedation requirements in adult patients receiving ECMO for 
cardio-respiratory failure. A retrospective chart review was used to collect sedation data for 30 consecutive 
patients who received venovenous or venoarterial ECMO between April 2009 and March 2011. To test for 
a difference in doses over time we used a regression model. The dose of midazolam received on eCMo 
support increased by an average of 18 mg per day (95% confidence interval 8, 29 mg, P=0.001), while the 
dose of morphine increased by 29 mg per day (95% confidence interval 4, 53 mg, P=0.021) The venovenous 
group received a daily midazolam dose that was 157 mg higher than the venoarterial group (95% confidence 
interval 53, 261 mg, P=0.005). We did not observe any significant increase in fentanyl doses over time 
(95% confidence interval 1269, 4337 µg, P=0.94). There is a significant increase in dose requirement for 
morphine and midazolam during eCMo. Patients on venovenous eCMo received higher sedative doses as 
compared to patients on venoarterial ECMO. Future research should focus on mechanisms behind these 
changes and also identify drugs that are most suitable for sedation during ECMO.
Key Words: extracorporeal membrane oxygenation, sedation and analgesia, drug toxicity, cardio-respiratory failure, 
pharmacokinetics
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comfort and eliminate pain, anxiety, agitation, 
delirium and other forms of distress induced by 
the intensive care unit (ICU) environment16. 
However, excessive sedation may lead to adverse 
outcomes. Use of objective scoring systems, 
sedation protocols17 allowing lighter sedation with 
daily interruptions17-19 and minimising administration 
of paralytic agents have all been shown to reduce 
morbidity in ICU. Although evidence-based, these 
practices may not always be applicable to a critically 
ill patient on ECMO. Sedation during ECMO 
minimises the risk of catheter malposition or 
dislodgement; as well as coughing, which induces 
‘suck down’ or chatter, resulting in haemolysis. Deep 
sedation and paralysis may be required, especially 
early in the course of VV ECMO to achieve better 
circuit flows, minimise oxygen consumption and 
optimise ventilation. These factors may lead to a 
degree of ‘permissiveness’ when sedating patients 
during ECMO. To overcome this problem, some 
centres perform an early tracheostomy20 but the 
risks of this procedure in a patient on extracorporeal 
life support (ECLS) cannot be underestimated. 
Although neonatal studies have highlighted the 
increased sedation requirements during ECMO21-24, 
no such data is available for adult patients.
The aim of the study was to retrospectively 
review the sedative and analgesic drug requirements 
in adult patients receiving ECMO in our intensive 
care unit. 
MeTHoDS
Study design and participants
A retrospective chart review was performed 
after obtaining local ethics approval (HReC/11/
QPCH/3). All patients undergoing eCMo since 
the commencement of the program at the Prince 
Charles Hospital, Brisbane, from April 2009 to 
February 2011 were included. One patient was 
excluded as death occurred in the operating room 
before meaningful data was charted. 
Details of sedation, ventilation and ECLS
Our local protocol requires patients to be 
heavily sedated (equivalent to a Riker Sedation-
Agitation Scale of 1 to 2) during the first few 
days of ECMO. This is particularly relevant 
for patients receiving VV ECMO to minimise 
oxygen consumption, optimise eCMo flows and 
ventilation. The senior nurses at the bedside titrate 
sedation and analgesia to patient comfort, degree 
of agitation, delirium and distress while preventing 
inadvertent disconnection of the circuit. Sedation 
is lightened where possible to assess neurology on 
a regular basis. Midazolam is used for sedation 
in all patients. Morphine is used for analgesia 
in patients with conserved renal function and 
fentanyl is used in patients with renal dysfunction 
or those requiring renal replacement therapy (RRT). 
Patients requiring additional sedation are given 
propofol, dexmedetomidine and thiopentone. Where 
necessary patients also may be prescribed enteral 
diazepam and/or neuroleptic agents if clinically 
indicated. Sedation is rapidly de-escalated after 
discontinuation of ECMO, particularly where a 
tracheostomy is performed. 
The patients in the VV group receive a tidal 
volume of less than 6 ml/kg lean body weight with a 
positive end expiratory pressure of 10 to 15 cmH2O, 
limiting plateau pressures and fractional inspired 
oxygen (FiO2) to less than 30 cmH2O and 0.5 res-
pectively. Ventilator settings in the VA group were 
chosen to offer adequate lung aeration, prevention 
of atelectasis, avoidance of overdistension and 
prevention of coronary and cerebral hypoxemia (tidal 
volume 6 to 8 ml/kg lean body weight, rate 6 to 
12 breaths/minute, FiO2 ≤0.5, positive end expira-
tory pressure >5 cmH2O, end tidal carbon dioxide 
-20 to 30 mmHg).
The standard ECMO circuitry comprised poly 
vinyl chloride tubing, centrifugal pump (Jostra 
Rotaflow™, Maquet, Germany) and a hollow fibre 
oxygenator (Quadrox D™, Maquet, Germany). 
RRT included both continuous (Aquarius™, Baxter 
International Inc., USA), using a percutaneous 
vascular catheter, and extended daily diafiltration 
(ARrT Plus™, Fresenius USA Inc., USA) directly 
via the ECMO circuit.
Data collection
Data collection from the medical record was 
performed using a detailed data collection instru- 
ment. Hourly total doses of midazolam, fentanyl 
and morphine including infusion and boluses were 
recorded from the time of ECMO commencement 
to the end of the day when ECMO was ceased. 
Drug dosing is described as total daily dose and 
was the study variable unless otherwise specified. 
Demographic and severity of illness data were 
obtained from the local ECLS database. Sequential 
Organ Failure Assessment (SOFA) scores were 
recorded on days 1, 3 and 5 of the ICU stay, and 
Acute Physiology and Chronic Health evaluation 
(APACHe) III scores within the first 24 hours of 
ICU stay.
Statistical analysis
To provide a visual display of drug dosing over 
time we plotted the daily drug dose for each patient. 
We also plotted the average drug dose per day to 
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show the average dosing over time. To test for 
differences in drug dosing over time we used a 
regression model. To allow each patient to have 
a different profile over time we used a mixed 
effects model and fitted a random intercept and 
slope for each patient. We examined the residuals 
of the final model to check for normality. We 
also included variables for RRT and VA/VV ECMO 
to examine differences in these patients both on 
average and over time. To examine the association 
between APACHe III and SoFA scores and 
midazolam dose, we used scatter plots and linear 
regression. These analyses used each patient’s 
mean midazolam dose over their entire eCMo run. 
Results are presented as means and 95% 
confidence intervals. We used a two-sided statistical 
significance level of 0.05. Analyses were performed 
using R version 2.12.2 (www.r-project.org).
RESULTS
Of the 29 patients analysed, 13 received VV 
and 16 received VA ECMO. In total, 342 days 
of ECMO support was cumulatively received by 
all patients; VV, median 356 hours (range 52 to 
645 hours); VA, median 160 hours (range 0 to 
514 hours). The patient characteristics and severity 
of illness data are presented in Table 1. 
Patients received between 0 and 1440 mg per 
day of midazolam. The median daily midazolam 
dose was 175 mg (range 24 to 1092 mg). Figure 1 
and Table 2 shows the summary results for 
midazolam, morphine and fentanyl. on average, 
the daily dose of midazolam increased by 18 mg 
per day (95% confidence interval 8, 29 mg, P=0.001) 
after commencement of ECMO, representing 
an increased dose of 10.2%. The VV group had 
a daily midazolam dose 157 mg higher on 
average than the VA group (95% confidence interval 
53, 261 mg, P=0.005). There was no statistically 
significant difference in average dose of midazolam 
for the RRT group (P=0.16). On average, the 
daily dose of morphine increased by 29 mg per day 
(95% confidence interval 4, 53 mg, P=0.02). 
There was no statistically significant increase in 
fentanyl doses over time (P=0.94). Fifteen of the 
29 patients required propofol (100 to 300 mg/hour) 
as a rescue agent at various times and there was an 
increased use between days 3 and 8. Nine of these 
15 patients received VV ECMO. Dexmedetomidine 
and thiopentone were used in two patients. All 
patients on VV ECMO received boluses of a 
neuromuscular blocker (vecuronium, median daily 
dose 20 mg, range 20 to 40 mg/day) early in their 
course of ECMO.
In Figure 2 the predicted daily doses of 
midazolam, fentanyl and morphine are graphed 
according to whether RRT was used. There was 
no significant influence of RRT on average doses 
over time (one to 21 days) for midazolam, morphine 
and fentanyl in both VA and VV groups. In 
Figure 3, measures of sickness severity, SOFA 
table 1
Demographic and severity of illness data
VV ECMO VA ECMO
Age, median, y 35 (18-55) 54 (16-77)
Gender, male (%) 6 (46) 12 (71)
Admission weight, kg 71.5 (47-106) 79 (44-112)
Duration of ECMO, h 356 (52-645) 160 (1-514)
APACHe II score 20 (16-35) 21 (9-39)
APACHe III score 80 (51-123) 79 (48-128)
APACHe III RoD estimate 0.39 (0.13-0.73) 0.36 (0.04-0.91)
SOFA score day 1 10 (6-16) 10 (6-16)
SOFA score day 3 10 (5-17) 10 (4-17)
SOFA score day 5 11(4-14) 10 (5-11)
Pre-eCMo creatinine, µmol/l 166 (35-422) 127 (65-383)
Pre-eCMo bilirubin, µmol/l 20 (4-189) 35 (6-101)
PRBC transfusion, units 11(4-53) 31(8-191)
VV=venovenous, ECMO=extracorporeal membrane oxygenation, 
VA=venoarterial, APACHe=Acute Physiology and Chronic Health 
Evaluation, ROD=risk of death, SOFA=Sequential Organ Failure 
Assessment, PRBC=packed red blood cells. 
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and APACHe III scores are compared with 
daily midazolam dose. Higher SoFA scores were 
associated with lower doses, although this association 
was of borderline statistical significance (P=0.053). 
Higher APACHe III scores were non-significantly 
associated with lower midazolam doses (P=0.14).
DISCUSSION
This study highlights the challenges in maintaining 
optimal sedation in patients receiving ECMO. The 
data presented are unique and advance our under-
standing of sedative drug use during ECMO, 
which is at present very limited. In general, most 
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Figure 1: Average dose requirements for morphine, midazolam and fentanyl appear  
to increase with the duration of ECMO. In some patients, this occurred despite the 
concurrent use of other sedative agents (propofol, dexmedetomidine and thiopentone). 
Tracheostomy on liberation from ECMO led to a significant decrease in sedative and 
analgesic drug requirements seen between days 25 to 30. This data is particularly  
influenced by patients on venovenous ECMO.
table 2
Mixed model results for midazolam, morphine and fentanyl
Drug Variable Mean 95% CI P value
Midazolam Day 18 8, 29 0.001
RRT=y -72 -175, 32 0.164
VA/VV=VV 157 53, 261 0.005
Morphine Day 29 4, 53 0.021
RRT=y -23 -247, 202 0.83
VA/VV=VV 129 -103, 361 0.24
Fentanyl Day -7 -198, 184 0.94
RRT=y 419 -1426, 2264 0.64
VA/VV=VV 166 -1698, 2030 0.86
To allow each patient to have a different profile over time we used a 
mixed effects model and fitted a random intercept and slope for each patient 
to examine changes in the daily doses of midazolam, morphine and 
fentanyl over time with or without RRT, and with or without VV or VA 
eCMo. on average the 24-hour dose increased by 18 mg for midazolam 
and 29 mg for morphine from the day of commencement of ECMO. There 
was no significant increase in fentanyl doses over time. CI=confidence 
interval, RRT=renal replacement therapy, y=yes, VA=venoarterial, 
VV=venovenous.
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patients received increasing doses of midazolam 
and morphine with time. This occurred despite the 
concurrent use of multiple sedative agents like pro- 
pofol, dexmedetomidine, thiopentone and neuro-
leptic drugs in some patients. Interestingly, in this 
small group of patients RRT did not significantly 
influence the drug doses used. The difference in the 
severity of illness between patients receiving VA and 
VV eCMo was not significant enough to explain the 
higher dose requirement in the VV group. Patients 
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Figure 2: Average doses for all patients over time (one to 21 days) for midazolam, morphine and fentanyl. 
Data is presented as to whether the patient was receiving renal replacement therapy (RRT) with the left 
panels representing doses without RRT and the panels on the right describing data in the presence of RRT. 
The grey line represents data from patients receiving venovenous ECMO and the black line represents data 
from patients receiving venoarterial eCMo. N=no, y=yes, VA=venoartertial, VV=venovenous.
Figure 3: Severity of illness and midazolam requirement during eCMo. Mean  
24-hourly midazolam dose for all patients plotted against the average Sequential organ  
Failure Assessment (SoFA) score (left panel) and Acute Physiology and Chronic Health  
evaluation (APACHe) II score (right panel). A log scale was used on the y axis to account for  
two patients who received very high doses. The fitted line is from a regression with log-transformed 
dose as the dependent variable and the SoFA or APACHe score as the independent variable.  
The R-squared for SoFA and midazolam is 42% and the P value is 0.024. The R-squared for 
APACHe and midazolam is 33% and the P value is 0.083. 
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in the VV group are more critically balanced from 
an oxygenation point of view and are very dependent 
on optimal circuit flows, especially early in their 
course of ECMO. While this may explain the 
increased sedation requirements early in the 
course of VV ECMO, the mechanisms behind the 
escalating sedation needs (later in the course of VV 
ECMO in patients with resolving lung injury) are 
poorly understood.  
It is unclear if the very high sedation requirement 
seen in our patients is entirely attributable to circuit 
factors alone. Mechanical ventilation, bleeding, 
delaying tracheostomy until liberation from ECMO, 
possible alterations in pharma-codynamics, develop-
ment of tolerance and recovering organ function 
with time may all have contributed to the increase 
in sedation requirements in this group of patients. 
However, it is possible that eCMo may influence 
pharmacokinetics (PK) significantly and this effect 
may be more pronounced for certain drugs depend-
ing on their physicochemical properties. The common 
mechanisms are likely to include increased volume of 
distribution, decreased clearance and adsorption 
of the drugs in the circuit25. ECMO probably consti-
tutes another compartment for drug distribution from 
a PK point of view. The pharmacodynamic effects 
of some of the sedative drugs may be further compli-
cated by the presence of their active metabolites.
The ability of ECMO to alter the PK of sedative 
drugs has been highlighted in studies involving 
neonates and simulated ECMO circuits. Neonates 
receiving ECMO demonstrated an escalation of 
fentanyl and morphine doses with time26,27. Develop-
ment of tolerance, organ maturation28 and resolution 
of organ failure may all account for increased drug 
clearance in the neonatal population in addition 
to circuit factors. Clearance of morphine and its 
metabolites was reduced in several studies and 
correlated with severity of illness29-31. Variable data 
exists regarding the PK of morphine and fentanyl in 
neonates receiving ECMO32,33. 
Midazolam and its metabolites exhibited similar 
properties during ECMO in neonates. There were 
substantial increments in doses over time despite 
1-hydroxy midazolam glucuronide accumulation 
during ECMO28,34,35. These effects have also been 
observed with lorazepam29,36. There is limited data 
on other sedative agents used during ECMO. A 
requirement for higher doses of phenobarbital has 
been reported22 during ECMO in neonates. The 
escalating sedation requirement with time in adult 
patients on ECMO appears to be similar to that in 
neonates despite the differences in development, 
physiology, PK and pharmacodynamics. 
Simulated circuit studies using neonatal circuits 
and pumps confirm the potential role of the 
extracorporeal circuit in altering the PK of 
administered drugs29,38. Though limited by variability 
in the technology used, these studies have clearly 
demonstrated the unpredictable behaviour of 
sedative drugs in the ECMO circuit21. Type of 
oxygenator36, pump39 and age of the membrane40  
have all been shown to have a variable influence 
on PK. 
Limitations of currently available studies include 
the fact that some data are from ex vivo and in 
vitro models that do not account for the altered 
physiology common to critical illness. Other data 
from neonates may not be applicable to adults, due 
to the developmental and age-related physiological 
differences. The studies that do exist have used 
different equipment, such as polymethylpentene 
vs silicone membrane oxygenators, or uncoated 
tubing, which is different from presently available 
equipment. The mean duration of ECMO support 
has increased with the changing demographics of 
ECMO41 leading to the possibility of saturation 
of circuit binding sites over time42. 
Critical illness and ECMO may have profound 
effects on the pharmacokinetics21,25,36,42-45 of drugs. 
Pathophysiological factors such as sickness severity, 
haemodilution42, altered serum protein concentra-
tions43, the inflammatory response induced by the 
extracorporeal circuit46, bleeding and massive trans-
fusion, changes in the extracellular fluid volume and 
total body water may all lead to an increase in the 
volume of distribution of administered drugs. Drug 
adsorption and/or sequestration in the extracorpor- 
eal circuit tubing and the oxygenator may further 
increase the volume of distribution39. Organ dys-
function, changes in gastrointestinal43, renal, hepatic 
and pulmonary blood flow47 as a result of a non-
pulsatile circulation48,49 may result in decreased drug 
clearance. Renal replacement therapy can further 
complicate the PK of drugs by adding another 
parallel extracorporeal circuit that can potentially 
filter drugs50.
There are clear limitations to this study which 
include the absence of an eCMo-specific sedation 
scale and use of Bispectral index monitoring51, the 
small sample size, absence of a control group and 
limited generalisability to other settings. Long-stay 
patients have more influence on the results over time 
due to their longer stays. The dose requirements for 
morphine, fentanyl and midazolam may have been 
much higher in the absence of other rescue drugs like 
propofol, thiopentone and dexmedetomidine, which 
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were used in our patients.  More detailed evaluation 
of organ function, total body water, extracellular 
fluid volume and the effects of RRT and its type are 
also required25. However, what is clear is that eCMo 
does dramatically increase sedative requirement and 
that this initial observational data supports the call 
for further prospective studies to improve safety and 
efficacy of eCMo.
The degree of variability seen in our study 
and limited existing data at present make it 
difficult to draw any meaningful conclusions on the 
use of sedative agents for patients on ECMO. 
However, the morbidity associated with excessive 
sedation calls for further research. Future studies 
should focus on development of sedation protocols 
that will allow optimal usage of available sedative 
drugs to meet the increased sedation requirements 
in this important subgroup of patients. It may be 
prudent to slowly taper opioid and benzodiazepine 
dosages after decannulation to prevent with-
drawal. Our patients received regular enteral 
benzodiazepines and opioid replacement after 
decannulation to minimise risks of withdrawal.
CONCLUSIONS
This preliminary study highlights the sedation-
related issues in patients receiving ECMO. Unfor-
tunately, a lack of knowledge of the underlying 
mechanisms presents challenges for clinicians. Future 
research should aim at characterising the effect of 
the circuit, drug and patient factors on the PK 
of sedatives and analgesics during ECMO. Identifying 
the sedative agents that are least affected by the PK 
alterations during ECMO, development of ECMO 
specific sedation protocols and further refinements 
in ECMO circuitry may minimise morbidity associ-
ated with excessive sedation in this most unwell 
cohort of intensive care patients. 
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2.1 PHARMACOKINETIC CHANGES IN PATIENTS RECEIVING EXTRACORPOREAL 
MEMBRANE OXYGENATION. 
 
2.1.1 Introduction to this publication 
This chapter represents the next logical step towards formulation of a research plan to 
address the complex issue of altered PK during ECMO. Most available PK data was 
available from neonates not surprisingly given that ECMO had its beginnings in this patient 
population. This review confirms significantly altered PK during ECMO in neonates and 
also highlights the limitations of translating neonatal data to adult patients. The review 
identifies an absolute paucity of data on sedative and antibiotic drug dosing in adult 
patients on ECMO and emphasises how suboptimal drug therapy may lead to adverse 
clinical outcomes based on adapt from critically ill patients not on ECMO. It also identifies 
research gaps and outlines potential approaches for systematic investigation of this 
complex problem. 
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elimination. While lipophilic drugs and highly protein-bound drugs (eg, voriconazole and fentanyl) are
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dosing guidance can be developed to improve clinical outcomes in this most unwell cohort of patients.
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Extracorporeal membrane oxygenation (ECMO) is a
temporary life support system that can provide partial or
complete support for patients with severe cardiorespiratory
failure [1,2]. It is usually used as a bridge to recovery but can
also be used as a bridge to long-term mechanical assist
devices or heart and/or lung transplantation [3-6]. Clinically,
ECMO is a temporizing measure that can facilitate planning
741.e10 K. Shekar et al.of deﬁnitive treatment, optimization of patient physiology,
and organ perfusion while the underlying pathology is being
assessed and treated [1].
Two main forms of ECMO are currently practiced.
Venovenous (VV) ECMO supports the lungs only, whereas
venoarterial (VA) ECMO provides support for both the heart
and the lungs. During VV ECMO, venous blood from the
patient is accessed from the large central veins and returned to
the venous system near the right atrium after it has passed
through the oxygenator. In VA ECMO, deoxygenated blood
is drawn from the right atrium, and oxygenated blood is
returned to the distal descending aorta. Regardless of whether
ECMO is used as VV or VA, a typical circuit will consist of
polyvinyl chloride (PVC) tubing, a hollow ﬁber (poly-
methylpentene) oxygenator, and a heat exchanger (Fig. 1).
More detailed reviews on the principles and practice of
ECMO can be found elsewhere [1,7-9].
Extracorporeal membrane oxygenation has established
itself as an effective tool in the treatment of neonates and
children with severe respiratory failure when compared with
contemporary conventional care [10-14].
Venoarterial ECMO is being increasingly used in adult
patients [15] with cardiac failure and has a reported survival
of up to 53%. The ﬁrst successful use of ECMO in adult
respiratory failure was reported in 1972 [16]. Initial adult
data failed to demonstrate signiﬁcant beneﬁt [17,18], but
more recent studies have reported a survival rate to
discharge of up to 78% in patients with severe respiratory
failure [19-21]. Extracorporeal membrane oxygenation
continues to broaden its scope [22,23] and holds great
promise, but it is not without risks. Issues surrounding
bleeding and anticoagulation have taken center stage in the
management of patients on ECMO. However, alterations inFig. 1 Schematic representation of ECMO. In both modalities, blood is
(red) to the arterial system, and in VV ECMO, it is returned to the venous s
by arrows.drug pharmacokinetics (PK) in the presence of ECMO are
infrequently addressed despite signiﬁcant preliminary data
from neonatal studies. It should be emphasized that PK data
from neonates cannot be extrapolated to older adults
because physiologic processes that inﬂuence absorption,
distribution, metabolism, and excretion are immature [24] in
a neonate and because their maturation while on ECMO
may signiﬁcantly inﬂuence the derived PK data. In clinical
circles, effective dosing of analgesics, sedatives, and
antibiotics, in particular, are considered a signiﬁcant
challenge. The aim of this structured review is to describe
changes in the PK of drugs commonly used during ECMO
and the implications for drug therapy for this complex
cohort of patients.2. Methods
Data for this review were obtained by searches of the
PubMed (1965 to August 2011), EMBASE (1965 to August
2011), and the Cochrane-Controlled Trial Register database
and references from those searched articles. Search terms
included “pharmacokinetics,” “ECMO,” “critical illness,”
“sedatives,” and “antibiotics.” Studies in languages other
than English were excluded. All relevant studies describing
the pharmacokinetic alterations during ECMO in in vitro and
ex vivo experiments, animals, neonates, and adults were
included in the review. The literature search identiﬁed 64
relevant articles, which included 35 PK studies in neonates,
infants, and children; 11 in vitro and ex vivo studies; 1
animal study; 5 case reports in adults; and 12 review articles.
These search results highlight the paucity of PK data in adult
patients receiving ECMO.drained from the venous system (blue). In VA ECMO, it is returned
ystem. The direction of blood ﬂow in the ECMO circuit is indicated
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Describing PK in individual patient populations is
essential to understand whether special dosing approaches
may be required. In critically ill patients, PK changes can be
highly signiﬁcant and are dictated by the patient, pathology,
and the drug [25]. Systemic inﬂammatory responses, organ
dysfunction, drug interactions, and organ support are all
known to affect PK. Pharmacokinetic changes in critically ill
patients not receiving ECMO have been reviewed exten-
sively and can be found elsewhere [25-31]. The available but
limited data suggest that PK changes seen during critical
illness are more pronounced in the presence of ECMO.
Generally, ECMO can alter PK by increasing the volume of
distribution (Vd), decreasing drug elimination, and seques-
tering drugs in the ECMO circuit [32]. Other factors affecting
drug PK in the presence of ECMO are summarized in Fig. 2.
The following sections will address the PK changes during
ECMO in greater detail.3.1. Extracorporeal membrane oxygenation and
drug sequestration
Drug sequestration in ECMO circuits is a well-known but
poorly characterized phenomenon. Drug properties such as
molecular size, degree of ionization, lipophilicity, and
plasma protein binding may all inﬂuence the degree of
binding to the circuit components [32,33]. Given the large
surface area of the tubing and membranes, signiﬁcant
amounts of drugs used in patients on ECMO may be
sequestered over a period of time, resulting in a signiﬁcant
increase in Vd (Fig. 3). Conversely, the circuit may continue
to release the sequestrated molecules once a particular drug
infusion is ceased. This phenomenon is unpredictable andECMO
HAEMODILUTION
FLUID SHIFTSSIRS, CO 
 CL Vd
LOW PLASMA 
CONCENTRATIONS 
THERAPEUTIC
FAILURE
Fig. 2 Impact of critical illness, inﬂammation, and ECMO on drug PK. Smay prolong the pharmacologic effect in a manner that is
undesirable [33].
The type and age of a circuit also appear to be signiﬁcant
factors in the level of sequestration [34,35]. In a single-dose
in vitro experiment using a membrane oxygenator and roller
pump circuits, up to 50% of morphine and 40% of
lorazepam were sequestered at 24 hours [36], with older
circuits recording higher losses. This may partly explain the
need to escalate sedative drug doses overtime as seen in
neonatal studies [36,37], but the mechanisms behind this
are unclear. A recent circuit study using neonatal and
pediatric circuits compared roller with centrifugal pumps
and silicone membrane with hollow ﬁber oxygenators [38].
Maximal drug recovery was observed in centrifugal pump
circuits with polypropylene hollow ﬁber membrane oxy-
genators as opposed to silicon membrane with roller pumps
(midazolam 63.00% vs 0.62%, fentanyl 33.00% vs 0.35%).
Preston et al [39] studied losses of fentanyl and morphine in
circuits with and without the oxygenator. Eighty percent of
fentanyl was lost in circuits without oxygenators, 86% in
the circuits containing the polypropylene Quadrox D
oxygenator, and 83% in the circuits with the membrane
oxygenator. Morphine losses were up to 40% in all circuits
and were not inﬂuenced by the presence of the oxygenator.
These contrasting results for morphine and fentanyl
probably stem from the relative differences in their
lipophilicity and are highly relevant for a patient on
ECMO. Despite the large surface area of the oxygenator
(1.8 m2), most of the drug losses occurred in the uncoated
PVC tubing. However, the newer modiﬁed surface-coated
PVC tubing have also been shown to sequester a signiﬁcant
amount of fentanyl (30%-40%) and morphine (35-58%) in
an in vitro study [40].
Another ex vivo study under physiologic conditions
estimated the amount of drug sequestered over time usingDRUG 
SEQUESTRATION
ORGAN 
DYSFUNCTION
 CL 
HIGH PLASMA 
CONCENTRATIONS 
TOXICITY 
IRS indicates systemic inﬂammatory syndrome; CO, cardiac output.
AB
C
Fig. 3 Signiﬁcant sequestration of drugs in the ECMO circuit increases their volumes of distribution, leading to suboptimal drug
concentrations in the body. A mere increase in administered dose for all drugs during ECMO may not sufﬁce because the less sequestered
drugs may reach toxic levels. A, PVC tubing. B, Pump head. C, Oxygenator.
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comparison of crystalloid and blood-primed circuits showed
a loss of 71% and 15% of ampicillin, 17% and 31% of
fosphenytoin, 33% and 53% of heparin, and 87% and 100%
of fentanyl, respectively, at 24 hours. There was a
statistically signiﬁcant decrease in overall drug concentra-
tions from 30 minutes to 24 hours, which could also be
considered clinically signiﬁcant, for both crystalloid (P =
.023) and blood-primed circuits (P = .04). Interestingly,
priming with blood increased the losses of fosphenytoin,
fentanyl, and heparin [41].
However, it is unclear how priming of a circuit with
various ﬂuids differentially affects drug sequestration. The
circuits are often primed with crystalloids, colloids, blood,
and added electrolytes to adjust for pH and are maintained at
normal body temperature. All of these factors could affect the
protein binding of injected drugs as well as adsorption onto
the PVC tubing and the oxygenator, although this has been
poorly characterized [36]. There may be a saturation point
for drug sequestration in the circuit; however, current
understanding of this is limited. In vitro simulated circuit
studies that duplicate physiologic conditions as closely as
possible using standardized adult ECMO circuits have the
potential to provide insights into circuit drug interactions and
help further reﬁne ECMO circuitry. Extracorporeal mem-
brane oxygenation is a technology in evolution [42], and
further studies are required to quantify drug losses in
miniaturized circuits that use polymethylpentene oxygena-
tors, magnetically levitated centrifugal pumps, coated tubing,
and cannulae.3.2. Extracorporeal membrane oxygenation and Vd
By deﬁnition, the apparent Vd of a drug is the theoretical
volume of ﬂuid into which the total drug administered will
have to be diluted to produce a concentration equal to that
observed in plasma. Extracorporeal membrane oxygenation
can independently alter the Vd of drugs by several
mechanisms as summarized in Table 2 and Fig. 2. However,
most of these data originate from neonates. Newborn infants
have a high proportion of total body water and a low
proportion of adipose tissue that results in higher Vd for
hydrophilic drugs (eg, β-lactams and aminoglycosides) and
lower Vd for lipophilic drugs (eg, ﬂuoroquinolones and
macrolides) relative to adults. Similarly, decreased plasma
protein binding in neonates increases the unbound drug
concentrations resulting in increased Vd [24], especially for
highly protein-bound drugs (eg, ceftriaxone and teicoplanin).
These physiologic alterations limit the use of neonatal PK
data to guide pharmacotherapy in adults.
Extracorporeal membrane oxygenation circuits probably
represent another PK compartment because they are thought
to sequester signiﬁcant amounts of drugs, thereby increasing
Vd [41,43]. Hemodilution from priming solutions on
commencement of ECMO, ongoing blood product trans-
fusions, and administration of volume to maintain circuit
ﬂows may all increase Vd, particularly for hydrophilic drugs.
Although hemodilution can often enhance the pharmacolog-
ic effect of highly protein-bound drugs by increasing the
unbound fraction of the drugs, redistribution of the free drug
into tissues may result in lower serum concentrations.
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in pH, which may lead to further alterations in protein
binding and drug distribution [33]. As with critically ill
patients not receiving ECMO, inﬂammation, ﬂuid shifts,
renal dysfunction, and ﬂuid retention can all lead to an
increased Vd. Up-regulation of the renin-angiotensin system
during a nonpulsatile circulation as in VA ECMO may
signiﬁcantly alter renal handling of ﬂuid and electrolytes,
resulting in increased circulating blood volume and, thereby,
Vd [44].
3.3. Extracorporeal membrane oxygenation and
drug clearance
Extracorporeal membrane oxygenation is associated with
reduced drug elimination and is thought to occur by several
mechanisms, in addition to those related to critical illness.
The incidence of renal dysfunction (serum creatinine
concentration N1.5 mg/dL) in adults has been reported as
32% and 47% for VV and VA ECMO, respectively [15].
Patients subjected to ECMO often have a preceding hypoxia/
hypoperfusion-related insult to their kidneys. Pulseless
perfusion of the kidneys during VA ECMO may be
associated with a decrease in glomerular ﬁltration [45].
However, available studies show similar elimination half-
lives for gentamicin in infants receiving VA and VV ECMO
[46], questioning the relevance of a pulsatile circulation in
the development of a kidney injury and altered PK.
Decreased clearance (CL) of drugs (eg, aminoglycosides
and β-lactams) during ECMO as demonstrated in neonatal
studies should, once again, be interpreted in the light of
immature glomerular and tubular functions [24]. It should be
noted that the hepatic metabolism for drugs in neonates
differs signiﬁcantly from that in adults because the
enzymatic pathways are still in the process of maturation,
resulting in reduced CL rates of those drugs (eg, macrolides
and linezolid), for which metabolism is a signiﬁcant
mechanism for elimination [47]. There may be alterations
in regional liver blood ﬂows, which can also affect CL of
drugs, especially those with a high extraction ratio [33].
Decreased pulmonary blood ﬂows [48], especially during
VA ECMO, may affect sequestration and metabolism of
many sedative and analgesic drugs by the lungs [49]. Drug
removal by the ECMO circuit may reduce the bioavailability
of the ﬁrst dose of a drug and also affect the overall CL of a
drug [36]. Decreased elimination predisposes patients to
drug toxicities, especially for drugs that have a narrow
therapeutic index.
3.4. Extracorporeal membrane oxygenation and
renal replacement therapy
The Extracorporeal Life Support Organisation recently
reported that up to 50% of patients on VV ECMO and
41% on VA ECMO may require some form of renalreplacement therapy (RRT) during the ECMO run [15].
Characterizing altered PK in patients receiving RRT while
on ECMO can be complex. Variability in the techniques
used for RRT and ECMO is a signiﬁcant limitation to PK
modeling. Although in vitro circuit studies may provide
insights into interactions between 2 independent ECCs,
population PK studies in patients receiving RRT on ECMO
may guide clinicians until such data become available.
However, given the paucity of data in this regard, most
clinical approaches are theoretical rather than evidence
based. Available studies have shown a signiﬁcant variabil-
ity that highlights the importance of therapeutic drug
monitoring [50]. Surprisingly, some drugs in the setting of
ECMO and RRT in infants and young children, such as
ribavirin and ticarcillin, are not recommended to have dose
adjustments, which may predispose to clinical failure
[50,51]. More research is needed to guide effective dosing
in the presence of this common cotreatment of ECMO in
critically ill patients.4. Pharmacokinetics of drugs commonly
prescribed during ECMO
As discussed previously, ECMO has the potential to
alter the PK of many drugs, although existing data are
almost exclusively available only for sedatives, analgesics,
and antibiotics.
4.1. Sedatives and analgesics
Extracorporeal life support (ECLS) is a highly invasive
treatment for patients who have failed conventional treat-
ment, and optimal sedation for this complex group of patients
is not clearly deﬁned. Evidence-based practices such as use
of sedation protocols [52], allowing lighter sedation with
daily interruptions [52-54] and minimizing administration of
paralytic agents, have all been shown to reduce morbidity in
critically ill patients. However, these practices may not
always be practical in a critically ill patient on ECLS. Apart
from the usual beneﬁts [55], sedation during ECLS
minimizes the risk of catheter malposition or accidental
dislodgement and coughing, which induces “suck down”
resulting in hemolysis within the circuit. Deep sedation and
paralysis may be required, especially early in the course of
VV ECLS, to optimize circuit ﬂows and ventilation and to
minimize oxygen consumption.
In clinical practice, it is observed that patients receiving
ECMO often have substantially higher sedative drug
dosing requirements than do corresponding patients not
on ECMO. There are no data on sedation practices in
adults during ECMO, and it is unclear if this increased
sedative dosing requirement is also present in neonates
[36,37,56]. Certainly, in neonates, PK variability can be
caused by non-ECMO factors including organ maturation
Table 1 Studies demonstrating the variability in Vd of
antibiotics during ECMO
Drug Vd during ECMO(L/kg) Reference
Gentamicin a 0.51-0.748 0.47-0.49
Vancomycin a 0.56–2.1 0.48-0.69
Ticarcillin a 0.26-0.27 0.26-0.27
Caspofungin b 0.137 0.13-0.16
Voriconazole b 1.38 1.39-4.6
Ceftriaxone a 0.73-3.02 0.39-0.45
The reference population comprises the critically ill neonates and adults
not on ECMO.
a Neonatal and pediatric studies.
b Adults [31,34,44,45,60-73].
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PK data can guide the clinician in rational drug dosing in
the presence of ECMO.
Neonatal studies consistently demonstrate a need to
escalate fentanyl doses with time. The reported fentanyl
dose range in these studies (9-71 μg kg−1 h−1) highlights the
variability involved [32]. Morphine is also a problem,
with one study reporting morphine CL as 0.57±0.3 L
kg−1 h−1 during ECMO, which nearly doubled to 1.05±
0.72 L kg−1 h−1 after its cessation [57]. The mean
serum morphine concentration during and after ECMO
was 87±58 and 35±17 μg/L, respectively. Metabolism to
morphine-3-glucuronide (the primary metabolite) and
morphine-6-glucuronide was found to be reduced in another
study [58]. The high serum levels, in part, reﬂect the higher
doses of morphine required clinically during ECMO. The
nonstandardized sedation practices during ECMO and the
presence of active metabolites add to the challenges in
interpreting these results. Variable data exist regarding the
degree of sequestration and CL of the 2 most commonly
used opioids, morphine and fentanyl, in neonates receiving
ECMO [59,60]. It appears that morphine may be superior to
fentanyl even after accounting for organ failures and the
presence of active metabolites because it has been reported
to provide superior analgesia compared with fentanyl, while
reducing drug withdrawal and length of hospital stay
signiﬁcantly [61].
A population PK model for midazolam and its major
metabolites in 20 neonates during VA ECMOwas developed
by Ahsman and colleagues [62]. The dose requirement
increased substantially after 5 to 7 days despite accumulation
of the metabolite 1-hydroxy midazolam glucuronide during
ECMO, up to 34% after 7 days. The Vd for midazolam
increased from 4.2 to 14.0 L/kg on the commencement of
ECMO. A similar study found a signiﬁcant increase in Vd
and plasma half-life for midazolam and its metabolite 1-
hydroxyl midazolam [63]. Dose concentration relationships
of midazolam in 20 neonates undergoing VA ECMO
demonstrated an increased midazolam requirement in ﬁrst
24 hours of ECMO [64]. Similar effects have been observed
with lorazepam [36,43]. The results from these studies
should be interpreted in the light of altered PK in the neonatal
population but do suggest that larger drug doses may be
required with ongoing ECMO prescription.
There are limited data on other sedative agents used in
the intensive care unit (ICU). Propofol, which is
lipophilic and highly protein bound, is signiﬁcantly
sequestrated in the circuit. In vitro studies have shown
recoveries of 65% and 25% of predicted concentrations at
5 and 120 minutes after the addition of propofol into the
circuit [65]. The degree of variability and limited PK data
at present make it difﬁcult to develop any evidence-based
guidelines for the use of sedative agents for patients on
ECMO, although, it may be prudent to slowly taper
opioid and benzodiazepine dosages after decannulation to
prevent withdrawal.4.2. Antibiotics
Antibiotics are commonly prescribed drugs in ICU, and
often, the success of ECMO may rely on the success of
antibiotic therapy. Unfortunately, PK data in adult patients on
ECMO are sparse. Neonatal and animal studies are available
but have shown signiﬁcant variability and unpredictability of
antibiotic PK during ECMO [32,35,46,50,66-79] (Table 1).
However, no dosing guidelines exist for this group of
patients. Vancomycin and gentamicin have been subject to a
number of neonatal PK studies [46,66,74,75]; however,
changes in ECMO technology over the last decademake them
less relevant to current practice.
The PK of cefotaxime and its active metabolite,
desacetylcefotaxime, was described in 37 neonates receiving
ECMO [80]. The standard cefotaxime dose regimen (50 mg/
kg of body weight twice a day [postnatal age, or PNA], b1
week), 50 mg/kg 3 times a day (PNA, 1-4 weeks), or 37.5
mg/kg 4 times a day (PNA, N4 weeks) provided sufﬁciently
long periods of supra-minimum inhibitory concentration to
provide adequate treatment of infants on ECMO. Neonatal
PK studies of gentamicin have demonstrated an increase in
the Vd for gentamicin (0.43-0.66 L/kg), a lower CL (41.0-
101.4 mL kg−1 h−1), and a prolonged elimination half-life
(5.2-12.9 hours) [32,35,46,66-69]. Clinically, it is recom-
mended to monitor gentamicin levels and extend the dosing
intervals where necessary for patients on ECMO.
Neonatal studies have uniformly shown an increase in Vd
for vancomycin (0.27-1.6 L/kg). A population PK model of
45 patients including term neonates, older children, and
adults conﬁrmed that the CL of vancomycin was decreased
and its Vd increased in patients receiving ECMO [75].
Interestingly, age- and weight-matched neonates on ECMO
and controls did not have any signiﬁcant differences in Vd and
CL, although an increased elimination half-life was present
[74]. Other studies on neonates support a lowerCL (0.78±0.19;
range, 0.49-1.07 mL min−1 kg−1) and, consequently, a longer
vancomycin half-life [73,74]. Loading doses are suggested
(20-30 mg/kg) to account for the larger Vd, with therapeutic
drug monitoring (TDM) recommended to guide maintenance
741.e15Pharmacokinetic changes in patients receiving ECMOdosing in patients receiving ECMO until further PK data
become available.
In clinical studies, adequate caspofungin peak (11.9
μg/mL) and trough levels (3.7 μg/mL) were maintained
during ECMO [72]. However, being more lipophilic,
voriconazole was signiﬁcantly sequestered in the circuit,
necessitating higher doses of the drug to maintain
adequate trough levels. Mehta et al [41] reporting a
71% loss of voriconazole in the circuit, which is highly
relevant because of the association between voriconazole
trough blood levels and outcome. A problem of this
circuit loss may be the circuit saturation that occurs with
time, meaning that the initial high doses should be later
decreased to avoid drug toxicity [70,72,81]. TDM of
voriconazole is suggested to guide this dosing.
Oseltamivir PK was not signiﬁcantly inﬂuenced by
ECMO in inﬂuenza A–infected children (0-18 years).
There was an increase in oseltamivir carboxylate plasma
concentrations consistent with a higher dose of oseltamivir
used to counter expected decreased plasma drug concentra-
tions during ECMO (b15 kg: 60 mg/d every 12 hours, 15-23
kg: 90 mg/d every 12 hours, 23-40 kg: 120 mg/d every 12
hours, and N40 kg: 150 mg/d every 12 hours) [82].
Intravenous ribavirin (20 mg/kg per day) was administered
to a neonate with disseminated adenovirus infection
requiring ECMO and hemoﬁltration. Despite plasma con-
centrations at steady state being low (4.81 to 8.47 μg/mL),Table 2 Summary of PK changes during ECMO and their clinical im
Changes in PK Therapeut
Priming/transfusion
Hemodilution ↑ Vd ↑ Loading
↓ Cmax
↑ Free drug concentrations ↑ Loading
↑ Frequen
Circuit-related factors
Drug sequestration ↑ Vd ↑ Loading
↓ Cmax
Drug inactivation ↑ CL ↑ Frequen
with circu↓ Bioavailability
Patient factors
Systemic
inﬂammation/sepsis
↑ Vd ↑ Loading
↓ Cmax
↑ CL
Organ failures ↓ CL ↓ Frequen
↑ Vd
Drug factors
Hydrophilicity ↑ Vd ↑ Loading
↓ Cmax ↑↓ Freque
↑↓ CL (dependent on
renal function)
Lipophilicity Vd largely unchanged ↑ Loading
↑ Circuit sequestration ↑ Frequen
↓↑ CL (dependent on
hepatic function)
Cmax indicates peak concentrations.results of viral cultures were negative within 48 hours of
initiation of ribavirin therapy [51]. Although these are only
small case studies and case series, the data may be useful for
the clinical use of these drugs.
The variations in antibiotic PK in these patients are
concerning. Although therapeutic failure and toxicity add
to the morbidity and mortality of an individual patient in
ICU, emergence of resistant microorganisms [83,84] may
have much wider implications, including those who never
require ECMO.
4.3. Other drugs
There are limited data available regarding the PK of other
drugs. The estimated CL for theophylline in term neonates
supported by ECMO was signiﬁcantly lower, and Vd higher,
as compared with patients of similar age not receiving
ECMO [85]. TDM is widely available for theophylline and
should be used in the presence of ECMO.
Signiﬁcant loss of frusemide in the circuit components has
been reported in in vitro studies [86], which may explain why
frusemide infusions were shown to be effective in a neonatal
study [87]. This is signiﬁcant because patients on VV ECMO
often receive diuretics to minimize their extra vascular lung
water and improve pulmonary compliance. Given that that
this drug is dosed to clinical end points, prescribers should be
aware that larger-than-usual doses may be required in theplications
ic implication Drugs affected
dose Hydrophilic drugs, eg, β-lactams
and aminoglycosides
dose Highly protein-bound drugs,
eg, teicoplanin and ceftriaxonecy
dose Lipophilic drugs, eg, ﬂuoroquinolones
fentanyl, and midazolam
cy regarding dose
it changes
dose Hydrophilic drugs, eg, β-lactams and
glycopeptides
cy Renally or hepatically excreted drugs
dose For example, β-lactams aminoglycosides
ncy
dose For example, ﬂuoroquinolones,
macrolides, and propofolcy
741.e16 K. Shekar et al.presence of ECMO. Limited data indicate that no dose
adjustments are required for neonates on ECMO [88].
A study on 13 term neonates with stable renal and hepatic
function who were treated with ECMO concluded that
standard ranitidine doses do not need to be administered
more frequently than every 12 hours [89].
Heparin PK was studied in 5 infants during ECMO and
demonstrated that more than one half of the administered
heparin is eliminated by the extracorporeal circuit itself or by
blood components in the circuit [90]. This may have
signiﬁcant implications because anticoagulation on ECMO
still remains a challenge and is, perhaps, one of the reasons
that make ECMO a high-risk therapy. It is unclear if newer
heparin-bonded circuits exhibit any heparin adsorption.
Despite of this, standard activated partial thromboplastin
time monitoring is essential for heparin in these patients and
more frequent monitoring may even be appropriate while
individualized patient doses are being identiﬁed.
Other data suggest that ECMO may also be associated
with loss of vital trace elements, vitamins, micronutrients and
macronutrients, and hormones [91,92]. A summary of the
key PK changes during ECMO and their clinical implications
can be found in Table 2.5. Future directions
There is an urgent need to more fully elucidate the
behavior of drugs during ECMO. This review is valuable
because it summarizes the data presently available while
highlighting the areas in need of further research. Relative
quantiﬁcation of the contributions of the drug, device, and
disease to the altered PK in a patient on ECMO is
challenging. Systematic research using in vitro circuit
models, animal models of ECMO, and clinical population
PK studies may be required to optimize drug therapy during
ECMO. These studies should focus on identifying drugs,
developing dosing regimes that are most suitable for use
during ECMO, and developing circuitry that has the least
inﬂuence on PK. In the interim, PK modeling of routinely
used drugs may help procure drug dosing strategies that will
increase the likelihood of achieving optimal pharmacologic
effects. It is also important to standardize ECMO circuitry for
the PK data to be widely applicable. Clearly, more research is
needed to make ECMO a standard of care rather than a
therapy of high risks.References
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3.1 KNOWLEDGE GAPS 
Following review of the literature, the following major knowledge gaps were identified; 
1. Current antimicrobial and sedative drug dosing on ECMO is arbitrary.  
2. There is a paucity of PK data in adult ECMO. 
3. PK alterations in neonatal and premature infants may represent developmental issues. 
4. Available in vitro and ex vivo mechanistic data uses out-dated technology and is not 
relevant. 
5. There is minimal in vivo mechanistic data to describe the interplay between drug, 
device and disease factors. 
6. No dosing recommendations exist for antibiotic and sedative drug dosing in this 
complex group of patients receiving ECMO. 
 
3.2 HYPOTHESIS 
ECMO represents a supportive therapy, thus effective drug therapy to reverse the 
underlying disease is critical for a successful outcome. The hypothesis of this thesis is: 
 
 
ECMO alters the PK of sedative, analgesic and antimicrobial drugs and their metabolites 
independently of patient and pathological factors, thereby contributing to elevated risk of 
therapeutic failure, drug toxicity and/or an emergence of antibiotic resistance in critically ill 
adult patients on ECMO. 
 
3.3 AIMS 
The overall aim was to investigate the complex array of factors affecting PK during ECMO 
using an incremental approach51 to delineate the interrelationships between the Drug, 
Device and the Disease and develop evidence-based dosing guidelines for use in adult 
patients on ECMO. 
 
3.4 OBJECTIVES 
This research will characterise the PK of 18 important drugs (Chapter 4) used during 
ECMO utilising validated ex vivo and large animal models of ECMO52,53 ,efficient drug and 
metabolite assays54 and a multi-national population PK collaboration55. This mechanistic 
data can be translated into clinical practice rapidly, facilitating optimal pharmacotherapy, 
minimizing the risk of therapeutic failure and the rise of antibiotic resistance from  
sub-therapeutic concentrations. 
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4.1 THE ECMO PK PROJECT: AN INCREMENTAL RESEARCH APPROACH TO 
ADVANCE UNDERSTANDING OF THE PHARMACOKINETIC ALTERATIONS AND 
IMPROVE PATIENT OUTCOMES DURING EXTRACORPOREAL MEMBRANE 
OXYGENATION. 
 
4.1.1 Introduction to this publication 
This chapter describes a holistic approach to a challenging clinical problem. Critically ill 
patients have significantly altered PK Isolating the independent effects of ECMO on PK in 
such patients is nearly impossible. ECMO creates a bio-synthetic interface between the 
circuit and the patient and the dynamic interactions between drug, device and the disease 
process may result in profound PK alterations. All these factors need to be investigated in 
isolation and then in the clinical setting in totality to improve mechanistic understanding 
and to develop population PK models that will inform the development of dosing guidelines 
for adult patients receiving ECMO. This chapter provides a detailed outline of research 
methods and also cites other methodology papers that are not included in this thesis. 
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Extracorporeal membrane oxygenation (ECMO) tem-
porarily supports patients with severe cardio-respiratory
failure that is not responsive to maximal conventional
treatment [1-4]. Following the 2009 H1N1 pandemic,
ECMO has re-emerged as a versatile device that not
only provides cardio-respiratory support when medical
therapy fails but also compliments existing mechanical
cardiopulmonary assist devices, heart /lung transplant-
ation, cardiology and hospital based cardiopulmonary
resuscitation services effectively. As ECMO is a sup-
portive therapy, effective drug therapy directed at re-
versing the underlying disease is critical to ensure
successful liberation from ECMO. Indeed, the clinicians
applying ECMO recognise that contemporary use of
this therapy is far from perfect with patients suffering
ongoing morbidity because the clinicians are no longer
able to confidently achieve the desired effects from
pharmacotherapies. Published data demonstrates that
ECMO dramatically affects pharmacokinetics (PK) in
the most severely ill patients who already have signifi-
cant PK changes [5-8].
It is essential that each of the drug, device and dis-
ease factors affecting PK during ECMO (Figure 1) is
studied to improve treatment and outcomes of pa-
tients. We hypothesise that ECMO negatively alters
the PK of sedative, analgesic and antibiotic drugs and
their metabolites independent of patient and patho-
logical factors, thereby contributing to elevated risk
of therapeutic failure, drug toxicity and/or an emer-
gence of microbial resistance in critically ill patients
receiving ECMO. Our aim is to use an incremental
research approach that include studies investigating
drug, circuit and critical illness factors in isolation
and combined to arrive at meaningful conclusions.DISEASE
DRUG DEVICE
PATIENT
PK
Figure 1 Three D’s affecting pharmacokinetics during ECMO.ECMO circuits are not passive conduits for blood
In critically ill patients not receiving ECMO, it has been
shown PK changes can result in highly significant
changes to drug exposure through interactions between
the patient, pathology and the drug [9-12]. The ECMO
system introduces additional variables, which are the cir-
cuit itself, and the effects of systemic inflammation due
to the prolonged use of an extracorporeal circuit. Seques-
tration of drugs in the circuit, increased volume of distri-
bution (Vd) and decreased clearance (CL) are the major
PK changes associated with ECMO [8], although the ex-
tent of change remains poorly characterised. Published
data from neonatal circuit studies highlight the influence
that drug properties such as molecular size, degree of
ionization at physiological pH, lipophilicity and plasma
protein binding have on drug disposition during ECMO
[13,14]. In a manner analogous to the lung it mimics,
ECMO is critically dependent upon the large surface area
of the oxygenator and associated tubing to ensure ad-
equate blood flows through the circuit and facilitate gas
transfer. This bio-synthetic interface results in significant
sequestration of the administered drugs resulting in a
compartmental effect on PK (Figure 2). The type and age
of circuit components including type of the pump, oxy-
genator and tubing as well as circuit priming may influ-
ence the level of drug sequestration [15-18]. Patient
factors such as systemic inflammation, haemodilution,
bleeding and transfusion, organ dysfunction and renal re-
placement therapy all add to the clinical challenges of
drug dosing during ECMO [8].
The burden of altered pharmacokinetics during ECMO
There is increasing awareness of the implications of altered
PK during critical illness in adult patients [19-21]. The PK
changes during critical illness appear to be magnified dur-
ing ECMO. This can affect any drug, however given the
scientific and clinical PK gap, robust PK data for sedative,
analgesic and antibiotic drugs are urgently required.
Excessive sedation use and related morbidity
Sedation practices in the ICU are changing and emerging
data supports its judicious use [22,23]. Neonatal studies
consistently demonstrate a need to escalate sedative doses
during ECMO [13,24-26]. In a retrospective review of 30
patients [7], the average 24-hourly dose increased by
18 mg per day for midazolam (95% CI: 8, 29 mg, p=0.001)
and 29 mg per day for morphine (95% CI: 4, 53 mg,
p=0.021) from the first day of ECMO. The VV group re-
quired a daily midazolam dose that was 157 mg higher on
average than the VA group (95% CI: 53, 261 mg, p=0.005).
Patients often received up to 1500 mg of morphine and
midazolam per day despite supplemental sedation with
propofol, dexmedetomidine and thiopentone. By acting as
a reservoir, ECMO may also prolong the pharmacological
AB
C
Figure 2 Significant sequestration of drugs in the ECMO circuit increases their volumes of distribution leading to suboptimal drug
concentrations in the body. A mere increase in administered dose for all drugs during ECMO may not suffice, as the less sequestered drugs
may reach toxic levels. A - PVC tubing, B- pump, C- oxygenator (Reproduced with Permission, Shekar et al Journal of Crit Care 2012).
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is concerning as it is now well established that excessive
sedation in critically ill patients is associated with increased
mortality and morbidity [27].
Infection, antibiotic failure, drug toxicities and emergence
of microbial resistance
ECMO is a supportive therapy and not a disease modifying
treatment in itself. The success of ECMO, especially in pa-
tients with severe pneumonia or a pandemic viral respira-
tory illness relies heavily on the success of antiviral/
antibiotic therapy. Optimal antibiotic therapy in these pa-
tients is a balance between potency and exposure
[12,28-31]. A recent review of Extracorporeal Life Support
Organization (ELSO) data [32] revealed a total of 2,418 in-
fections during 20,741 (12%) ECMO cases. Infections in-
creased the duration of ECMO, post-ECMO ventilator
support and were associated with an increased risk of
death. Neonatal studies have reported severe PK variations,
however limited data is available to guide antibiotic therapy
in adults [13,16,33-37]. Sub-optimal prescription of antibi-
otics in patients on ECMO can worsen the problem by
selecting for resistant microorganisms [29].
Methods/design
A rational approach to understand the pharmacokinetic
changes
Although data from clinical studies of the impact of
ECMO on altering the PK of drugs used in patients onECMO will have great applicability for optimisation of
pharmacotherapy, mechanistic research is required to
identify the specific factors contributing to these PK
changes. To gain insight into these factors, research
using simulated circuits and large animal models are re-
quired so that individual variables can be altered in a
systematic manner enabling the impact of each change
to be quantified in an accurate and cost-effective
manner. Additionally, this will define the interplay be-
tween critical illness and the extracorporeal circuit
that result in altered PK during ECMO. The new
knowledge to be generated has major implications for
improving patient outcomes during ECMO therapy and
extracorporeal technology in general. A proposed re-
search plan that is being currently being implemented
uses an incremental approach as shown schematically
in and Figures 3 and 4. The study drugs are tabulated
in Table 1.
Drug factors
Ex vivo controls to examine baseline stability of drugs at
37°C is an important consideration in interpreting the
PK alterations during ECMO. Stability testing in fresh
human and sheep whole blood will be performed for all
study drugs (Table 1). This is critical as drug losses in
the circuit can only be meaningfully interpreted after
establishing stability. Preliminary results highlight this as
drugs such as meropenem [38] are highly unstable at
37°C.
Ex vivo drug 
stability at 
37oC
Studies in ex vivo ECMO circuits
(5 circuits per variable)
Studies in healthy sheep
(single/repeat dose PK)
Studies in critically ill sheep 
(single/repeat dose PK)
Clinical  
PK 
studies
Studies
Stability 
testing in 
fresh human 
(n=5) and 
sheep (n=5) 
whole blood
Human blood
(24 hrs)
Sheep blood
(24 hrs)
12 hr run
(single dose)
24 hr run
(re-dose)
12 hr run
(single dose)
24 hr run
(re-dose) PK 
studies in 
patients 
on 
ECMO
• Physiologic
• Re dose PK
• Flow rates 2.5  
vs. 5.0 L/min
• Circuit without 
oxygenator 
• Physiologic
• Hyperoxia
• Hypothermia
Ventilated Ventilated  
ECMO
Ventilated
S-ALI
Ventilated 
S-ALI 
ECMO
Sample 
size (n)
n=10 n=25 n=15 n=12 n=12 n=12 
Incremental Approach
Own controls Own controls
Figure 3 Proposed approach to quantify the PK changes and identify factors underlying these changes to inform the development of
guidelines for antibiotic and sedative drug therapy during ECMO. S-SLI-smoke inhalation acute lung injury.
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These studies will identify the PK changes attributable
to the circuit and drugs and will be used to describe sin-
gle and repeat dose kinetics in standard circuits.
Disposition of drugs in standard ECMO circuit
A validated ex vivo model of ECMO has been previously
published [38,39]. Briefly, Maquet PLS ECMO circuits
will be used (Maquet Cardiopulmonary AG, Hechinger
Straße, Germany). A reservoir bladder (Medtronic R38)
will allow sampling from the closed circuit (Figure 5).
The circuit will be primed with Plasmalyte, 4% albumin
followed by fresh whole blood to obtain a post oxygen-
ator pressure of 230–250 mmHg. The final estimated
volume of the pressurised circuit is 668 mL. A centrifu-
gal pump maintained a circuit flow rate of 4–5 L /min.
Oxygen tension and circuit temperature and pH will be
maintained at 100–150 mm Hg and 37°C. Carbon diox-
ide gas or sodium bicarbonate solution will be added toEx vivo drug 
stability
testing
Disposition in
ex vivo 
circuits
Healthy 
sheep
on ECMO
Drug factors Circuit factors Critical illness 
MECHANISTIC
Figure 4 Proposed methods to understand the pharmacokinetic chan
oxygenation (ECMO).the circuit to maintain the pH of the circulating blood in
the range 7.25–7.55. Study drugs (Table 1) will be
injected post oxygenator to achieve clinically relevant
concentrations in the circuit. Serial samples will be
obtained post oxygenator over 24 hours. For re-dose PK
studies, study drugs will be reinjected at 6, 8 or 12 hours
(as per clinical dosing guidelines). This will further in-
vestigate potential saturation of the circuit with time
and its affect on drug disposition during ECMO.
Disposition of drugs in modified ECMO circuit
Circuit primed with fresh whole human Blood
Circuit without oxygenator These studies will exam-
ine the role of the oxygenator in sequestering drugs
in the ECMO circuit. By comparing the data from
standard ECMO circuit experiments, the relative con-
tribution of the oxygenator may be quantified. It has
been established in neonatal circuit studies that theCritically ill 
Patients on
ECMO
Critically ill
sheep on 
ECMO
factors Population PK
TRANSLATIONAL
Develop 
dosing 
guidelines
Improve outcomes
ges and optimise drug therapy during extracorporeal membrane
Table 1 Study drugs for which mechanistic and clinical pharmacokinetic (PK) data will be generated
Studies Sedatives & analgesics Antivirals /antifungals Antibacterials
Ex vivo stability Morphine Fluconazole Ceftriaxone
Ex vivo circuits Morphine -3 -glucuronide Caspofungin Meropenem
Ovine ECMO Morphine -6 –glucuronide Vancomycin
Population PK Fentanyl, nor-fentanyl Ciprofloxacin
Midazolam Gentamicin*
1 & 4 hydroxy midazolam
Ex vivo stability Propofol ,Thiopentone Oseltamivir Piperacillin/tazobactum Ticarcillin/clavulunate
Population PK Dexmedetomidine Voriconazole Cefepime, Linezolid
OC –oseltamivir carboxylate. * Gentamicin will not included in the ex vivo circuit studies due to its incompatibility with other study drugs.
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drug PK [15].
Circuit at varying flow rates (2.5 and 5.0 L/min)
Flow rates are thought to influence PK [40], however
this has not been adequately tested. Higher ECMO
flows usually reflect greater severity of illness and
identifying the PK alterations is essential to maximise
the chances of survival in this very unwell subgroup
of patients. This experiment will also provide insightA
B C
D
E
Figure 5 Ex vivo ECMO circuit model. A -reservoir bladder,
B- oxygenator, C- centrifugal pump, D-drug injection and sampling
port, E- circuit tubing.into whether or not flow rate adjusted standardisation
of drug therapy is required.
Circuits primed with fresh whole sheep blood
Circuit under hyperoxic conditions (PaO2 300–400 mm Hg)
Hyperoxia is not uncommon in patients receiving ECMO
[41]. Hyperoxic conditions may affect PK by changes in the
catalytic activity of drug metabolising enzymes and changes
in membrane permeability, affecting drug distribution [42].
Carbon dioxide gas or sodium bicarbonate solution was
added to the circuit to maintain the pH of the circulating
blood in the range 7.25–7.55.
Circuit under hypothermic conditions (32–34°C)
Hypothermia can affect PK significantly [43,44] however
there is limited published data. Circuits will be primed
with sheep blood as it is relatively easy to replicate an
in vivo experiment if required in sheep. The cooling de-
vice (Jostra™ Heater-Cooler Unit HCU 30 A) will be
added to the ECMO circuit to induce hypothermia. This
is relevant as patients on ECMO following CPR often
receive therapeutic hypothermia as part of their post
resuscitation care. Hypothermia may sometimes be in-
duced to minimise oxygen consumption during VV
ECMO. Patients on cardiopulmonary bypass are rou-
tinely exposed to hypothermia. Understanding the ef-
fect of hypothermia on PK is an important aspect for
optimisation of drug dosing during ECMO.
Host factors
Healthy and critically ill controls
Baseline PK samples will be obtained from healthy
sheep and sheep with smoke inhalation acute lung in-
jury (S-ALI) over a 12 hour period prior to commence-
ment of ECMO. In an appropriately equipped theatre, a
central venous line will be placed in the right internal
jugular vein (IJV) under local anaesthesia. Alfaxalone,
ketamine and midazolam was used for induction and
maintenance of anaesthesia. Buprenorphine 0.01 mg/kg
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be intubated and ventilated with a Hamilton Galileo ven-
tilator (Hamilton Medical AG). The facial artery will be
cannulated for invasive arterial blood pressure monitor-
ing. A pulmonary artery catheter will provide continuous
measurements of the central venous pressure, mixed
venous saturation and cardiac output (CO). Additional
sheaths will be placed in both IJV to facilitate ECMO
cannulation and intra-cardiac echo (ICE). Sedative study
drug infusions will be titrated to clinical effect. Antibi-
otics will be infused over 30 mins and serial blood sam-
ples will be obtained for drug assays using validated
LC-MS/MS methods, and subsequent PK analysis.
For critically ill control sheep, S-ALI will be induced
using a validated, reproducible technique that has been
published [45]. Briefly, a stainless steel plate will be
heated to 750°C and placed on top of 8 g of cotton in a
cup. The smoke resulting from combustion will be de-
livered to the sheep by manual compression of the bel-
lows (tidal volume VT, 10–12 mL/kg) to achieve a
carboxyhaemoglobin content of 45–50% is achieved.
The sheep will be ventilated using ARDSNet criteria
(VT 4–6 ml/kg, PEEP 10–15 cm H2O) for lung protect-
ive ventilation [46]. Sedative study drug infusions will
be titrated to clinical effect. Antibiotics will be infused
over 30 mins and serial blood samples will be obtained
for drugs assays using validated LC-MS/MS methods,
and subsequent PK analysis. Such an approach will pro-
vide insights into the effects of critical illness on seda-
tive and antibiotic drug PK.
Healthy sheep on ECMO
Following 12 hours of ventilation and PK sampling the
healthy control sheep will be maintained on ECMO for
24 h. We have recently published a detailed description
of our ovine model (Figure 6) of ECMO [39]. Cannula-
tion will be performed in the supine position by rewir-
ing the previously placed IJV venous sheaths. A 21Fr
(50 cm) femoral Carmeda Bioactive Surface coated
(CBASW) venous cannula (Medtronic Inc, Minneapolis,
MN, USA) will be inserted into the right IJV using a
Seldinger technique and positioned using intra cardiac
echocardiography (ICE) [47] in the proximal inferior
vena cava (IVC). A 19Fr (50 cm) Carmeda coated fem-
oral venous cannula will be used for return blood and
also inserted in the right IJV and positioned at the mid
right atrium using ICE. Pump speeds will be titrated to
target flows at least 2/3rd of pre-ECMO CO (or 60–
80 mL/kg). Sedative study drug infusions will be ti-
trated to clinical effect. Antibiotics will be infused over
30 mins upon commencement of ECMO and at 8 and
12 h (for re-dose PK) to obtain serial blood samples
for drug assays using validated LC-MS/MS methods,
and subsequent PK analysis.Critically ill sheep on ECMO
After 12 h of lung protective ventilation, the control
S-ALI sheep will be maintained on ECMO for 24 h. Can-
nulation, ECMO set up and initiation of ECMO have
been described in earlier sections. Sedative study drug in-
fusions will be titrated to clinical effect. Antibiotics will
be infused over 30 mins upon commencement of ECMO
and at 8 and 12 h (for re-dose PK) to obtain serial blood
samples for drugs assays using validated LC-MS/MS
methods, and subsequent PK analysis. Upon completion
of these studies, PK data from critically ill sheep on
ECMO will be compared with data from controls and
healthy sheep on ECMO to obtain crucial PK data that
will inform our understanding of the factors underpin-
ning the PK changes induced by ECMO that is distinct
from the impact of critical illness itself.
The physiologic data collection for the sheep experi-
ments will include; weight, advanced haemodynamic and
respiratory monitoring data, ECMO flow rates, urine
output, fluid balance, inotrope and vasopressor use and
blood loss if any. Eight hour urinary creatinine clearance,
serum creatinine, serum total protein, serum albumin,
alpha1-acid glycoprotein, serum bilirubin, alanine ami-
notransferase (ALT) measurements will be performed
prior to (controls) and during ECMO. Pharmacokinetic
studies in critically ill patients on ECMO.
An international multi-centre, clinical PK study [48]
will enrol critically ill patients admitted to the inten-
sive care units in Australia and New Zealand. The
study centres include; The Prince Charles Hospital,
Brisbane, St Vincent’s Hospital, Sydney; The Alfred,
Melbourne; Auckland City Hospital, Auckland and
Princess Alexandra Hospital, Brisbane. Informed con-
sent will be obtained from the patients or from their
next of kin as appropriate. A total of 10–12 patients
will be enrolled for each study drug (Table 1) for this
descriptive study. Sedative drugs will be titrated to
clinical sedation scores and bispectral index. Anti-
biotic drug selection and dosing is at the discretion of
the treating clinicians. In some patients, blood sam-
ples relating to only antibiotics may be collected,
whereas in other patients, samples for analysis of an-
algesics and sedatives may also be collected. Patient
selection will be based on the below criteria;
Inclusion criteria
 Age > 18 years and < 90 years
 Currently undergoing ECMO for respiratory and/or
cardiac dysfunction
 Clinical indication for the antibiotics listed in
Figure 3
 Clinical indication for the sedatives and analgesics
listed in Figure 3
Figure 6 Validated ovine ECMO model. Reproduced with permission, Fung et al, ISBT Science Series 2012.
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 No consent
 Known allergy to study drug
 Pregnancy
 Serum bilurubin > 150 μmol/L
 Ongoing massive blood transfusion requirement
(> 50% blood volume transfused in the previous
8 hours)
 Therapeutic plasma exchange in the preceding
24 hours
Our clinical service model of ECMO has been recently
published [49]. Feasibility studies are now completed
and the study protocol has now been validated and pub-
lished [48]. Eight hour urine creatinine or effluent cre-
atinine (in patients on renal replacement therapy [RRT])
will provide estimates for renal clearance. Plasma assays
and PK modelling will be undertaken for the study drugs
(Table 1) using techniques described below.
PK sample analysis
To reduce the sample burden per patient, validated
bioanalytical methods are required to quantify multiple
drugs and their metabolites selectively and sensitively
in small volumes of plasma. A validated bioanalytical
method that uses a fully automated on-line solid phase
extraction (SPE) system (Symbiosis, SPARK Holland)
combined with liquid chromatography-mass spectrom-
etry (LC-MS/MS –API 5000) to simultaneously quan-
tify morphine, morphine 3-β-D-glucuronide, morphine
6-β-D-glucuronide, midazolam, 1- hydroxymidazolam,
4-hydroxymidazolam, fentanyl and nor-fentanyl in samples
of human plasma has been developed [50]. The techniquewill also be expanded to analyse propofol, thiopentone
and dexmedetomidine. This approach enables simultan-
eous measurement of the plasma concentrations of these
molecules of interest with high accuracy and precision in
a single specimen. Previously developed and validated
antibiotic assays (HPLC and LC-MS/MS) will be used in
these studies.
PK modelling and statistical analysis
The sample size calculations used 10 circuits/subjects,
with 10 observations over time per circuit/subject, and
an 80% power with a 2-sided 5% significance level. The
detectable differences over time are on a standardised
scale (Cohen’s d). The within correlations are from pre-
vious data. We have the power to detect relatively small
changes with our small sample sizes because of the mul-
tiple observations per circuit/subject.
Circuit studies
Data will be plotted over time and analysed for statisti-
cally significant temporal losses. Mixed-effects regres-
sion models with random slopes will be used to estimate
the loss over time. Octanol-water partition coefficients
(log P) for the individual drugs are available from the
University of Alberta Drug bank website. We will exam-
ine the relation between the partition coefficients and
the extent of drug loss in the circuit using simple linear
regression. Correlation between log P values and drug
loss will be calculated by using two-sided Spearman test.
Animal and clinical studies
Data from these studies will be analysed using non-
linear mixed-effects models. This allows the estimation
of typical population PK parameters and their inter- and
Heat exchanger
RRT
ECMO
Figure 7 Challenges in drug dosing during extracorporeal
membrane oxygenation (ECMO). This critically ill patient received
concomitant venovenous ECMO, renal replacement therapy (RRT)
and induced hypothermia, all of which can significantly alter
pharmacokinetics of vital drugs.
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random variability. We will fit random intercepts and
slopes to allow for between patient differences in their
average response and changes over time. This modelling
allows us to visualise the average patient and individual pa-
tients. It also allows PK to be described in the absence of
fixed protocol times, making it ideally suited to calculate
PK parameters from drug concentration data collected at
with varying times during routine care. Differential equa-
tions will be used to describe the population PK of study
drugs and their metabolites expressed as PK parameters.
Where relevant, results will be normalised to a median pa-
tient bodyweight of 70 kg, using allometry.
Ethical considerations
Appropriate ethics approval has been obtained for all
the phases of the ECMO PK project,
 Ex vivo circuit experiments using human blood
(HREC/12/QPCH/90)
 In vivo ovine studies and ex vivo circuit experiments
that utilise sheep blood (approval no. 1100000053)
 Multi-site ethics approval for the clinical studies in
Australia (HREC/11/QPCH/121)
 Single-site ethics approval for the clinical study in
New Zealand (LRS/12/06/020)
Collaborating organisations
This project is co-ordinated by The Critical Care Re-
search Group at The Prince Charles Hospital in Brisbane,
Australia. This group will collaborate closely with The
Burns Trauma and Critical Care Research Centre, and The
Centre for Integrated Preclinical Drug Development, The
University of Queensland in Brisbane for antibiotic and
sedative drug assays. The Critical Care Research Group will
also collaborate closely with all clinical sites involved in the
multi-centre population PK study.
Discussion
This research will not only identify the drugs that are
most suitable for use during ECMO but our findings will
also inform the development of strategies for drug ad-
ministration using PK/PD principles in critically ill pa-
tients receiving ECMO. These patients receive a variety
of pharmacological and other extracorporeal therapies
such as RRT and these modalities have a potential to
interact with each other (Figure 7). A lack of under-
standing of the impact of ECMO on drug Vd and CL
predisposes to an increased likelihood of therapeutic fail-
ure or drug toxicity. PK modelling is crucial to drug
safety. The ECMO PK Project seeks to provide the key
information for development of evidence-based dosing
schedules and sedation protocols for use by clinicians
looking after patients receiving ECMO.Using the right sedative agent at an appropriate dose
may minimise ICU morbidity related to risk of infec-
tions, duration of mechanical ventilation and length of
hospital stay, inotrope and vasopressor requirement,
drug withdrawal, post traumatic stress etc. This not only
has resource implications but significantly affects patient
outcomes [27]. The clinical study will also evaluate the
adequacy of existing ICU sedation protocols as com-
pared to bispectral index monitoring and provide data to
inform recommendations for improving sedation prac-
tices during ECMO.
There is widespread consensus that in-hospital anti-
biotic resistance influences patient outcome and the
allocation of resources. Optimal antibiotic prescrip-
tion has significant implications not only for the pa-
tient on ECMO but also for other ICU patients and
the community in general. Antibiotic PK studies in
patients receiving ECMO will help the development
of dosing regimes that are effective against the micro-
organism, but not harmful to the patient. The right
dose of the right antibiotic will not only lead to im-
proved microbiological and clinical cure rates in an
individual patient, but also will reduce the emergence
of multi-resistant organisms.
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Systematic research that integrates both mechanistic and
clinical research is necessary when investigating the com-
plex area of pharmacokinetic alterations during ECMO.
The methods described in this paper will result in an ad-
vanced understanding of drug, circuit and critical illness
factors that influence PK during ECMO. This will allow
meaningful interpretation of clinical population PK data so
that rational and robust guidelines may be generated to
guide clinicians in optimising antibiotic, sedative and anal-
gesic drug therapy during ECMO. The research methods
described here are resource intensive and rely on extensive
collaborations. Hopefully such an effort can be extended to
comprehensively investigate many of the other complex is-
sues in intensive care practice.
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4.2 DEVELOPMENT OF SIMULATED AND OVINE MODELS OF EXTRACORPOREAL 
LIFE SUPPORT TO IMPROVE UNDERSTANDING OF CIRCUIT - HOST 
INTERACTIONS. 
 
4.2.1 Introduction to this publication 
This chapter describes the development of ex vivo and ovine models of VV ECMO that 
were crucial to an advanced mechanistic understanding of the PK changes. At that time of 
publication, this was the first ever report of a large animal model of VV ECMO. Prior to 
this, Zwischenberger et al 76 had published pathophysoiology of smoke inhalation in an 
ovine model of VA ECMO. It should be noted that VA ECMO is quite a contrasting 
extracorporeal life support technique used to support patients with predominant cardiac 
failure. VV ECMO is predominantly used for respiratory support2 and has significantly 
different pathophysiological consequences on the host when compared with VA ECMO. 
Equally, the ECMO circuit components used in our model are far more refined than those 
reported by Zwischenberger et al 20 years ago. Lung injury was induced by smoke 
inhalation in both these models. This allowed us compare the effects of smoke inhalation 
and VV ECMO on ovine pathophysiology with the effects of smoke inhalation and VA 
ECMO reported by Zwischenberger et al. Detailed pathophysiological comparisons 
between these models are outside the scope of this thesis and will be reported elsewhere.  
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research in this group of patients is challenging
multitude variables that are difficult to control in
study. Simulated extracorporeal circuits and in-
models provide valuable means to undertak
systematic research into complex clinical scenar
ECLS, and to identify strategies for optimis
interventions.Critical Care and Resuscitation  VABSTRACT
Background:  Extracorporeal life support (ECLS) is a life-
saving technology that is being increasingly used in patients 
with severe cardiorespiratory failure. However, ECLS is not 
without risks. The biosynthetic interface between the 
patient and the circuit can significantly alter inflammation, 
coagulation, pharmacokinetics and disposition of trace 
elements. The relative contributions of the pump, disease 
and patient in propagating these alterations are difficult to 
quantify in critically ill patients with multiple organ failure.
Objective:  To design a model where the relevance of 
individual components could be assessed, in isolation and in 
combination.
Design and subjects:  Four ECLS models were developed  
and tested — an in-vitro simulated ECLS circuit; and ECLS in 
healthy sheep, sheep with acute lung injury (ALI), and sheep 
with ALI together with transfusion of old or new blood.
Main outcome measures:  Successful design of in-vitro 
and in-vivo models.
Results:  We successfully conducted multiple experiments 
in the simulated circuits and ECLS runs in healthy and ALI 
sheep. We obtained preliminary data on inflammation, 
coagulation, histology, pharmacokinetics and trace element 
disposition during ECLS.
Conclusions:  The establishment of in-vitro and in-vivo 
models provides a powerful means for enhancing 
knowledge of the pathophysiology associated with ECLS 
and identification of key factors likely to influence patient 
outcomes. A clearer description of the contribution of 
disease and therapeutic interventions may allow improved 
design of equipment, membranes, medicines and 
Crit Care Resusc 2012; 14: 105–111
physiological goals for improved patient care.Use of extracorporeal life support (ECLS) in cardiorespiratory
failure refractory to maximal medical therapy is now well
described, and use in adults is increasing.1,2 Patients requir-
ing ECLS are a critically ill, although otherwise heterogen-
eous, cohort with varying diagnoses, age, body size and
degrees end-organ dysfunction. ECLS itself can induce
myriad additional pathophysiological changes. Clinical
, given the
 any given
vivo animal
e detailed,
ios such as
ing clinical
An ideal animal model should mimic the severity of
patient illness, reproduce key haemodynamic and immuno-
logical aberrations, serve as its own control, mimic histo-
logical findings in relevant organs, and provide a means to
gain insight into factors contributing to interpatient variabil-
ity.3 There are many well established ovine models used to
study clinically relevant interventions and pathological states,
such as cardiopulmonary bypass, myocardial reperfusion,
burn injury, sepsis and acute lung injury (ALI).4-16 These
models highlight the appropriateness of the use of sheep in
the study of human cardiopulmonary disease.
To assess the relative contribution of circuit factors to ECLS
ovine model outcomes, we have also established a validated
Abbreviations
ABP Arterial blood pressure
ACT Activated clotting time
ALI Acute lung injury 
CCO Continuous cardiac output 
CVP Central venous pressure
ECG Electrocardiogram
ECLS Extracorporeal life support  
ECMO Extracorporeal membrane oxygenation
ICE Intracardiac echocardiography
IJV Internal jugular vein
IVC Inferior vena cava 
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ORIGINAL ARTICLESin-vitro model of simulated ECLS using contemporary cir-
cuitry. Simulated circuits provide conditions that allow control
of one variable at a time, which is difficult to achieve in
animal and clinical studies. Hence, the aim of this study was
to develop and validate more extensive and informative
descriptors of ECLS using in-vitro and in-vivo models.
Methods
Establishment of a simulated model of extracorporeal 
life support
We used PLS ECLS circuits (Maquet Cardiopulmonary, Hirr-
lingen, Germany). This circuit comprises Bioline tubing, a
PLS Quadrox D oxygenator and Rotaflow pump head. An
R38 reservoir bladder (Medtronic, Minneapolis, Minn, USA)
was added to allow fluid sampling from the closed circuit.
The circuits were primed with 900 mL Plasma-lyte 148
(Baxter, Sydney, NSW, Australia), then exchanged for
500 mL Albumex 4 (human albumin, 40 g/L; CSL Bioplasma,
Melbourne, Vic, Australia). Porcine mucous heparin
(5000 U; Pfizer Australia, Sydney, NSW, Australia) was
added to the circuits. Fresh whole human blood (mean
volume, 420 mL [SD, 52 mL]) was used for the final prime to
obtain postoxygenator pressures of 230–250 mmHg. The
final circuit configuration is shown in Figure 1.
The final volume of the pressurised circuit was 668 mL
(SD, 2 mL) with a mean haemoglobin concentration of 64 g/
L (SD, 13 g/L). Activated clotting time (ACT) was maintained
between 220 and 250 seconds. A Jostra Rotaflow centrifu-
gal pump (Maquet Cardiopulmonary) was used
to maintain a circuit flow rate of 4–5 L/min.
Oxygen tension was maintained between 150
and 200 mmHg. Circuit temperature was main-
tained at 37C. Carbon dioxide gas or sodium
bicarbonate solution was added to the circuit to
maintain the pH of the circulating blood
between 7.25 and 7.55.
This simulated circuit model system was used
to study the effect of circuit factors on drug
concentrations, coagulation, inflammation and
platelet cell functions under standard physiologi-
cal conditions. In future, this model will incorpo-
rate variables that are of high relevance for a
patient on ECLS, such as hypoxia, hyperoxia and
hypothermia.
Establishment of an ovine model of 
extracorporeal life support
Establishment and validation of the ovine model
of ECLS was conducted with approval of the
Queensland University of Technology Animal
Ethics Committee (approval no. 1100000053).
An overview of the ECLS ovine model is pre-
sented in Figure 2. A summary of the key steps
(Figure 3) and rationale is outlined below.
Theatre set-up
The theatre was set up to incorporate all equip-
ment required to manage and monitor animal
health and wellbeing. The operating table was
equipped with a warming blanket to maintain
normothermia during chronic instrumentation.
A cradle was used to safely maintain the sheep’s
sternum in the recumbent position, and a “head
box” was used to immobilise the head and neck
in a natural position.
Figure 1. Simulated extracorporeal life support circuit model; 
circuits primed with fresh whole human blood
Figure 2. Overview of experimental model
ECMO = extracorporeal membrane oxygenation. PRBC = packed red blood cells. 
SALI = smoke-inhalation acute lung injury.
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ORIGINAL ARTICLESElectrocardiograms (ECGs), physiological and pump pres-
sures, saturation and end-tidal carbon dioxide were meas-
ured with a Marquette Solar 8000 monitor (GE Healthcare,
Little Chalfont, UK) and recorded at 5 s intervals using
custom software. Ventilation data were recorded on a
breath-by-breath basis using software provided by the
manufacturer (Hamilton Medical, Reno, Nev, USA), and
ECLS pump data were recorded at 5 s intervals using
custom software. Mixed venous saturation (SvO2) and
continuous cardiac output (CCO) were measured with a
Vigilance II Monitor (Edwards Lifesciences, Irvine, Calif,
USA) and recorded at 5 s intervals using software provided
by the manufacturer. Syringe drivers and large- and small-
volume infusion pumps were used for anaesthesia mainte-
nance and drug/fluid administration. A fibre-optic broncho-
scope was used to obtain bronchoalveolar lavage samples.
The operating theatre was set up as shown in Figure 4.
Venous access, induction of anaesthesia and airway 
management
The sheep were 18-month-old ewes and weighed 40–
45 kg. After fasting overnight, the animal was brought
into the preparation room in a sling with face, neck and
chest shaved. A multilumen central venous catheter and
8 Fr sheath were placed in the left internal jugular vein
(IJV) under local anaesthesia. Baseline blood samples
were taken. Anaesthesia was induced with intravenous
midazolam (0.5 mg/kg) and alfaxalone (3 mg/kg). The
animal was intubated with an orotracheal tube, brought
into the operating room and positioned in the left lateral
position; mechanical ventilation was commenced with
expired air capnography. The sheep was ventilated with a
Galileo ventilator (Hamilton Medical) using the Acute
Respiratory Distress Syndrome Network criteria for lung-
protective ventilation.17 No muscle relaxants were used.
Anaesthesia was maintained with infusions of alfaxalone
(4–6 mg/kg/h), midazolam (0.25–0.5 mg/kg/h), and keta-
mine (3–5 mg/kg/h). Doses were titrated to physiological
and clinical parameters such as arterial blood pressure
(ABP), heart rate, respiratory rate, central venous pressure
(CVP), jaw movements, loss of the eyelash reflex and limb
withdrawal response to ensure a constant surgical plane
and optimal depth of anaesthesia and analgesia. A bolus
dose of intravenous buprenorphine 0.01 mg/kg was given
for analgesia and subsequently every 6 hours. Three
venous sheaths (10 Fr) were introduced in the right IJV.
These would later be used for intracardiac echocardiogra-
phy (ICE) and extracorporeal membrane oxygenation
(ECMO) cannulation. A tracheostomy was performed
using a size 10 Portex (Smiths Medical, London, UK)
tracheostomy tube and the endotracheal tube removed.
The length of the sheep’s neck otherwise would prevent
adequate bronchoscopy.
Establishment of monitoring
Routine monitoring consisted of pulse oximetry, ECG, ABP,
CVP, pulmonary artery pressure and CCO. A pulmonary
artery catheter was inserted via the left IJV sheath to
measure CCO and SvO2. A urinary catheter and orogastric
tube were inserted. The facial artery was exposed and
cannulated under direct vision for ABP monitoring.
Figure 4. Operating room equipped for monitoring 
and organ support
Figure 3. Steps in development of an ovine model 
of extracorporeal life support
ECMO = extracorporeal membrane oxygenation.
Preparation: ethics, stafﬁng, animal selection, theatre
Access, anaesthesia, airway control, monitoring 
Smoke inhalation, lung-protective ventilation 
ECMO set-up, cannulation, intracardiac echocardiography
Maintenance of ECMO 
•  Anticoagulation 
•  Haemodynamic management 
•  Fluid and electrolyte management 
•  General supportive care 
Euthanasia and postmortem handling Critical Care and Resuscitation  Volume 14 Number 2  June 2012 107
ORIGINAL ARTICLESInducing acute lung injury
Our validated reproducible smoke-inhalation ALI method
was used and has been described in detail elsewhere.18
Briefly, a stainless steel plate is heated to 750C and placed
on top of 8 g of cotton in a cup. A bellows with transparent
walls and a tidal volume of 400 mL is placed on top. The
smoke from the combustion then passively fills the bellows.
The bellows are then compressed by hand, exhaling the
smoke through the base to a one-way valve, acting as one
tidal volume breath (10–12 mL/kg) to the sheep. Exhalation
is via a one-way valve, thus minimising rebreathing. Twelve
breaths are delivered with first load of cotton. After the first
cycle, new fuel is placed in the cup, and the process is
repeated with eight breaths per cycle. Blood gas analysis
provides both oxygenation details and carboxyhaemoglobin
content (target 45%–50%), which demonstrates the repro-
ducibility of the smoke “dose” between sheep.
Extracorporeal life support circuit set-up and cannulation
The circuits were primed with 900 mL Plasma-lyte 148
(Baxter) and then exchanged for 500 mL Albumex 4 (human
albumin, 40 g/L; CSL Bioplasma). The oxygenator was con-
nected to a water heater (Cincinnati Sub-zero, Cincinnati,
Ohio, USA) to maintain ovine normothermia (39C). A PLS
ECMO circuit was used (Maquet Cardiopulmonary AG). This
circuit comprised Bioline tubing, a PLS Quadrox D oxygena-
tor and Rotaflow pumphead. The circuit was primed with
900 mL Plasma-lyte 148 (Baxter), then exchanged for
500 mL Albumex 4 (CSL Bioplasma). Porcine mucous
heparin (1000 U; Pfizer Australia) was then added to the
circuit. The pump driver was a Bio-Medicus 550 Bio-
Console pump speed controller (Medtronic) with external
drive head. All data from the Bio-Medicus device were
captured using the serial data port. Precise mixing of air and
oxygen was achieved using a Sechrist air–oxygen mixer
(Sechrist Industries, Anaheim, Calif, USA).
Cannulation was performed in the supine position by
rewiring the previously placed venous sheaths. A 21 Fr
(50 cm) femoral Carmeda BioActive Surface coated venous
cannula (Medtronic) was first inserted into the right IJV
using the Seldinger technique and positioned using ICE in
the proximal inferior vena cava (IVC). After insertion of an
access cannula, 30 U/kg of unfractionated porcine heparin
(Pfizer Australia) was administered intravenously. A 19 Fr
(50 cm) Carmeda BioActive Surface coated femoral venous
cannula was used for return blood and also inserted in the
right IJV using the Seldinger technique and positioned at
the mid right atrium using ICE. Sheep femoral vessels are
too small for ECLS cannulation, whereas the jugular veins
are much more capacious. Arterial cannulae (25 cm) were
too short for this model.
On confirmation of correct cannula positioning, each
cannula was locked with unfractionated heparin (10 U/mL)
and saline, and anchored around the neck with white
endotracheal tube tape. Standard cyanoacrylate adhesive
was found to be very effective in fixation of the cannula,
but it limited any subsequent manipulation. The sheep was
then repositioned from the supine to the sternal recumbent
position. The clamped ECLS circuit was connected to the
access and return cannulae. The pump speed was dialled to
1000 rpm before releasing the clamps. Pump speed was
further increased to target flows at least two-thirds of pre-
ECLS cardiac output (or 60–80 mL/kg). Gas flow was set to
80% of pump flows and inspired oxygen concentrations set
at 100%. Ventilator settings were then set to “rest”
settings (respiratory rate, 6; FiO2, 0.21; tidal volume, 4–
6 mL/kg, positive end-expiratory pressure, 10 cmH2O).
PaCO2 was adjusted by altering sweep gas flows with
ventilator settings held constant. A schematic model of the
sheep ECMO model is shown in Figure 5.
Intracardiac echocardiography and confirmation of 
cannula position
Echocardiography plays a fundamental role in initiating and
maintaining ECLS.19,20 Conventionally, transoesophageal
echocardiography is used to determine cannula positioning
in the clinical setting.21 However, sheep have a particularly
capacious oesophagus, preventing good transducer contact
and hence poor images are produced. Transthoracic
echocardiography is possible in sheep, but there are limited
acoustic windows available. ICE has the dual benefits of
excellent spatial resolution combined with multiple accessi-
ble acoustic windows.22
Figure 5. Schematic diagram of sheep on 
extracorporeal life support
Sheep have capacious jugular veins, which make multiple 
cannulations in the vein possible.
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A 10 Fr ICE catheter was connected to an ACUSON Sequoia
C512 echocardiography machine (Siemens, Munich, Ger-
many) via a Swiftlink catheter connector (Siemens). The ICE
catheter was passed down the sheath, through the right
heart and into the IVC before cannulation. The guide wire
for the access cannula was then passed through the heart
and into the IVC under ICE guidance. The access cannula
was inserted over this guide wire, and the tip could be
visualised on the ICE images as it passed into the IVC and
positioned as appropriate. A similar process was followed
for the return cannula, but the imaging was performed
more proximally. The ICE catheter was withdrawn into the
mid right atrium. Appropriate passage of the return guide
wire was confirmed with ICE. The return cannula was then
passed over this wire and positioned in the mid right atrium
(Figure 6).
Anticoagulation
The heparin infusion was commenced 4 U/kg/h for a target
ACT of 200–300 s. The ACT checks were measured at 1
hour, 2 hours and every 2 hours subsequently.
Haemodynamic management
Invasive monitoring allowed for standardised management
of haemodynamic variables using crystalloids (0.9% sodium
chloride solution), colloids (human albumin, 40 g/L), vaso-
pressor (vasopressin, noradrenaline) and inotrope (adrena-
line) infusions as required.
Fluid and electrolyte management
Sheep were weighed on the day before and the day of
surgery. Volume administration was determined by stand-
ard haemodynamic variables including elevated systemic
vascular resistance, poor urine output and a low CVP.
Maintenance fluids were run at 2 mL/kg/h throughout the
study. Additional fluid boluses were allowed to maintain
circuit flow and/or for resuscitation. Electrolyte levels were
checked via regular blood gas analysis. Serum potassium
levels were maintained > 3 mmol/L. If required, a potassium
chloride infusion was commenced at a rate of 5–20 mmol/
h, depending on serum potassium concentrations, urine
output, and gastric losses. Any large-volume gastric content
lost was returned to normalise acid balance.
Temperature management
Temperature control was facilitated by the heater unit
connected to the oxygenator. The ambient room tempera-
ture could also be adjusted to maintain goal temperatures.
Euthanasia and postmortem handling
At completion of experimentation, animals were eutha-
nased with sodium pentobarbitone (295 mg/mL, 0.5 mL/
kg). Death was confirmed by loss of cardiac electrical
activity, ABP and cardiac output. After euthanasia, organs
were retrieved surgically. Histological analysis of organs,
including the right lung (right lower lobe), left lung (left
lower lobe), heart (left and right ventricles), liver, pancreas,
kidneys, spleen, adrenals, stomach, intestine and brain, was
performed. The remains of the animals were frozen and
stored until disposed of via high temperature incineration.
Results
The simulated ECLS circuit experiments (n = 4) examining
drug disposition in the extracorporeal circuit primed with
fresh whole human blood have showed significant altera-
tions in drug behaviour. Preliminary data show significant
Figure 6. Intracardiac echocardiography to confirm cannula position
A. Arrow points to the tip of the venovenous return cannula. Asterisk denotes Swan–Ganz catheter. B. Venovenous outflow in diastole with 
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important clinical implications.
By commencing with a short-term ECLS experiment using
healthy sheep, we conducted multiple experiments in the
sheep comprising 2-hour ECLS runs in healthy (n = 6) and
ALI sheep (n = 6). We were also successful with 24-hour
runs in healthy (n = 4) and ALI sheep (n = 1). Significant
preliminary data were obtained in relation to inflammation,
coagulation, histology, pharmacokinetics, biomarkers and
trace element disposition.
From a technical point of view, the cannulation, initiation
and maintenance of ECLS were uneventful. We captured up
to 70% of the cardiac output through our IVC access
cannula with minimal recirculation, which is a significant
improvement over previously reported ovine models,23 and
is the key to maintaining satisfactory oxygenation in animal
models of severe ALI. We had no serious issues related to
bleeding or clotting, unlike the clinical situation.24 We have
now optimised our anticoagulation, haemodynamic man-
agement and overall conduct of the experiment.
Discussion
This article describes the use of standard circuitry that
includes centrifugal pumps and polymethyl pentene oxy-
genators to establish simulated circuit and ovine models of
ECLS. Previously reported models have used variable tech-
nology comprising roller pumps, membrane oxygenators
and drainage reservoirs.23,25-28 Some models have used
venoarterial ECLS, which is not entirely comparable to the
venovenous group. Changes in technology influence cir-
cuit–host interactions significantly and having a contempo-
rary model adds to clinical relevance.
A major advantage of the sheep as an animal model of
human disease is their large size. With mean body weight
between 30 and 90kg, depending on breed,29 the size is
comparable to adult humans (67–87kg).30 Haemodynamic
and respiratory measurements can be made using the same
clinical techniques and equipment that are used in clinical
intensive care units. Also, large volumes of blood, plasma and
bronchoalveolar lavage samples can be collected at serial
time points during an experiment without compromising the
animal’s health. Apart from the size, there are immunological
similarities, which are important when studying host–circuit
interactions.9,31-34 Previous successful use of other ovine
models of human disease, especially ALI,3 as well as closer
similarities between sheep and human pulmonary anatomy
and physiology, immunology and size, justify the choice of
sheep as a relevant in-vivo large animal model of ECLS.
The simulated circuit and ovine models of ECLS
described here allow an incremental and systematic
approach to characterising the effects of ECLS on host
physiology. Knowledge of how each ECLS component
contributes to tissue injury will provide novel insight to
inform new strategies to control, reduce or eliminate extra-
corporeal associated tissue injury, which will result in
improved ECLS survival rates. The information gathered from
this study will also benefit other extracorporeal therapies
such as cardiopulmonary bypass. Knowledge gained using
this ovine model of ECLS will improve our preparedness for
future severe influenza outbreaks. Finally, the establishment
and validation of this in-vivo ovine ECLS model provides a
means for evaluating interventions (eg, drugs such as serine
protease inhibitors) to reduce extracorporeal induced inflam-
mation and tissue injury.
Future work beyond the scope of that described here will
use simulated circuits together with healthy and critically ill
sheep receiving ECLS to gain insight into the contributions of
circuit factors relative to the influence of critical illness on
changes in the pharmacokinetics of drugs such as antibiotics,
sedatives and analgesics that are used in patients receiving
ECLS in the clinical setting. These studies, together with
studies in patients receiving ECLS, will provide important data
for informing the development of antibiotic dosing guide-
lines as well as specific sedation protocols for patients
receiving ECLS.
Conclusions
We have successfully established reproducible in-vitro and
ovine models of ECLS that will be used in future studies to
provide novel insight on altered pathophysiology during
ECLS. Our on-going work involves collaborative research
between major ECLS centres across Australasia and our
model systems described herein will enable clinical hypoth-
eses to be tested in a systematic fashion in order to optimise
patient outcomes and further refinements in the use of
ECLS in the clinical setting.
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4.3 ASAP ECMO: ANTIBIOTIC, SEDATIVE AND ANALGESIC PHARMACOKINETICS 
DURING EXTRACORPOREAL MEMBRANE OXYGENTION: A MULTI-CENTRE STUDY 
TO OPTIMISE DRUG THERAPY DURING ECMO.  
 
4.3.1 Introduction to this publication 
Designing this international multi-centre population PK study was crucial to translation of 
the research findings. The ASAP ECMO study in many ways pioneered international multi-
centre research in the field of ECMO. This effort represents collaboration between 
pharmacists, ECMO and PK experts with experience in guideline development.  This study 
will generate vital PK data that would then lead to development of robust dosing guidelines 
for 18 key antibiotic, sedative and analgesic drugs used in ECMO patients.  
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Extracorporeal membrane oxygenation (ECMO) is an
invaluable tool for the management of acute severe car-
diac and/or respiratory failure in patients failing max-
imal medical therapy [1]. ECMO is a temporary organ
support system and is currently used only for a limited
time as a “bridge to recovery”, “bridge to bridge” or
“bridge to decision” device [2,3]. Veno-venous (VV)
ECMO supports the lungs only, whereas veno-arterial
(VA) ECMO provides support for both the heart and
lungs. The reported survival for VA ECMO in adult
patients with cardiac failure is up to 53% [4]. VV
ECMO has a survival rate of up to 71% in patients with
severe respiratory failure [5]. The findings of the
CESAR trial [6], and the Australian and New Zealand
Intensive Care Society ECMO investigator study into
H1N1 [5], partly support its role in the advanced man-
agement of respiratory failure [7]. With refinements in
technology, expanding scope [3] and favourable out-
comes in recent studies, it is likely that ECMO may
emerge as an indispensible tool in management of crit-
ically ill adult patients with cardio-respiratory failure.
However, as ECMO finds its niche in adult intensive
care as an adjunct to medical therapy, it is important
that its effects on the pharmacokinetics (PK) of com-
monly used intensive care drugs are fully understood to
ensure optimal drug therapy and improve patient out-
comes. Given that drugs are important for reversing the
underlying disease process, unknown interactions be-
tween ECMO and pharmacotherapy may seriously im-
pair patient recovery.
In critically ill patients not receiving ECMO, numerous
PK studies have demonstrated highly significant changes
to drug exposure through interactions between the pa-
tient, pathology and the drug [8-11]. The ECMO system
introduces additional variables, which are the circuit it-
self, as well as the systemic inflammation that results
from prolonged use of an extracorporeal circuit. Seques-
tration of drugs in the circuit, increased volume of dis-
tribution (Vd) and decreased clearance (CL) are the
major PK changes associated with ECMO [12], although
the extent of such changes remains poorly characterised.
Neonatal studies have reported significant alterations in
antibiotic, sedative and analgesic PK [13], but these
results may not be generalisable to adult patients due to
the developmental and physiologic differences [14].
There is emerging data on the altered dose requirements
in adult patients on ECMO [15,16]. In vitro studies in
the neonatal circuit studies highlight the influence that
drug properties such as molecular size, degree of
ionization at physiological pH, lipophilicity and plasma
protein binding have on drug sequestration during
ECMO [13,17]. Recently, significant antibiotic, sedative
and analgesic drug sequestration has been demonstratedin ECMO circuits used for adult patients [18]. The type
and age of circuit components including the type of the
pump, oxygenator and tubing, as well as circuit priming,
may influence the level of drug sequestration [19-22].
Patient factors such as systemic inflammation, haemodi-
lution, bleeding and transfusion, organ dysfunction and
renal replacement therapy (RRT) all add to the clinical
challenges of drug dosing during ECMO [23-25].
Methods/Design
The Antibiotic, Sedative and Analgesic Pharmacokinetics
during Extracorporeal Membrane Oxygenation (ASAP
ECMO) study is a prospective, multi-centre, open-label,
descriptive, PK study of 19 drugs commonly used during
ECMO. This study will recruit over 200 patients from 5
ICUs across Australia and New Zealand over 3 years.
The primary and secondary aims are:
Primary aim
 To develop PK models for the antibiotic, sedative
and analgesic study drugs and their relevant
metabolites described in Table 1 in patients
receiving ECMO.
Secondary aims
 To assess the adequacy of current antibiotic dosing
regimens in patients on ECMO.
 To develop guidelines for antibiotic drug dosing
during ECMO.
 To develop ECMO-specific sedation protocols.
Participants
Informed consent will be obtained from study partici-
pants or surrogate decision makers as applicable. Eli-
gible patients will be the critically ill admitted to
the ICUs at The Prince Charles Hospital, Brisbane,
Australia; St Vincent’s Hospital, Sydney, Australia;
The Alfred, Melbourne; Auckland City Hospital,
Auckland, New Zealand; The Princess Alexandra Hos-
pital, Brisbane, Australia and who have a clinical indi-
cation for ECMO. These patients will be receiving
sedation and analgesia as part of their routine care, as
well as being prescribed a study antibiotic for a clin-
ical indication. A target of 10–12 patients will be en-
rolled for each study drug. We will examine key
antibiotics, analgesics and sedatives (Table 1), and will
opportunistically collect blood samples. In some
patients, blood samples relating to only antibiotics
may be collected, whereas in other patients, samples
for analysis of analgesics and sedatives may also be
collected.
Table 1 Study drugs and their relevant metabolites for which population PK models will be developed
Sedative and analgesics Antiviral/antifungal Antibacterial
Morphine Fluconazole Ceftriaxone
Morphine-3 & 6-glucuronide Caspofungin Meropenem
Fentanyl & nor-fentanyl Voriconazole Vancomycin
Midazolam Oseltamivir Ciprofloxacin
1& 4 hydroxy midazolam Oseltamivir carboxylate Gentamicin
Propofol Piperacillin-tazobactum
Dexmedetomidine Ticarcillin-clavulunate
Thiopentone Linezolid
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 Age > 18 years and < 90 years.
 Currently undergoing ECMO for respiratory and/or
cardiac dysfunction.
 Clinical indication for the antibiotics listed in
Table 1.
 Clinical indication for the sedatives and analgesics
listed in Table 1.
Exclusion criteria
 No consent
 Known allergy to study drug
 Pregnancy
 Serum bilurubin > 150 μmol/L
 Ongoing massive blood transfusion requirement
(> 50% blood volume transfused in the previous
8 hours)
 Therapeutic plasma exchange in the preceding
24 hours
Drug administration
Antibiotics
Antibiotic selection and dosing will be at the discretion
of the clinician, based on the clinical context and unit
guidelines. Doses will be reconstituted in 10 ml of di-
luent and given as bolus intravenous (IV) infusion in
50 ml over 30 minutes (except ciprofloxacin, vanco-
mycin and linezolid – 1 or 2 hour IV infusion), or as
per local hospital protocols. Antifungals will be infused
IV as per local hospital guidelines and oseltamivir will
be administered via enteral feeding tube (contents
of capsule mixed in 20mL water followed by further
20-50mL water flush).
Sedative and analgesic drugs
Sedative and analgesic drugs will be administered
according to local policies at each ICU. As a guide, IV
infusions and boluses of morphine (10–30 mg/hr) and
midazolam (10–30 mg/hr) titrated to a Richmond Agita-
tion Sedation Scale (RASS) [26] of −3 to −4 and abispectral index (BIS) [27] of 40–45. Patient ventilator
interactions may also be used as a guide to titrate
sedation especially in patients on venovenous ECMO.
Therapeutic paralysis is at the discretion of the treat-
ing clinician and will be guided by neuromuscular
monitoring.
Additional IV sedation if required may be provided
with one of the following agents:
 Propofol IV (10–200 mg/hr)
 Dexmedetomidine IV (1 mcg/kg bolus and
0.1–1.5 mcg/kg/min)
 Fentanyl IV (50–300 mcg/hour) if morphine is
discontinued for clinical reasons
 Thiopentone IV (100–200 mg/hour)*
* Note- Thiopentone is uncommonly used as an ultim-
ate rescue sedative in some patients on ECMO.
Sample collection
Blood samples will be drawn from an existing arterial
line and collected in 2 ml tubes with a lithium hep-
arin anticoagulant. Where possible, a closed loop Ven-
ous Arterial blood Management Protection system
(VAMPTM, Edward Life sciences, Canada Inc) will be
used to minimise blood loss during sampling. The
minimum sample volume is 2 mL per time point. An-
other 0.5 mL of blood will be drawn for each add-
itional drug studied. It is considered unlikely for a
patient to be receiving more than 4 study drugs at a
given time during PK sampling. Labels for the storage
tubes will be provided by the central laboratory and a
site specific study number will be allocated to each
patient.
Blood sampling: antibiotics
All patients will be sampled over a single dosing period
during ECMO. Where two or more antibiotics of inter-
est are prescribed for one patient, data on the timing of
administration for both drugs will be collected (Figure 1)
with sampling performed according to the antibiotic
with the longer dosing interval. For example if
Figure 1 Sampling schedule for antibiotic drugs.
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were both prescribed, sampling would be performed
according to the vancomycin 12-hourly dosing schedule.
 Six-hourly dosing schedule – Blood will be sampled
from an existing arterial line at the following times:
0, 15, 30, 45, 60, 90, 120, 180 and 360 minutes.
 Eight or 12-hourly dosing schedule – Blood samples
will be collected from an existing arterial line at the
following times: 0, 15, 30, 45, 60, 90, 120, 180 and
480 minutes.
Blood sampling: sedatives and analgesics
Blood samples will be taken from an existing arterial
line at 0, 15, 30, 45, 60, 120, 180 and 240 minutes on
commencement or cessation of a new sedative drug in-
fusion. The details of drugs, doses and rates of adminis-
tration to be documented are on the data sheet
(Figure 2).
Urine specimens
Urinary creatinine clearance collections will be per-
formed for patients not receiving renal replacement
therapy as an 8-hour urinary collection. Assay of the
urine specimens will be performed by the localpathology service as a surrogate for glomerular filtration
rate. For patients receiving RRT the type and dose of the
treatment will be documented on the data sheet.
Data collection and management
For each patient various de-identified clinical and demo-
graphic data will be collected by trained research staff at
each participating centre and entered onto a data collec-
tion form (Figure 3). Each study site will maintain an
electronic database for their subjects which will be sub-
sequently consolidated into a single database. The data
to be collected includes.
Demographic data
 Age
 Gender
 Weight
 Height
Clinical data
 Admission diagnosis, allergies
 Illness severity scores [Sequential Organ
Failure Assessment (SOFA)on the day of PK
Figure 2 Sampling schedule for sedative and analgesic drugs. BIS- bispectral index, RASS- Richmond Agitation Sedation Scale.
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Evaluation (APACHE III) on admission]
 Use of renal replacement therapy
 Sedation scores (RASS, BIS)
Organ function data
 Serum bilurubin, total protein and albumin
concentrations
 Serum creatinine concentrations
 8-hour urinary creatinine clearance
 24 h fluid balance and blood product requirementsECMO data
 Days of ECMO
 ECMO flows during sampling
period
 Type of oxygenator and pump
Study drug dosing data
 Dose, time and frequency
 Time of sampling
 Day of therapy
Figure 3 Demographic and clinical data collection form.
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Samples will be centrifuged at 3000 g for 10-minutes to
separate plasma. Samples containing sedatives and
analgesics will be stored locally at −20°C. Samples con-
taining antibiotics will be stored locally at −80 °C. Labelsand cryovials will be provided by the central laboratory
to the participating sites. Dichlorvas (an inhibitor of
plasma esterase activity) will be added to the tubes dedi-
cated to oseltamivir and oseltamivir carboxylate assays.
Fluoride oxalate tubes can be used as an alternative.
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to the Burns Trauma and Critical Care Research Centre
and the Centre for Integrated Preclinical Drug Develop-
ment at The University of Queensland, Brisbane, Austra-
lia. The distribution of samples to the central laboratory
will be handled by a commercial clinical trials courier
company.Pharmacokinetic sample analysis
To reduce the sample burden per patient, validated
bioanalytical methods have been developed to quantify
multiple drugs and their metabolites selectively and
sensitively in small volumes of plasma. A fully auto-
mated on-line solid phase extraction (SPE) system
(Symbiosis, SPARK Holland) combined with liquid
chromatography-mass spectrometry (LC-MS/MS API
5000) to simultaneously quantify morphine, morphine
3-β-D-glucuronide, morphine 6-β-D-glucuronide, mida-
zolam, 1- hydroxymidazolam, 4-hydroxymidazolam, fen-
tanyl and nor-fentanyl in samples of human plasma has
been developed [28]. The technique will also be
expanded to analyse propofol, thiopentone and dexme-
detomidine. Antibiotic concentrations in the collected
plasma samples will be determined by separate vali-
dated chromatographic assay (HPLC and LC-MS/MS)
methods. All samples will be assayed alongside calibra-
tion standards and quality control samples, and met
the acceptance criteria.Statistical and pharmacokinetic analysis
This study aims to explain the variability of PK para-
meters between patients. Previous experience has shown
that 8–12 patients are sufficient for to meet this object-
ive [29]. Plots of drug doses over time for each patient
will be used to visually identify trends and outliers. We
will perform population PK modelling for each study
drug and metabolite of interest using a non-linear mixed
effects modelling approach (NONMEMW; Version 6.1,
GloboMax LLC, Hanover, MD, USA) as previously
described [30-32]. The residuals of the models will be
checked to verify model adequacy and influential obser-
vations and subjects will be identified. The models will
be used to create plots of the predicted mean doses over
time. The models will also be used to determine if sig-
nificant associations exist between the demographic or
clinical variables and the pharmacokinetics. Any vari-
ables found to have a significant effect on the pharmaco-
kinetics of the drug, will be incorporated into the final
pharmacokinetic model. For example, if age is shown to
be an important predictor of dose, then we will plot the
predicted doses by age group. After developing and test-
ing these PK models, we aim to perform Monte Carlo
dosing simulations, which can then form the basis fordosing guidelines for antibiotics and sedative use in
patients on ECMO.
Ethical considerations
Multi-site ethics approval has been obtained (HREC/11/
QPCH/121) for the 5 sites in Australia and Lower South
Regional Ethics Committee approval for the site in New
Zealand (LRS/12/06/020).
Collaborating organisations
This multi-centre study is co-ordinated by The Critical
Care Research Group at The Prince Charles Hospital in
Brisbane, Australia. This group will collaborate closely
with The Burns Trauma and Critical Care Research
Centre, and The Centre for Integrated Preclinical Drug
Development, The University of Queensland in Brisbane
for antibiotic and sedative drug assays.
Sample size and power
We estimate that a minimum of 12 patients for each
study drug will be sufficient for population PK analysis.
A minimum of 12 patients per antibiotic is based on
data from previous non-interventional PK studies in crit-
ically ill patients [29-31].
Discussion
This study will identify the sedative and antibiotic drugs
whose PK are most influenced by the presence of by
ECMO. It will also inform the development of strategies
for drug administration using PK and pharmacodynamic
principles in critically ill patients receiving ECMO. A
lack of understanding of the impact of ECMO on drug
Vd and CL may increase the likelihood of therapeutic
failure or drug toxicity [33-35]. PK modelling is crucial
to drug safety. This study aims to provide the key infor-
mation for development of evidence-based dosing sche-
dules and sedation protocols for use by clinicians caring
for patients receiving ECMO. This study will be compli-
mented by PK studies in the simulated ECMO circuits
and ovine models of ECMO [36] which are currently
being conducted by the same group. Using the correct
sedative agent at an appropriate dose will minimise ICU
morbidity, thereby improving patient outcomes [37].
Similarly, the right dose of the right antibiotic [38,39]
will not only improve microbiological and clinical cure
rates in an individual patient, but may also reduce the
emergence of multi-resistant organisms.
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CHAPTER 5  
DRUG AND CIRCUIT FACTORS  
75 
 
5.1 SEQUESTRATION OF DRUGS IN THE CIRCUIT MAY LEAD TO THERAPEUTIC 
FAILURE DURING EXTRACORPOREAL MEMBRANE OXYGENATION. 
 
5.1.1 Introduction to this publication 
This chapter, for the first time reported significant antibiotic and sedative drug losses in 
ECMO circuit components used in adult patients. The circuits were primed with fresh 
whole human blood and this experiment was used to study drug and circuit interactions in 
the absence of a critically ill patient. Also, by performing drug stability testing in controls, 
this experiment overcame the short comings of previous neonatal experiments. This 
experiment also identified lipophilicty as a key factor in determining circuit sequestration of 
antibiotic and sedative drugs. Although this was previously reported in neonatal studies 
that used older generation circuits, there were no reports on drug disposition in new 
generation circuits at the time of this publication. This study also helped the choice of 
study drugs for the ovine experiments. 
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Abstract
Introduction: Extracorporeal membrane oxygenation (ECMO) is a supportive therapy, with its success dependent
on effective drug therapy that reverses the pathology and/or normalizes physiology. However, the circuit that
sustains life can also sequester life-saving drugs, thereby compromising the role of ECMO as a temporary support
device. This ex vivo study was designed to determine the degree of sequestration of commonly used antibiotics,
sedatives and analgesics in ECMO circuits.
Methods: Four identical ECMO circuits were set up as per the standard protocol for adult patients on ECMO. The
circuits were primed with crystalloid and albumin, followed by fresh human whole blood, and were maintained at
a physiological pH and temperature for 24 hours. After baseline sampling, fentanyl, morphine, midazolam,
meropenem and vancomycin were injected into the circuit at therapeutic concentrations. Equivalent doses of
these drugs were also injected into four polyvinylchloride jars containing fresh human whole blood for drug
stability testing. Serial blood samples were collected from the ECMO circuits and the controls over 24 hours and
the concentrations of the study drugs were quantified using validated assays.
Results: Four hundred samples were analyzed. All study drugs, except meropenem, were chemically stable. The
average drug recoveries from the ECMO circuits and the controls at 24 hours relative to baseline, respectively, were
fentanyl 3% and 82%, morphine 103% and 97%, midazolam 13% and 100%, meropenem 20% and 42%,
vancomycin 90% and 99%. There was a significant loss of fentanyl (p = 0.0005), midazolam (p = 0.01) and
meropenem (p = 0.006) in the ECMO circuit at 24 hours. There was no significant circuit loss of vancomycin at
24 hours (p = 0.26).
Conclusions: Sequestration of drugs in the circuit has implications on both the choice and dosing of some drugs
prescribed during ECMO. Sequestration of lipophilic drugs such as fentanyl and midazolam appears significant and
may in part explain the increased dosing requirements of these drugs during ECMO. Meropenem sequestration is
also problematic and these data support a more frequent administration during ECMO.
Introduction
Extracorporeal membrane oxygenation (ECMO) is
increasingly being used in adult patients with cardiac or
respiratory failure refractory to conventional therapy or
with both. ECMO can be an effective bridge to recovery,
clinical decision-making, long-term mechanical cardiac
support, and, less commonly, heart/lung transplantation
[1]. Patients on ECMO receive multiple drugs that
include sedatives and analgesics, antibiotics, anticoagu-
lants, and vasoactive agents. The success of ECMO may
rely on the successful use of these therapies. Although
sedatives and vasoactive agents can be titrated to effect
clinically, there are no reliable clinical markers to guide
antibiotic therapy in critically ill patients. Antibiotics are
commonly prescribed in patients on ECMO, and subop-
timal therapy may result in therapeutic failure [2-5],
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adversely affecting patient outcomes. Despite the avail-
able endpoints for titration of sedation and analgesia in
the intensive care unit [6] and efforts to minimize seda-
tive drug use in this group [7], studies have reported
escalating sedative doses over time in patients on
ECMO [8-10].
There are limited data to guide drug therapy in adult
patients receiving ECMO. Data from neonatal circuit
experiments reveal significant sequestration of drugs in
the ECMO circuit [11,12], and the extent of loss
depends upon their physicochemical properties, type
and age of the circuit, and the pumps used [10,13].
Pharmacokinetic (PK) studies in neonates [11,12] have
consistently demonstrated increased volume of distribu-
tion (Vd) and decreased drug clearance (CL) during
ECMO. Sequestration of drugs in the circuit appears to
add to the increased Vd along with other factors related
to critical illness, such as third spacing [11,14]. These
studies in neonates highlight the important issue of
altered PK during ECMO, but further extrapolation of
the neonatal data to adult intensive care practice may
not be relevant given the developmental and physiologi-
cal differences between the two populations [15].
Systematic research in this area by using contemporary
circuitry is required to develop evidence-based dosing
guidelines for antibiotic therapy in adult patients receiv-
ing ECMO. The aim of this study was to describe the dis-
position of the analgesics fentanyl and morphine, the
sedative agent midazolam, and the antibiotics merope-
nem and vancomycin in an ex vivo ECMO circuit model.
Materials and methods
Ethics approval was obtained from the local Human
Research Ethics Committee (HREC/12/QPCH/90).
Extracorporeal membrane oxygenation circuits
The methods for the development of our ex vivo model
of ECMO have been published previously [16]. Four
permanent life support (PLS) ECMO circuits (Maquet
Cardiopulmonary AG, Rastatt, Germany) were used.
Each circuit consisted of Bioline tubing™, a PLS Quad-
rox D oxygenator, and RotaFlow pump head. A reservoir
bladder (R-38; Medtronic Pty Ltd, Minneapolis, MN,
USA) was added to allow fluid sampling from the closed
circuit. The circuits were primed with 900 mL of Plas-
malyte P-148 (Baxter Healthcare, Toongabbie, New
South Wales, Australia) and then exchanged for 500 mL
of Albumex 4 (Human Albumin 40 g/L; CSL Limited,
Broadmeadows, Victoria, Australia). Porcine mucous
heparin (Pfizer Australia, West Ryde, New South Wales,
Australia) was added to the circuits (5,000 U). Fresh
whole human blood (less than 5 days old, mean volume
of 420 ± 52 mL, provided by Australian Red Cross
Blood Service, Melbourne, Victoria, Australia) was used
for the final prime, and the circuits were pressurized to
obtain post-oxygenator pressures of 230 to 250 mm Hg.
The final volume of the pressurized circuit was 668 ±
1.7 mL, and the mean hemoglobin value was 64 ± 13 g/L.
The mean total protein and albumin concentration in the
circuit were 33 ± 2.5 g/L and 25 ± 0.9 g/L, respectively.
Activated clotting time was maintained between 220 and
250 seconds. A centrifugal pump (Jostra RotaFlow;
Maquet Cardiopulmonary AG) was used to maintain a
circuit flow rate of 4 to 5 L/minute. Oxygen tension in
the circuit blood was maintained between 150 and
200 mm Hg. Circuit temperature was maintained at
37°C. Carbon dioxide gas or sodium bicarbonate solution
was added to the circuit to maintain the pH of the circu-
lating blood in the range of 7.25 to 7.55. Fentanyl (20 μg),
morphine (100 μg), midazolam (100 μg), meropenem
(10 mg), vancomycin (40 mg), propofol (1 mg), dexmede-
tomidine (5 μg), thiopentone (20 mg), ceftriaxone
(50 mg), linezolid (10 mg), ciprofloxacin (5 mg), flucona-
zole (10 mg), and caspofungin (5 mg) were injected post-
oxygenator as a single bolus. The drugs with known
incompatibilities to study drugs (for example, gentamicin
and ticarcillin/clavulunate) were excluded. These bolus
doses were selected to produce concentrations similar to
clinical concentrations. Larger doses were used for the
drugs that exhibit high protein binding.
Controls
Four polyvinylchloride jars with tight caps were filled with
50 mL of fresh human whole blood. Unfractionated
heparin (500 U) was added to the jars for anticoagulation.
Fentanyl (1.5 μg), morphine (7.5 μg), midazolam (7.5 μg),
meropenem (0.75 mg), vancomycin (3 mg), propofol
(75 μg), dexmedetomidine (0.375 μg), thiopentone
(1.5 mg), ceftriaxone (3.75 mg), linezolid (0.75 mg), cipro-
floxacin (0.375 mg), fluconazole (0.75 mg), and caspofun-
gin (0.375 mg) were added to the control jars after
collection of baseline blood samples. These amounts were
chosen in order to produce study drug concentrations that
were similar to those achieved in the ECMO circuit. The
jars were then placed in an incubator at 37°C and rocked
continuously to ensure even distribution of the drugs.
Blood sample collection
Post-oxygenator blood was collected into lithium heparin
tubes (5 mL) at baseline and at 2, 5, 15, 30, 60, 120, and
360 minutes and at 12 and 24 hours after addition of the
drugs to the circuit. Blood samples (5 mL) were also
obtained from the control jars at time intervals identical
to that of the circuit. All blood samples were stored on
ice and centrifuged (10 minutes at 3,000g), and the
plasma was separated and stored in clean pre-labeled
polypropylene cryogenic vials and stored at -80°C until
analysis.
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Measurement of drugs in plasma samples
An on-line solid-phase extraction (SPE) Symbiosis
Pharma system (Spark Holland, Emmen, The Nether-
lands) was used to extract the analytes of interest (fenta-
nyl, morphine, and midazolam) and two internal
standards (morphine-d3 and 1-hydroxymidazolam-d5)
from plasma samples simultaneously [17]. Mass spectro-
metry in ESI (electrospray ionization) mode (API 5500;
AB Sciex, Framingham, MA, USA) triple quadropole sys-
tem was used as the detector. Liquid chromatography
and extraction method were created by Symbiosis Pro for
Analyst (version 2.1.0.0) and submitted to the MS con-
trolling software (Analyst 1.5.1). Meropenem and vanco-
mycin concentrations in the collected plasma samples
were determined by separate validated chromatographic
assay methods. Meropenem and the internal standard
(cefotaxime) were detected by ultraviolet absorbance at
304 nm. Vancomycin analysis was by liquid chromatogra-
phy-tandem mass spectrometry on an Applied Biosys-
tems API2000 (Applied Biosystems, Foster City, CA,
USA) with Shimadzu autosampler (Shimadzu Corpora-
tion, Kyoto, Japan). Vancomycin and the internal stan-
dard (teicoplanin) were detected by positive-mode MRM
(multiple reaction monitoring). All samples were assayed
alongside calibration standards and quality control sam-
ples and met the acceptance criteria.
Statistical analysis
Linear mixed effects modeling was used to examine the
change in concentration over time. This model accounts
for the repeated responses from the same circuit by using
a random intercept. The mixed effects model was fitted
by using the R statistical software [18] version 2.13.2 and
the ‘lme4’ library. The concentration-versus-time curves
(mean ± standard error of the mean) were plotted by
using GraphPad Prism version 5.03 (GraphPad Software,
Inc., La Jolla, CA, USA).
Results
The ex vivo circuits were maintained under physiological
conditions for 24 hours with no complications during the
run. Four hundred samples (80 per drug) were analyzed.
The changes in drug concentrations in the ex vivo model
are summarized in Figures 1 and 2, and the actual drug
concentrations determined in plasma samples from the
control jars and the ECMO circuits are presented in
Table 1. In this paper, only the data for fentanyl, mor-
phine, midazolam, meropenem, and vancomycin are pre-
sented. Validated assays are being developed for the
remaining study drugs, and the results will be made avail-
able in due course.
Testing confirmed that all baseline plasma samples
were free of study drugs. There were no statistically sig-
nificant differences in drug recoveries between the four
circuits. The mean drug recoveries from the circuits and
the control jars at 24 hours relative to baseline were,
respectively, fentanyl 3% and 82%, morphine 103% and
97%, midazolam 13% and 100%, meropenem 20% and
42%, and vancomycin 90% and 99%. Up to 70% of fenta-
nyl and 50% of midazolam were lost in the circuit
within the first hour of ECMO run. Fentanyl levels were
undetectable in the circuit by 24 hours. This may be
related to the lipophilicty of these drugs. Morphine,
which is less lipophilic than fentanyl, was stable in both
the circuit and the controls. Antibiotics were less signifi-
cantly affected. The hydrophilic and minimally protein-
bound drug meropenem was stable in the circuit and
the controls in the first 120 minutes, and 62% of the
drug was recovered from the circuit at 6 hours. This
was statistically significant (P = 0.01) even after account-
ing for spontaneous degradation (21%). There was no
significant loss of the moderately protein-bound hydro-
philic drug vancomycin in the circuit at 12 hours (P =
0.41) or 24 hours (P = 0.26).
Discussion
This is the first systematic investigation of drug disposi-
tion in the adult ECMO circuitry. The findings highlight
the role of the circuit in altering the PK of sedative,
analgesic, and antibiotic drugs during ECMO and clearly
show that there is considerable between-drug variability
in the degree of drug sequestration. Drugs that are
unstable at physiological temperature (meropenem) and
lipophilic drugs (fentanyl and midazolam) were more sig-
nificantly affected. These findings may have significant
implications for both the choice and the dosing of a par-
ticular drug prescribed during ECMO. Given the ongoing
exteriorization of blood onto the circuit during ECMO,
in vivo instability of drugs may also play a significant role
in apparent PK during ECMO. By excluding the patient
factors, this ex vivo model provides evidence that the
adult ECMO circuit is not simply a benign conduit for
blood but actively modulates drug PK.
The circuit factors were identical for all drugs. In this
context, it is difficult to determine which of the drug fac-
tors contributed to the significant disparity in the degree
of drug sequestration in the circuit and ex vivo stability.
Differences in molecular size and lipophilicity and the
differences in protein binding may all have contributed
to the findings. This is important as a blanket increase in
doses of all antibiotic drugs to avoid under-dosing with-
out identifying the drugs that are most sequestered by
the ECMO circuit may potentially result in drug toxicity.
Similarly, drug sequestration in the circuit may also
explain the increasing sedation requirements seen in
patients on ECMO [8,9]. Using sedative and analgesic
agents that are highly sequestered in the circuit may
necessitate the use of very high doses of these drugs to
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achieve the desired pharmacological effect and may add
to the associated morbidity [6]. This calls for further
research in this area to improve drug prescription during
ECMO.
Given that meropenem and vancomycin both rely on
time-dependent bacterial killing, the data presented here
on altered antibiotic concentrations may be clinically
relevant and require evaluation in a clinical PK study.
Meropenem is degraded and sequestered significantly in
the circuit beyond 4 to 6 hours. Hence, a more frequent
dosing or use of higher doses may be required to maxi-
mize the time above minimum inhibitory concentration
of the pathogen [19] as demonstrated in a recent clinical
study [20]. Furthermore, administration of meropenem
by infusion is questionable given the instability issues at
room temperatures [21]. The utility of more stable car-
bapenem antibiotics such as doripenem may have to be
explored in future studies. Clinically, there are no data
on meropenem PK in patients receiving ECMO. Neona-
tal studies have uniformly shown an increase in Vd for
vancomycin and a lower CL and consequently a longer
vancomycin half-life [22,23]. Similarly, PK studies in
neonates have shown increased Vd and decreased CL
for morphine, midazolam, and their metabolites during
ECMO [24,25]. The extent to which these PK alterations
during ECMO are related to sequestration of these
drugs in the circuit is currently unclear.
Studies in the neonatal ECMO circuits have demon-
strated significant sequestration of sedative and antibio-
tic drugs in the circuit. Also, there is drug sequestration
variability based on the different circuits, oxygenators,
and pumps used [13]. A recent in vitro study [13]
reported meropenem and vancomycin recovery of 89%
and 67% at 180 minutes in neonatal circuits that used a
centrifugal pump and polypropylene hollow-fiber mem-
brane oxygenators. Whereas the meropenem recovery at
180 minutes is comparable to our results, vancomycin
recovery was much lower in the neonatal circuits. In
contrast, the fentanyl and midazolam circuit losses seen
in this study are consistent with the results of the neo-
natal circuit studies [13,26-28]. Morphine appears to be
relatively stable in both neonatal and adult ECMO cir-
cuits and may be the preferred analgesic during ECMO.
Future clinical studies should compare the efficacy of
different classes of drugs to rationalize sedation and
analgesia during ECMO.
Studies that compare drug losses in clinically used
versus new neonatal circuits have demonstrated signifi-
cant variability in drug sequestration between the used
and new circuits [10,13,28]. Consequently, it is still
unclear whether there is saturation of the drug-binding
sites in the ECMO circuit over time. Similarly, the effect
Figure 1 Percentage of drug remaining in extracorporeal
membrane oxygenation circuits and the controls plotted
against time. Lipohilic drugs such as fentanyl and midazolam were
significantly sequestered in the circuit despite being stable in the
controls. Morphine was relatively stable in both controls and the
circuits.
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of priming with various solutions on drug sequestration
is not well characterized in the available literature. Drug
sequestration in blood-primed circuits has been shown
to be much lower than that in crystalloid-primed cir-
cuits [27]. It is possible that some of the blood compo-
nents may compete with drugs for circuit-binding sites.
Even though ECMO circuits are not routinely primed
with blood prior to their use in adult patients, the cir-
cuits get primed with the patient’s own blood once
ECMO is commenced.
In our study, we tried to replicate the clinical situation
ex vivo which allowed us to study the interactions
between the drug and the device in the absence of dis-
ease-related factors which independently can significantly
alter PK [29,30]. Repeat dose experiments are required in
long-term model systems to estimate the degree of circuit
saturation with time. The concurrent presence of several
other physically compatible study drugs in the circuit and
control jars mimicked the clinical scenario in which
patients receive these drugs concurrently, but the drugs
may have had an impact on competitive binding to blood
proteins or the circuit components. The presence of a
reservoir bladder may have influenced the circuit drug
losses. Similarly, quantification of drug lost in control
jars because of binding of drugs to the polypropylene
container was not feasible. However, the results confirm
the findings of neonatal ECMO circuit studies.
Conclusions
This ex vivo study highlights the role of the ECMO cir-
cuit in altering PK during ECMO. These alterations are
more pronounced for lipophilic drugs and may result in
Figure 2 Percentage of meropenem and vancomycin remaining in extracorporeal membrane oxygenation circuits and the controls
plotted against time. Meropenem was unstable in the controls; however, the extracorporeal membrane oxygenation circuit losses significantly
exceeded the levels of degradation seen in the controls at 6 hours. Vancomycin was stable in both controls and the circuits.
Table 1 Measured study drug concentrations in the control jars and the extracorporeal membrane oxygenation
circuits at 5 minutes and at 1, 6, 12, and 24 hours
Drug, units of concentration 5 minutes 1 hour 6 hours 12 hours 24 hours
C E C E C E C E C E
Fentanyl, ng/mL
Median 27 1 25 0.4 26 0.1 22 0.1 22 0
Range 26-29 1-1 24-25 0.2-0.5 26-28 0-0.2 20-24 0-0.2 20-24 0-0.1
Morphine, ng/mL
Median 136 7 139 8 137 8 139 8 135 8
Range 134-140 6-7 132-141 7-9 134-140 8-9 135-143 8-8 134-141 7-9
Midazolam, ng/mL
Median 134 175 131 117 138 59 124 42 128 31
Range 126-155 144-356 124-137 109-261 127-147 54-124 117-132 41- 96 120-131 30-61
Vancomycin, μg/mL
Median 71 73 70 73 72 71 72 71 69 67
Range 66-80 67-83 69-76 70-86 67-76 69-74 68-74 68-71 67-70 64-70
Meropenem, μg/mL
Median 18 15 17 14 14 10 11 6 7 3
Range 17-18 11-16 16-18 10-15 13-15 7-11 11-11 4-8 7-8 2-5
C, control jars; E, extracorporeal membrane oxygenation circuits.
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therapeutic failure. Morphine may be a useful alternative
to fentanyl in a patient with escalating sedative and
analgesic drug requirements. Less lipophilic sedative
agents may have to be considered in patients receiving
unusually high doses of midazolam. Given the instability
issues and circuit sequestration, meropenem may have
to be dosed more frequently or in higher doses pending
future clinical PK studies. Vancomycin is less signifi-
cantly affected, and therapeutic drug monitoring as cur-
rently practiced can guide optimal treatment. PK studies
in adult patients on ECMO are indicated for future
research in order to generate the data to guide antibio-
tic, sedative, and analgesic therapy during ECMO.
Key messages
• Lipophilic drugs appear to be more significantly
sequestered in the ECMO circuit, although further
study with different lipophilic drugs is required to
confirm this observation.
• Fentanyl and midazolam are more significantly
sequestered than morphine.
• Meropenem may have to be administered more
frequently during ECMO.
• Physical instability of meropenem may affect its
delivery by a continuous infusion.
• Sequestration of drugs in the circuit may have
implications on both the choice and dosing of a par-
ticular drug prescribed during ECMO.
Abbreviations
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5.2 PROTEIN-BOUND DRUGS ARE PRONE TO SEQUESTRATION IN THE 
EXTRACORPOREAL MEMBRANE OXYGENATION CIRCUIT: RESULTS FROM AN  
EX VIVO STUDY. 
 
This experiment highlighted the importance of drug protein binding on drug disposition in 
ECMO circuits and also identified that drug factors lipophilicity and protein binding can 
have an additive effect with the drugs that are highly lipophilic and protein bound 
demonstrating the greatest loss in ex vivo ECMO circuits. 
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in the extracorporeal membrane oxygenation
circuit: results from an ex vivo study
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Introduction: Vital drugs may be degraded or sequestered in extracorporeal membrane oxygenation (ECMO)
circuits, with lipophilic drugs considered to be particularly vulnerable. However, the circuit effects on protein-bound
drugs have not been fully elucidated. The aim of this experimental study was to investigate the influence of plasma
protein binding on drug disposition in ex vivo ECMO circuits.
Methods: Four identical ECMO circuits comprising centrifugal pumps and polymethylpentene oxygenators and
were used. The circuits were primed with crystalloid, albumin and fresh human whole blood and maintained
at a physiological pH and temperature for 24 hours. After baseline sampling, known quantities of study drugs
(ceftriaxone, ciprofloxacin, linezolid, fluconazole, caspofungin and thiopentone) were injected into the circuit to
achieve therapeutic concentrations. Equivalent doses of these drugs were also injected into four polypropylene jars
containing fresh human whole blood for drug stability testing. Serial blood samples were collected from the
controls and the ECMO circuits over 24 hours, and the concentrations of the study drugs were quantified using
validated chromatographic assays. A regression model was constructed to examine the relationship between circuit
drug recovery as the dependent variable and protein binding and partition coefficient (a measure of lipophilicity) as
explanatory variables.
Results: Four hundred eighty samples were analysed. There was no significant loss of any study drugs in the controls
over 24 hours. The average drug recoveries from the ECMO circuits at 24 hours were as follows: ciprofloxacin 96%,
linezolid 91%, fluconazole 91%, ceftriaxone 80%, caspofungin 56% and thiopentone 12%. There was a significant
reduction of ceftriaxone (P = 0.01), caspofungin (P = 0.01) and thiopentone (P = 0.008) concentrations in the ECMO
circuit at 24 hours. Both protein binding and partition coefficient were highly significant, with the model possessing a
high coefficient of determination (R2 = 0.88, P <0.001).
Conclusions: Recovery of the highly protein-bound drugs ceftriaxone, caspofungin and thiopentone was significantly
lower in the ECMO circuits at 24 hours. For drugs with similar lipophilicity, the extent of protein binding may determine
circuit drug loss. Future clinical population pharmacokinetic studies should initially be focused on drugs with greater
lipophilicity and protein binding, and therapeutic drug monitoring should be strongly considered with the use of
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Extracorporeal membrane oxygenation (ECMO) is es-
tablishing itself as a viable ultimate support therapy for pa-
tients with severe cardiorespiratory failure resulting from a
variety of clinical conditions, and its scope continues to
expand [1-3]. Patients on ECMO receive multiple drugs in
an attempt to either reverse the underlying pathology or
to minimise and/or treat complications. In venovenous
ECMO, a high proportion of the native cardiac output is
required to pass through the oxygenator to achieve ad-
equate systemic oxygenation. In venoarterial ECMO, the
ECMO circuit flows may exceed native cardiac output [4].
This transit of blood through the extracorporeal circuit
may result in degradation and/or sequestration of circulat-
ing compounds, including administered drugs [5].
In addition, ECMO is associated with significant phar-
macokinetic (PK) alterations [6], most important of which
is an increased volume of distribution (VD) and decreased
drug clearance (CL). From a PK point of view, the addition
of an extracorporeal circuit that can sequester and/or de-
grade drugs during transit, as well as modulate their VD
and CL, which presents a significant challenge. The drug,
device and disease factors affecting PK during ECMO are
very difficult to characterise in a critically unwell patient,
and, as such, laboratory-based research that mimics the
clinical scenario [7] should be used to fully understand the
complex mechanisms behind the PK alterations.
Drug factors such as protein binding and lipophilicity
play a key role in their absorption, distribution, metabolism
and excretion. Drugs are transported partly as unbound
drug and partly reversibly bound to blood components
such as plasma proteins and blood cells. The unbound
drug then diffuses to extravascular or tissue sites, where
the pharmacologic effects are observed. The dynamic rela-
tionship between unbound drug concentrations in the
blood and tissue sites determines the overall efficacy of
the drug. The distribution of the drug and its tissue pene-
tration are determined mainly by the extent of protein
binding, degree of ionization, and lipophilicity [8]. Lipo-
philicity is the main determinant of a drug’s permeability.
It is traditionally assessed by measuring the drug distribu-
tion between immiscible phases of n-octanol and water.
The ratio of a drug’s concentration in n-octanol and water
is referred to as the partition coefficient (P), the logarithm
of which (log P) is commonly used to describe the lipophi-
licity of therapeutic drugs [9].
ECMO circuits, by binding both circulating proteins
and the drugs, can therefore significantly influence the
PK of administered drugs in critically ill patients. How-
ever, most available data on disposition of drugs in ECMO
circuits are derived from neonatal studies that have used
older generation of ECMO circuits [6]. Data from these
studies reveal significant sequestration of drugs in the
ECMO circuit [6,10], with the extent of loss dependentupon their physicochemical properties, type and age of
the circuit and the pumps used [11,12]. There are limited
data from studies based on circuits used in adult patients.
Even though lipophilicity of drugs is widely believed to be
a major drug-related factor for circuit sequestration [5,11],
the implication of protein binding on circuit disposition
has not been fully elucidated.
To address this, we undertook drug disposition studies
in contemporary ECMO circuitry in adult patients using
an ex vivo model of ECMO. We hypothesised that lipo-
philic and protein-bound drugs are more prone to seques-
tration in ECMO circuits. We have previously reported
results for five drugs (meropenem, vancomycin, fentanyl,
midazolam and morphine [5]), which highlighted the role
of drug stability and lipophilicity in determining circuit
drug loss. In this article, we present results for another six
study drugs (ceftriaxone, ciprofloxacin, linezolid, flucona-
zole, caspofungin and thiopentone) and describe the influ-
ence of protein binding on drug disposition in ECMO
circuits.
Materials and methods
Ethical approval was obtained from the Research, Ethics
and Governance Unit, The Prince Charles Hospital, Metro
North Hospital & Health Service, Brisbane, Australia
(HREC/12/QPCH/90). Informed consent was not rele-
vant, as no human subjects were enrolled in this study.
The methods have been published previously [5,13], and
therefore only a brief overview of the methods is pre-
sented here.
Extracorporeal membrane oxygenation circuits
Four pulse life support (PLS) ECMO circuits were used.
They consisted of Bioline tubing (Netafim, Fresno, CA,
USA), a QUADROX D oxygenator and RotaFlow pump
head (MAQUET Cardiopulmonary, Hirrlingen, Germany).
A bladder reservoir (R-38; Medtronic, Minneapolis, MN,
USA) was added to provide compliance to the circuit and
allow multiple fluid sampling from the closed circuit. The
circuits were primed with Plasma-Lyte P-148 (Baxter
Healthcare, Toongabbie, Australia) and then exchanged
with ALBUMEX 4 (human albumin 40 g/L; CSL, Parkville,
Australia) and fresh human whole blood (less than 5 days
old, mean volume 420 ± 52 ml, provided by the Australian
Red Cross Blood Service). Porcine mucous heparin (Pfizer
Australia, West Ryde, Australia) was added to the circuits
(5,000 U).
The final volume of the pressurised circuit was 668 ±
1.7 ml. Activated clotting time was maintained between
220 and 250 seconds. The circuit flow rate, oxygen ten-
sion and temperature were kept between 4 and 5 L/min,
between 150 and 200 mmHg and at 37°C, respectively,
to maintain the pH of the circulating blood in the range
of 7.20 to 7.55 by addition of carbon dioxide gas to the
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morphine (100 μg), midazolam (100 μg), meropenem (10 mg),
vancomycin (40 mg), propofol (1 mg), dexmedetomidine
(5 μg), thiopentone (20 mg), ceftriaxone (50 mg), linezolid
(10 mg), ciprofloxacin (5 mg), fluconazole (10 mg) and
caspofungin (5 mg) were injected postoxygenator as a
single bolus. The drugs with known incompatibilities
to study drugs (for example, gentamicin and ticarcillin/
clavulanate) were excluded. These bolus doses were se-
lected to produce concentrations similar to clinical con-
centrations. Larger doses were used for the drugs that
exhibit high protein binding.
Controls
Four polypropylene jars with tight caps were filled with
50 ml of fresh human whole blood, and 500 U of unfrac-
tionated heparin were added to the jars for anticoagula-
tion. Fentanyl (1.5 μg), morphine (7.5 μg), midazolam
(7.5 μg), meropenem (0.75 mg), vancomycin (3 mg), pro-
pofol (75 μg), dexmedetomidine (0.375 μg), thiopentone
(1.5 mg), ceftriaxone (3.75 mg), linezolid (0.75 mg), cip-
rofloxacin (0.375 mg), fluconazole (0.75 mg) and caspo-
fungin (0.375 mg) were added to the control jars after
collection of baseline blood samples. These quantities
were chosen to produce study drug concentrations simi-
lar to those achieved in the ECMO circuit. The jars were
then placed in an incubator at 37°C and rocked continu-
ously to ensure even distribution of the drugs.
Blood sample collection
Postoxygenator blood was collected into lithium heparin
tubes (5 ml) at baseline and at 2, 5, 15 and 30 minutes
and 1, 2, 6, 12 and 24 hours after addition of the drugs
to the circuit. Blood samples (5 ml) were also obtained
from the control jars at time intervals identical to those
of the circuit. All blood samples were stored on ice prior
to centrifugation (10 minutes at 3,000 g), and the plasma
was separated and stored in clean, prelabelled polypro-
pylene cryogenic vials at −80°C until analysis.
Measurement of drugs in plasma samples
A robotic online solid-phase extraction (SPE) Symbiosis
Pharma system (Spark Holland, Emmen, The Netherlands)
was used to extract the thiopental and thiopental-d5
(internal standard) from plasma samples. The SPE was con-
ducted using a HySphere C18 cartridge (Spark Holland),
and the analytes eluted from the cartridges were directly
transferred to an XTerra MS C18 column (Waters,
Milford, MA, USA). Mass spectrometry (MS) in electro-
spray ionization in negative mode (QTRAP 5500; AB SCIEX,
Concord, ON, Canada) was used as the detector. The liquid
chromatography and extraction methods used were created
by Symbiosis Pro for Analyst (version 2.1.0.0; Spark Holland)
and submitted to the MS controlling software (Analyst 1.6).For antibiotic analysis, plasma sample aliquots (100 μl)
were combined with an internal standard before protein
precipitation by addition of trichloroacetic acid (ciprofloxa-
cin) or acetonitrile (ceftriaxone, caspofungin, linezolid and
fluconazole). Ceftriaxone supernatant was washed with
dichloromethane prior to instrumental analysis. Ceftri-
axone and ciprofloxacin were analysed on a Prominence
high-performance liquid chromatography system (Shimadzu,
Kyoto, Japan). Caspofungin, Linezolid and Fluconazole were
analysed on a Nexera-8030+ ultra-high-performance liquid
chromatography tandem MS (Shimadzu, Kyoto, Japan).
All separations were performed by reverse-phase chroma-
tography. Ciprofloxacin was detected by fluorescence,
ceftriaxone by ultraviolet detection, and caspofungin,
linezolid and fluconazole by triple-quadrupole MS. All
assays were validated and conducted according to the
US Food and Drug Administration guidance on bioa-
nalysis [14].
Statistical analysis
The data consisted of a longitudinal and correlated time
series. For each drug in both the control and experimen-
tal (circuit) assays, the drug assayers were assumed to be
independent of one another. For continuous data, normal-
ity was checked using a Shapiro-Wilk test. Non-normally
distributed data were transformed. The data were analysed
using a time series in a generalized linear model with a
normal link function. The results are reported as the
mean ± standard deviation (SD) for normally distributed
data, median (interquartile range) for non-normal or cat-
egorical data and the proportion—either fractional or as a
percentage—for binary data. For the purposes of analysis,
all drug levels were referenced to the concentration of that
drug at zero hours (baseline) and are reported as the per-
centage change from that baseline.
An ordinary (least-squares) regression model was con-
structed to examine the relationship between the two
explanatory variables, protein-bound fraction (FB) and
log partition coefficient (log P) and the outcome vari-
able, fraction of drug remaining at 24 hours (FC24).
Model coefficients and their 95% confidence intervals
are reported. The final model was also tested for fit to
the data (adjusted R2), and its residuals were examined
for normality and homoscedasticity. Throughout, the
level of significance was set at P <0.05. STATA™ software
(version 12.0; StataCorp, College Station, TX, USA) was
used for all analyses.
Results
The ex vivo circuits were maintained under physiological
conditions for 24 hours without complications. The
mean (SD) total protein and albumin concentrations in
the circuits were 33 (2.5) g/L and 25 (0.9) g/L, respect-
ively. The measured mean (SD) pH in the individual
Shekar et al. Critical Care  (2015) 19:164 Page 4 of 8circuits over the 24-hour period were 7.20 (0.4), 7.33
(0.15), 7.39 (0.3) and 7.26 (0.14). A total of 480 samples
(80 per drug) were analysed. The changes in drug con-
centrations relative to the baseline over time are sum-
marised in Figure 1. Testing confirmed that all baseline
plasma samples (prior to study drug injection into the
circuit) were free of study drugs. There were no statisti-
cally significant differences in individual study drug re-
coveries between the four circuits or controls. The mean
drug recoveries from the circuits and the control jars at
24 hours relative to baseline were, respectively, 80% and
102% for ceftriaxone, 96% and 119% for ciprofloxacin,
91% and 102% for linezolid, 91% and 102% for flucona-
zole, 56% and 99% for caspofungin, and 12% and 102% for
thiopentone. The reduction in ceftriaxone (P = 0.01), cas-
pofungin (P = 0.01) and thiopentone (P = 0.008) concen-
trations in the ECMO circuit at 24 hours were all
significant. Although there was some variability in pH be-
tween circuits, there was no significant independent effect
of pH on individual drug disposition in the circuits.Figure 1 Percentages of drug remaining in ex vivo extracorporeal me
time. For clarity, 95% confidence intervals are shown only for the experime
identified by the continuous lines and open symbols. The circuit group is iDrug physicochemical data were obtained from the
DrugBank online database [15] and then correlated with
circuit drug behaviour. The relationships of study drug
lipophilicity and protein binding with circuit drug con-
centrations are summarised in Table 1 and Figure 2. A
linear regression model was constructed to examine the
association between log P and the FB in the prediction
of FC24. In this model, both predictors were highly sig-
nificant, with model diagnostics revealing normally
distributed, homoscedastic residuals. The following model
equation was used:
FC24 ¼ 1:21 − 0:17 log P − 0:69 FB R2 ¼ 0:88ð Þ:
The confidence intervals and associated P-values for the
coefficients were as follows:
Log P −0:17; −0:13½ ; P < 0:001
FB −0:86; −0:52½ ;P < 0:001mbrane oxygenation circuits and the controls plotted against
ntal (circuit) group at times 6, 12 and 24 hours. The control group is
dentified by the dashed lines and solid symbols.
Table 1 Drug recoveries in ex vivo circuits and controls relative to baseline and their relationship to lipophilicity and
protein-binding characteristicsa
Drug Mean (SD) drug recovery (%)
from controls at 24 hr
Mean (SD) drug recovery (%)
from circuits at 24 hr
Lipophilicity (log P) Protein binding (%)
Ciprofloxacin 119 (4) 96 (17) 2.3 20 to 40
Fluconazole 102 (1) 91 (4) 0.4 12
Linezolid 102 (4) 91 (4) 0.9 31
Ceftriaxone 102 (1) 80 (6) −1.7 95
Caspofungin 99 (8) 56 (13) 0.1 97
Thiopentone 102 (8) 12 (5) 2.3 80
Fentanyl* 82 (6.3) 3 (3.8) 3.9 85
Midazolam* 100 (3.6) 13 (2) 3.9 92
Meropenem* 42 (1.5) 20 (7) −0.6 2
Vancomycin* 98 (9) 91 (11) −3.1 55
Morphine* 103 (11) 97 (2.6) 0.8 30
aLog P, Log; SD, Standard deviation. Drugs that are significantly lost in the extracorporeal membrane oxygenation circuit are highlighted. Asterisks indicate
previously published data from the same experiment [5].
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This systematic investigation provides useful insights
into the drug factors that influence drug disposition in
circuitry currently used in adult patients undergoing
ECMO. Based on a representative group of study drugs
with diverse lipophilicity and protein-binding character-
istics, this study demonstrates the importance of drug
factors altering PK during ECMO. More important, the
results indicate that for a given degree of lipophilicity,
the extent of protein binding may determine circuit drug
disposition. This is highly relevant, as the PK of highly
protein-bound drugs are significantly affected during
critical illness [16,17], and therapeutic drug monitoring
(TDM) for many of these drugs is not routinely available
at the current time.
The findings also highlight that there is considerable
between-drug variability in the degree of drug sequestra-
tion. Drugs with significantly reduced concentrations at
24 hours were either highly protein-bound (>80%), highly
lipophilic (log P >2.3) or both. As previously reported [5],
meropenem (protein binding: 2%, log P: −0.6) was the
only drug that did not conform to this trend, and its cir-
cuit loss can be attributed to its instability at physiological
temperature [5,18]. Most other drugs that do not exhibit
extremes of protein binding or lipophilicity remained
relatively stable in the ex vivo ECMO circuit. Thus,
drug stability at room temperature and at 37°C is also
an important consideration for drugs prescribed dur-
ing ECMO.
For a given solubility characteristic, the degree of pro-
tein binding appeared to be the main determinant of circuit
drug concentration. For example, although ciprofloxacin
and thiopentone have similar lipophilicity (log P: 2.3),
greater reductions in 24-hour plasma concentrations were
observed for thiopentone (88%), the more protein-bounddrug as compared with ciprofloxacin (4%). For the hydro-
philic drugs vancomycin and ceftriaxone (log P: −3.1
and −1.7, respectively), protein binding (55 and 83%
to 95%, respectively) once again appeared to be the key
determinant of circuit drug recovery (91% and 80%, re-
spectively) at 24 hours.
The mean (±SD) total protein and albumin concentra-
tions (33 ± 2.5 g/L and 25 ± 0.9 g/L, respectively) in the
ex vivo circuit were quite similar to what is encountered
in critically unwell patients [19]. As unbound study drug
concentrations were not measured, it remains unclear
whether protein-bound or -unbound fractions are more
susceptible to circuit degradation and/or sequestration.
In one study, there was a more significant loss of ampicil-
lin (a relatively hydrophilic and less protein-bound drug)
in neonatal ex vivo crystalloid-primed circuits [20] than in
blood-primed circuits (72% vs. 15% lost at 24 hours). This
indicates that the ECMO circuits can bind both pro-
teins and drugs, and it is unclear if there is any competi-
tive binding between them and, if so, whether such a
phenomenon is concentration-dependent. Thus, the net
circuit loss of a drug may represent a balance between
binding to circuit components versus extent of protein
binding. In addition, similar to their critically ill counter-
parts [16], patients receiving ECMO have physiological al-
terations that may influence protein binding, and a
resulting increase in unbound drug fraction may enhance
circuit losses [6]. This may, in part, explain the high VD re-
ported for drugs in patients receiving ECMO.
It is unclear if protein binding and lipophilicity have
an additive effect on circuit drug sequestration, as some
of the greatest decrements in circuit drug concentrations
(>80%) reported at 24 hours [5] relate to drugs that have
high degrees of both lipophilicity and protein binding
(fentanyl, midazolam and thiopentone). This may be further
Figure 2 Recovery of drugs in percent from extracorporeal membrane oxygenation circuit at 24 hours. (a) Lipophilicity expressed as log
partition coefficient (log P) values. (b) Protein binding expressed as percentage. For each drug, the mean concentration is indicated by a crossbar
and the upper and lower 95% confidence intervals are indicated by crosses. FCZ, Fluconazole; LEL, Linezolid; CRF, Ciprofloxacin; STP, Sodium
thiopentone; CTX, Ceftriaxone; CPF, Caspofungin.
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ciprofloxacin (despite having a lipophilicity similar to that
of thiopental) remained relatively stable in the circuit. The
mechanisms that independently lead to circuit sequestra-
tion of a highly protein-bound drug are currently unclear.
In a study using ex vivo neonatal circuits [21], up to 80%
of the lipophilic and highly protein-bound drug fentanyl
was lost in ECMO circuits without oxygenators at 6 hours,
and addition of an oxygenator to the circuit only increased
the losses by another 6%. It is possible that circuit sitesthat bind albumin and other circulating proteins upon
priming or after passage of patients’ own blood may in
turn bind to the administered drugs that exhibit high pro-
tein binding. Studies in which researchers have compared
drug losses in clinically used versus new neonatal circuits
have demonstrated significant variability in drug sequestra-
tion between the used and new circuits [11,12,22]. Conse-
quently, it is still unclear if saturation of the drug-binding
sites in the ECMO circuit over time occurs. Given that
ECMO therapy may continue for many weeks, the time
Shekar et al. Critical Care  (2015) 19:164 Page 7 of 8taken for saturation of both the protein- and drug-binding
sites in the ECMO circuit also remains a subject for future
studies. This could potentially be investigated with repeat
dose experiments in a similar ex vivo model.
Studies in neonatal ECMO circuits have also demon-
strated variable sequestration of drugs based on the dif-
ferent circuits, oxygenators and pumps used [11]. Even
though these studies clearly identify lipophilicity as a
factor for circuit drug sequestration, there are no pub-
lished experiments that explore the impact of protein
binding to the extent described in this study. Wildschut
et al. [11] reported an 84% recovery for hydrophilic drug
cefazolin (protein binding of 84%) at 3 hours in circuits
with centrifugal pumps and polypropylene hollow fibre
oxygenators. With silicone membrane oxygenators, the
drug recoveries observed in blood-primed circuits by
Mehta et al. for ampicillin, cefazolin and voriconazole
were 85%, 79% and 29%, respectively. Although these
three drugs exhibit contrasting degrees of lipophilicity
(log P: −2, −1.5 and 1.0, respectively) and protein bind-
ing (25%, 84% and 58%, respectively), it should be noted
that the least protein-bound and lipophilic drug of the
three drugs—ampicillin—had the best recovery profile at
24 hours, despite its instability issues.
This ex vivo study has some limitations. The concur-
rent presence of several other physically compatible
study drugs in the circuit and control jars mimicked the
clinical scenario where patients receive these drugs con-
currently, but it may have had an impact on competitive
binding to blood proteins or the circuit components. Al-
though there was some variability in pH between cir-
cuits, there was no significant independent effect of
change in pH on individual drug disposition in the cir-
cuits, and similar drug loss trends were observed in all
circuits. A reservoir bladder was necessary to allow re-
moval of multiple blood samples from the otherwise
non-compliant circuit, which may have influenced the
circuit drug loss. Similarly, quantification of drug lost in
control jars due to binding of drugs to the polypropylene
container was not feasible, although this is suspected of
being negligible because the surface area of the control
experiment was significantly less.
The findings of this study may have significant impli-
cations for both the choice and the dosing of an indi-
vidual drug prescribed during ECMO. Although any
drug can be affected, these findings will inform the
design of future clinical PK studies [23] that are the
next logical step in the evaluation of the impact of
the circuit and drug factors on PK in critically unwell
patients receiving ECMO and in the development of
robust dosing guidelines. Given that most of these drugs
are highly relevant for this patient population, TDM,
where available, is also strongly recommended, pend-
ing clinical PK data.Conclusions
This ex vivo study highlights the role of the ECMO cir-
cuit and drug factors in altering PK during ECMO. In
addition to previously identified drug factors such as in-
stability and lipophilicity, this study highlights the influ-
ence of protein biding on drug disposition in ECMO
circuits. The drugs that are most significantly affected need
expedited evaluation in clinical population PK studies and
in further mechanistic studies in animal models so that
the in vivo impact of such circuit drug losses are fully elu-
cidated. Such mechanistic and clinical PK data can then
assist the development of meaningful dosing simulations
and robust dosing guidelines for the prescription of anti-
biotic and sedative drugs given during ECMO.
Key messages
 Drug stability, lipophilicity and protein binding are
the three key drug factors that influence drug
disposition in ECMO circuits.
 Protein-bound drugs appear to be more significantly
sequestered in ex vivo ECMO circuits.
 When multiple drugs with similar degrees of protein
binding are administered, circuit drug loss is
determined by degree of lipophilicity and vice versa.
 Sequestration of drugs in the circuit may have
implications on both the choice and dosing of a
particular drug prescribed during ECMO.Abbreviations
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CHAPTER 6 
CRITICAL ILLNESS AND CIRCUIT 
FACTORS  
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6.1 PHARMACOKINETICS OF MIDAZOLAM AND ITS METABOLITES IN HEALTHY 
AND CRITICALLY ILL OVINE MODELS OF EXTRACORPOREAL MEMBRANE 
OXYGENATION.  
 
6.1.1 Introduction to this submitted manuscript 
This chapter describes the results from an in vivo ovine experiment that was designed to 
test the combined effects of ECMO and critical illness on PK. This experiment was critical 
as it is ethically impossible to study PK in a healthy human volunteer on ECMO. The 
protein-bound and lipophilic drug midazolam was used to compare PK in healthy and 
critically ill sheep receiving ECMO with critical illness being the study variable in question. 
Interestingly, the addition of critical illness had limited additional influence on midazolam 
PK in this experiment and both healthy and critically ill sheep had significantly increased 
peripheral Vd after commencement of ECMO. This finding is important as up to 72% 
midazolam was lost in the circuit during ex vivo experiments and this may have played a 
significant part in altering PK even in in vivo conditions despite the other perturbations to 
PK that may arise from critical illness itself. 
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6.1.2 Submitted version of manuscript  
 
Abstract 
Introduction: Patients on extracorporeal membrane oxygenation (ECMO) often receive 
sedation at doses much higher than their critically ill counterparts who are not on ECMO. 
However, the mechanisms behind this are not clear. This study aimed to compare 
pharmacokinetics of midazolam and its metabolites, 1-hydroxy midazolam and 4-hydroxy 
midazolam between healthy and critically ill sheep undergoing ECMO. 
Methods: Twelve healthy sheep were anesthetised and mechanically ventilated. Smoke 
inhalation acute lung injury (S-ALI) was induced in five sheep after which they were 
ventilated for 2 hours prior to commencing venovenous ECMO. Similarly, the 7 healthy 
sheep were ventilated for two hours prior to initiation of venovenous ECMO. In addition to 
intravenous anaesthetic agents (alfaxalone and ketamine), the sheep also received 
intravenous midazolam (bolus then continuous infusion) prior to and after commencement 
of ECMO. Serial blood samples were collected and midazolam and metabolite assays 
performed using validated chromatographic methods. Pharmacokinetic analysis was 
undertaken using non-compartmental and population methods. 
Results: There were no significant differences in average areas under the curve (AUC) 0-t 
for midazolam (17028 vs. 15255 mg.hr/L, p=0.71), 1-hydroxy midazolam (4438 vs. 3168 
mg.hr/L, p=0.26) and 4-hydroxy midazolam (1578 vs.1141 mg.hr/L, p=0.20) between 
healthy and SA-ALI sheep. The AUC0-t ratios for the 1-hydroxy midazolam and 4-hydroxy 
midazolam relative to the parent compound in healthy and SA-LI sheep were respectively 
0.28 vs. 0.23 (p=0.28) and 0.11 vs. 0.11(p=0.44). There was a significant reduction in 
peripheral volumes of distribution for midazolam in both healthy and S-ALI sheep upon 
commencement of ECMO [pre ECMO 191 (147 – 306) L vs. 86 (66 – 137) L on 
commencing ECMO, p=0.015)].  
Conclusion(s): The significant reduction in peripheral volume of distribution of midazolam 
seen upon commencing ECMO in both healthy and S-ALI sheep indicates sequestration of 
midazolam in ECMO circuits. The influence of critical illness itself on midazolam or 
metabolite pharmacokinetics was not significant and did not affect overall drug/metabolite 
exposure in S-ALI sheep. Clinical PK studies in ECMO patients are indicated to not only 
confirm these findings but also to evaluate the pharmacodynamic significance of our 
findings. 
Key words: Pharmacodynamics; sedation and analgesia; therapeutic failure; volume of 
distribution; clearance 
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Introduction 
The scope of extracorporeal membrane oxygenation (ECMO) is expanding and it is being 
increasingly used in adult patients with acute severe cardiorespiratory failure who are 
unresponsive to conventional treatment2,56. The spectrum of available extracorporeal life 
support (ECLS) techniques2 are being increasingly applied in tailored fashion to bridge 
eligible patients to recovery, further mechanical assist device or transplantation. Sedation 
and analgesia play a vital role in management of these patients. Although, changing 
paradigms explore the potential for ambulatory ECLS, some patients still need optimal 
sedation to maintain ECMO flows and oxygenation57,58. This is particularly relevant in 
patients with severe respiratory failure with high cardiac output who rely on relatively high 
circuit flows to ensure oxygenation57,58. Adequate sedation is also necessary to alleviate 
physical and psychological distress and to prevent accidental circuit related complications 
such as dislodgement /displacement or obstruction all of which may have catastrophic 
consequences11. 
Patients on ECMO often have unusually high sedation requirements when compared with 
their critically ill counterparts11 and the mechanisms behind this are still unclear. Studies 
have demonstrated a decrement in sedative drug and metabolite concentrations upon 
commencement of ECMO9 and such a phenomenon in adult patients may be largely 
attributed to circuit sequestration of sedative drugs as the haemodilution that results upon 
commencement of ECMO is not significant enough to explain the reductions in sedative 
drug concentrations. Experiments in ECMO circuits have confirmed that sedative drug 
sequestration can occur even in modern day circuitry and centrifugal pumps10,59.  
 Apart from sequestering drugs, the ECMO circuits may also contribute to significant 
pathophysiological and pharmacokinetic (PK) perturbations12 in a critically ill patient.  
Available neonatal data22 and emerging data in adult patients suggests that these 
pharmacokinetic changes may be more pronounced in patients on ECMO11,16,60. Increased 
volume of distribution (Vd) and decreased clearance (CL) of various antibiotic drugs during 
ECMO have been consistently reported in the neonatal literature22. These alterations may 
result from drug sequestration in the circuit24, physiologic effects of the extracorporeal 
circuit and from the critical illness itself 60. However, because these data are from critically 
ill patients, they probably reflect the combined effects of the ECMO circuit and critical 
illness on pharmacokinetics. Given that it is not possible to obtain pharmacokinetic data 
from healthy human subjects on ECMO, studies examining the effect of ECMO circuit on 
pharmacokinetics in healthy animals are desirable51 and may further our understanding of 
the reasons for increased sedation in ECMO patients. 
96 
 
This study was designed to compare the PK of midazolam and its metabolites in healthy 
and critically ill sheep receiving ECMO.   
Materials and methods 
Animal preparation: 
Ethics approval was obtained form the local Animal Research Ethics Committee (approval 
no. 1100000053). Our validated model of ovine ECMO has been published previously51-53. 
In an appropriately equipped theatre, twelve healthy sheep after overnight fasting were 
anesthetised and mechanically ventilated with a Hamilton Galileo ventilator (Hamilton 
Medical AG). Haemodynamic monitoring included invasive arterial blood pressure 
monitoring in the facial artery and continuous measurements of the central venous 
pressure, mixed venous saturation and cardiac output using a pulmonary artery catheter. 
Smoke inhalation acute lung injury (S-ALI) was induced in five sheep using a validated 
technique,61 after which they were ventilated for another 2 hours prior to commencing 
venovenous ECMO. Similarly, the 7 healthy sheep were ventilated for 2 hours prior to 
initiation of venovenous ECMO. A 21 Fr (50 cm) femoral Carmeda Bioactive Surface 
coated (CBAS®) venous cannula (Medtronic Inc, Minneapolis, MN, USA) was inserted into 
the right IJV using a Seldinger technique and positioned in the proximal inferior vena cava 
(IVC). A 19 Fr (50 cm) Carmeda coated femoral venous cannula was used for return blood 
and also inserted in the right IJV and positioned at the mid right atrium. Intra cardiac 
echocardiography was used to confirm cannula position. The clamped ECMO circuit was 
connected to the access and return cannulae. Pump speeds were titrated to target flows at 
least 2/3rd of pre-ECMO cardiac output (or 60–80 mL/kg). The sheep were maintained on 
ECMO for 24 hours and then euthanised. Serial blood sampling was performed for 
midazolam and metabolite assays (at baseline, prior to and after commencement of 
ECMO) and subsequent PK analysis.  
 Drug administration and PK sampling  
In addition to intravenous anaesthetic agents (alfaxalone 4–6 mg/kg/h and ketamine 3–5 
mg/kg/h), all the sheep also received intravenous midazolam (0.5mg/kg bolus followed by 
0.25 mg/kg/h) prior to and after commencement of ECMO. The animals did not receive 
any pharmacological paralysis. Blood samples were drawn at the baseline and at 15, 30 
45, 60, 90,120 minutes after initiation of midazolam infusion and at 15, 30, 45, 60, 90, 120, 
180, 240, 360, 480 and 720 minutes after commencement of ECMO. 
Midazolam and metabolite assay 
Aliquots of plasma samples (150 µL) was mixed with 150 µL of 1-hydroxymidazolam-d5 
solution (50 ng/mL) (Internal standards) and were shaken vigorously for 5 min before 
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transferring to the 96-well plate. Samples were diluted 3 and 30 times with blank plasma to 
fit inside the calibration range for all analytes. The on-line Solid phase extraction (SPE) 
Symbiosis System (SPARK Holland, Netherland) was used to extract all compounds of 
interest and the internal standards simultaneously from plasma. Mass spectrometer QTrap 
5500 (AB Sciex, concord, ON, Canada) was used as the detector. The calibration range 
for midazolam, 1-hydroxymidazolam and 4-hydroxymidazolam were: 0.5-100, 2.5-500 and 
1-200 ng/mL, respectively54.    
Statistical analysis 
Statistical analyses were performed using the SPSS 13.0 for Windows NT software 
package (SPSS Inc. 2004). Discrete variables were expressed as counts (percentage) and 
continuous variables as means ± SD. Demographics and clinical differences between 
study-groups were assessed using a chi-square, Fisher’s exact test, Student’s t-test, or 
Mann-Whitney U test, as appropriate. A p < 0.05 was considered to be statistically 
significant. We used a mixed model with a random intercept to describe the mean 
differences in physiology between healthy and SALI over 1 to 24 hours. This included a 
linear time trend using each sheep‘s baseline (time zero) as a covariate. 
Pharmacokinetic Analysis 
The pharmacokinetics of midazolam, 1-OH-midazolam and 4-OH midazolam were 
calculated by using both non-compartmental and population methods. 
Non-compartmental Analysis 
The area under the concentration-time curve from 0 h to the end of the sampling time (t; 
AUC0-t) was calculated using the trapezoidal rule. The formation of the metabolites was 
described using the ratio of AUC0-t for each metabolite to the corresponding AUC0-t of the 
parent compound. 
Population Pharmacokinetics Analysis 
The concentration-time data for midazolam in sheep plasma were fitted using Non-Linear 
Mixed-Effects Modeling (NONMEM version 7.2, Globomax LLC, Hanover, USA) [30]. A 
Digital Fortran compiler was used and the runs were executed using Wings for NONMEM 
(http://wfn.sourceforge.net). Data were analyzed using the first-order conditional estimation 
method with interaction (ADVAN3). Between subject variability (BSV) was calculated using 
an exponential variability model and was assumed to follow a log normal distribution. 
Residual unexplained variability (RUV) was modeled using an exponential error model. 
Visual inspection of diagnostic scatter plots and the NONMEM objective function value 
(OFV) were used to evaluate goodness of fit. Statistical comparison of nested models was 
undertaken in the NONMEM program on the basis of a χ2 test of the difference in OFV. A 
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decrease in the OFV of 3.84 units (p < 0.05) was considered statistically significant. 
Decreases in BSV of one of the parameters of at least 10% were also accepted for 
inclusion of a more complicated model. Specifically, we calculated midazolam CL, central 
volume of distribution (V1), inter-compartmental clearance (Q) and peripheral volume of 
distribution (V2). The final base model was evaluated by performing a visual predictive 
check (VPC), and by nonparametric bootstrapping.  
Results 
Seven healthy sheep and five S-ALI sheep completed the 24-hour ECMO run without any 
complications. Baseline demographic and physiologic data from all 12 sheep prior to 
smoke inhalation and ECMO are presented in Table 1. Data on the mean differences in 
physiological data between healthy compared with S-ALI sheep are presented in Table 2. 
Mean arterial pressure, 24 h fluid balance, haemoglobin, pH, lactate, total protein and 
albumin varied significantly (p<0.05) between the two groups.  
 
Table 1. Baseline demographic and physiology data compared between sheep allocated to 
healthy ECMO group (Group1,n=7) and or smoke inhalation acute lung injury and ECMO 
group (Group 2, n=5) prior to commencement venovenous ECMO. BP- blood pressure, 
PAP-pulmonary artery pressure, CVP-central venous pressure CCO- continuous cardiac 
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output, Svo2- mixed venous oxygen saturation, PEEP-positive end expiratory pressure, 
pO2 –partial pressure of oxygen, pCO2-partial pressure of carbon dioxide. 
 
 
Table 2. Mean difference in smoke inhalation acute lung injury (S-ALI) group (n=5) 
compared with healthy ECMO group (n=7) over the sampling interval.  Using a mixed 
model with a random intercept for each sample. Results presented as mean difference and 
95% confidence intervals. Including a linear time trend and using each sheep‘s baseline 
(time zero) as a covariate. BP- blood pressure, PAP-pulmonary artery pressure, CVP-
central venous pressure CCO- continuous cardiac output, Svo2- mixed venous oxygen 
saturation, PEEP-positive end expiratory pressure, Fio2-fraction of inspired oxygen, pO2 –
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partial pressure of oxygen, pCO2-partial pressure of carbon dioxide, Hb –haemoglobin, 
Lac –Lactate, ALT –alanine amino transferase,  AST-aspartate amino transferase. 
 
The concentration time curves for midazolam, 1- and 4-OH midazolam are plotted in 
Figure 1. The mean (±SD) steady-state concentrations (last concentrations during 
continuous infusion) of midazolam, 1-OH-midazolam and 4-OH midazolam in the healthy 
and S-ALI sheep were 1.16 (.52), 0.33 (.09) and 0.15 (.07) mg/L and 1.49 (.76), 0.28(.20) 
and .12(.05) mg/L respectively and the differences were not statistically significant.   
The average AUC0-t for the healthy sheep for the measured molecules was 17028, 4438 
and 1578 mg.hr/L for the healthy sheep and 15255, 3168 and 1141 mg.hr/L for the S-ALI 
sheep (p=0.71, 0.26, 0.20 respectively).The AUC0-t ratios for the 1-OH-midazolam and 4-
OH midazolam relative to the parent compound were 0.28 and 0.11 respectively in the 
healthy sheep and 0.23 and 0.10 in the S-ALI sheep suggesting little PK differences 
resulting from the S-ALI ( p=0.28 and 0.44).  The ratios of 1and 4 –OH midazolam and 
midazolam concentrations in both healthy and S-ALI sheep over time are presented in 
Figure 2.  
Differences in areas under the curve and log-transformed areas under the curve ratios for 
midazolam and its metabolites between healthy and S-ALI sheep using healthy sheep on 
ECMO as the reference group are presented in Tables 3 and 4. 
 
Drug/metabolite Group Mean Lower Upper p-value 
Midazolam SALI -1773.25 -12085.42 8538.92 0.71 
1-OH midazolam SALI -1269.73 -3678.01 1138.56 0.26 
4-OH midazolam SALI -436.68 -1152.34 278.98 0.20 
 
Table 3. Difference in areas under the curve and for midazolam and its metabolites 
between healthy and smoke inhalation acute lung injury (SALI) sheep (n=5) using healthy 
sheep on ECMO (n=7) as the reference group Results are presented as mean differences 
and 95% confidence intervals. 
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Figure 1. Concentration time curves for midazolam, 1- hydroxy midazolam and 4 –hydroxy 
midazolam. All sheep received 0.5mg/kg bolus followed by 0.25 mg/kg/h of midazolam by 
a continuous infusion for 2 hours prior to commencement of ECMO.  
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Figure 2. Ratio of parent 1and 4 –hydroxy midazolam and midazolam concentrations in 
both healthy (n=7) and smoke inhalation acute lung injury (SALI) sheep (n=5) plotted 
against time. 
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Metabolite/drug Group Mean Lower Upper p-value 
1-OH MDZ/MDZ SALI -0.43 -1.29 0.42 0.28 
4-OH MDZ/MDZ SALI -0.32 -1.22 0.58 0.45 
 
Table 4.  Difference in log-transformed areas under the curve ratios for 1-hydroxy 
midazolam (1-OH MDZ) and 4-hydroxy midazolam (4-OH MDZ) relative to midazolam 
(MDZ) between healthy and smoke inhalation acute lung injury (S-ALI) sheep (n=5) using 
healthy sheep on ECMO (n=7)as the reference group. Results are presented as mean 
differences and 95% confidence intervals.  
 
Pharmacokinetic model building 
The time-course of midazolam in plasma was best described by a two-compartment linear 
model with exponential residual error and BSV on CL, Q and V2. This model included zero 
order input of drug into the central compartment. The goodness of fit plots were acceptable 
and suggested that the model described the data sufficiently (population predicted versus 
observed concentrations R2 = 0.50; and individual predicted versus observed 
concentrations R2 = 0.78). After screening all relevant biologically plausible covariates and 
body weight, only the presence of ECMO was included on V2 in the final model. When this 
covariate was added, the objective function value reduced statistically significantly 
(p<0.05) and improved the goodness of fit plots. The objective function value for the final 
covariate model was -200.020. The median (IQR) population PK parameter estimates for 
the final covariate model were: CL 3.58 (2.64 – 6.05) L/h, V1 8.45 (no BSV included) L and 
Q 44.9 (23.7 – 75.9) L/h and V2 191.3 (147.1 – 305.7) L. The model predicted V2 pre-
ECMO commencement and then afterward was 55% lower, 191.3 (147.1 – 305.7) L and 
86.0 (66.1 – 137.4) L respectively which was statistically significant (p=0.015). 
Discussion 
This PK study mechanistically confirms the independent effects of ECMO on midazolam 
PK in the in vivo setting. This is important as midazolam PK estimated in critically ill 
patients on ECMO cannot distinguish the contributing impact of the host pathophysiology, 
ECMO circuit or the drug factors. For the severity of illness seen in the S-ALI sheep on 
ECMO, the effects of critical illness itself on midaozlam PK was modest. However, a 
significant increase in peripheral Vd in both healthy and critically ill sheep on ECMO is an 
interesting finding.  This reveals midazolam sequestration/inactivation in the circuit and 
highlights the “compartmental” effect the ECMO circuit has on drug PK. This finding also is 
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in keeping with significant midazolam losses seen in ECMO circuits in ex vivo experiments 
that used both adult and neonatal circuit components10,24,59.  
An increase in peripheral Vd for midazolam in both healthy and S-ALI sheep upon 
commencement of ECMO was the key finding in this study. There was no significant 
difference in exposure to midzolam and its metabolites between groups.  Midazolam is a 
highly plasma –protein bound drug (92%) and relatively lipophilic, both of which shown to 
be significant risk factors for sequestration10,59 in the ECMO circuit resulting in an 
increased peripheral Vd. Equally, larger Vd and accumulation of midazolam in peripheral 
body tissues have been reported in the critically ill population. However, this does not 
explain an increased Vd seen in healthy sheep upon initiating ECMO as these sheep did 
not manifest any physiologic signs of systemic inflammation or organ dysfunction post 
initiation. Increased Vd is also not explained by the degree of haemodiluation that may 
have occurred by addition of the primed ECMO circuit (average prime volume 667±20 mL) 
to a large animal. Similarly, despite the inflammation, shock and significant 
hypoproteinaemia, the S-ALI ECMO sheep exhibited PK characteristics similar to those of 
healthy sheep on ECMO. All of these findings indicate that midazolam sequestration in the 
circuit may play a significant role in PK and hence pharmacodynamics (PD) during ECMO.  
There was no significant difference in midazolam or metabolite CL in both groups and this 
may be attributed to insignificant differences in organ failures between the groups. 
Midazolam undergoes hydroxylation by the hepatic cytochrome P 450 (CYP) system to 
form three metabolites that are excreted through the renal system62. The active metabolite 
of significance 1-OH midazolam is 20% less potent than the parent drug with a half life of 
0.8-1 h in patients with intact renal function. The glucouronidation of 1-OH midazolam 
results in less potent 1-OH midazolam glucuronide which is also really excreted and prone 
to accumulation. Although, the ECMO circuit can independently reduce drug and 
metabolite CL even in patients with normal renal function, renal dysfunction is not 
uncommon during ECMO63. The eventual target site concentrations of midazolam and its 
metabolites during ECMO are determined not only by dosing and method of administration 
but also by the magnitude of the increase in Vd and decreased CL in an individual patient.  
 
These findings are clinically relevant as they show that altered PK may have to be 
considered whilst planning sedation or whilst assessing patient’s neurological status. The 
ECMO circuit by sequestering large amounts of the sedative drug and its metabolites may 
actively modulate PK/PD. This may manifest clinically as higher than usual midazolam 
dose requirement to achieve the desired sedative effect on ECMO. Equally, patients may 
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take longer than usual to wake and clinicians should be cautious especially when they 
deduce futility of ongoing care based on neurological status in the absence of significant 
central nervous system pathology on imaging.   
The study groups were well separated physiologically from a compromised hemodynamic 
and respiratory function point of view but the biochemical differences in hepatic and renal 
functions were non- significant during the sampling interval. It should be noted that ,the 
degree of hepatic dysfunction that need to present in a critically ill patient64 to significantly 
impact midazolam metabolism  is unclear and is not easy to quantify this based on 
biochemical tests65. Hepatic blood flows and critical illness may also impact CYP activity66, 
even when biochemical liver derangements are not apparent. Occasionally, ECMO 
patients (especially those ones supported with venoarterial ECMO for cardiac failure) may 
have significant biochemical derangement in hepatic function.   Available data does not 
indicate a significant difference in sedation requirement between patients on venovenous 
and venoarterial ECMO11. Given the most venovenous ECMO patients have reasonably 
preserved hepatic function based on biochemical tests, absence of significant liver 
dysfunction in the S-ALI animal may limit the interpretation of our PK data. 
Although there are no PK data for midazolam and its metabolites from healthy subjects 
undergoing ECMO to compare, the available corresponding PK data from critically ill 
patients on ECMO concurs with the findings of our study. Neonates on ECMO have been 
shown to develop an increased Vd upon commencement of ECMO and an increasing CL 
for both midazolam and 1-OH midazolam. Ahsman et a43l reported a greater than 3-fold 
increase in central Vd (1.43 to 4.86 L/Kg) and a 3-fold increase in CL with in the first 5 
days (up to 0.46 and 1.77 L /h /Kg) upon commencement of venoarterial ECMO. Increased 
central Vd for midazolam upon commencement venovenous ECMO (0.81 ± 0.5 and 4.1 ± 
0.5 L/Kg) was also reported by Mulla et al 67in neonates.  In these studies, volume 
expansion from addition of a primed circuit, presence of a critical illness and circuit binding 
of drugs were hypothesised to be possible mechanisms behind an increased Vd43. 
Increased CL was attributed to maturity of organs, disease progression and possible 
stabilisation of blood flow especially in neonates on venoarterial ECMO43. A reduction in 
midazoalm and its metabolite level with an associated increase in bispectral index scores 
and awakening has also been described in adult patients upon commencement of ECMO9. 
These data demonstrate that the PK of midazolam and its metabolites during ECMO is 
significantly affected by circuit sequestration of the drug in addition to illness related 
factors. Given that lipophilic and protein-bound drugs are preferentially sequestered in 
ECMO circuits10,59, the available drug choices for sedation during ECMO in adult patients 
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may have to be carefully considered based on physicochemical properties until population 
PK data becomes available for commonly used drugs. This may also apply for analgesic 
agents as drugs such as fentanyl 10, which are highly sequestered in the ECMO circuit.  
A short acting, potent, less protein bound drug with limited lipophilicity, that has no active 
metabolites and minimal other systemic effects, with rapid offset and onset of action may 
be an ideal agent for sedation and analgesia during ECMO. Not many current drugs have 
such favourable physicochemistry and most highly protein bound sedative drugs are also 
lipophilic. Equally, the lipophilic drugs are more likely to readily penetrate and distribute in 
effect sites within the central nervous system68,69. This along with the fact that sedative 
drugs can be titrated to clinical effect would mean that relatively less protein bound and 
lipophilic sedative and analgesic drugs may have to be simply used in higher doses than 
usual to provide sedation and analgesia in ECMO patients. These doses may often 
exceed the maximum recommended doses and raise safety concerns. Clinical PK/PD 
studies55 are indicated to establish the ideal sedative agent for use during ECMO.  
This PK study has limitations. Midazolam PK data was not available from non ECMO 
controls. Although using animals as their own controls for PK sampling prior to ECMO 
commencement was a positive, the sampling interval (2 h) prior to ECMO commencement 
may be considered too short to attain a steady state. There were no PD endpoints and 
midazolam was administered as a constant dose infusion as the study entirely focussed on 
PK of midazolam and its metabolites. It should be noted that ECMO may induce PD 
alterations which are beyond the scope of this study.  
 
Conclusion 
An increase in peripheral Vd was observed upon commencement of ECMO in both healthy 
and critically ill sheep. The overall exposure to midazolam and its metabolites 1 and 4 –OH 
midazolam did not differ significantly. The PK changes observed in healthy sheep provide 
preliminary insights into the role of the ECMO circuit itself in exerting a compartmental 
effect and modulating PK during ECMO. 
 
Key messages 
- Midazolam  sequestration in ECMO circuits affects PK significantly 
- There was an increase in peripheral Vd upon commencement of ECMO 
- No significant effects of critical illness on midazolam PK was observed in this study 
- These findings explain the increased sedation requirement seen during ECMO 
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- Clinical studies are indicated to further confirm these findings and to develop 
sedation protocols for ECMO patients 
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6.2 CAN PHYSICOCHEMICAL PROPERTIES OF ANTIMICROBIALS BE USED TO 
PREDICT THEIR PHARAMCOKINETICS DURING EXTRACORPOREAL MEMBRANE 
OXYGENATION? ILLUSTRATIVE DATA FROM OVINE MODELS. 
  
6.2.1 Introduction to this publication 
This chapter describes the results of a mechanistic investigation into altered PK of 
antibiotics during ECMO. Using ovine models of increasing complexity and eight antibiotic 
study drugs with a range of lipophilicty and protein binding, this study for the first time 
highlighted the utility of these physicochemical properties in predicting their PK in ECMO 
patients. The findings of this study confirm the findings of ex vivo studies in ECMO circuits 
and provide preliminary evidence that drug circuit interactions play a key role in altering PK 
in a critically ill patient. This supports the hypothesis that drug and circuit factors may in 
play an independent role in altering antibiotic PK in critically ill patients on ECMO. 
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With refinements in technology, extracorporeal mem-
brane oxygenation (ECMO) and extracorporeal life
support (ECLS) in general now represent a significant
development in intensive care practice [1–4]. A wide
range of acutely ill patients with cardiorespiratory fail-
ure are now being successfully rescued with ECLS
therapies, but clinicians await definitive evidence sup-
porting their use. Invasive ECLS therapies such as
ECMO are complex supportive interventions, and out-
comes rely not only on technology but also on user
experience [5]; optimisation of other aspects of intensive
care unit (ICU) management, established processes and
other available services in each centre; and optimisa-
tion of pharmacotherapy to minimise and/or treat com-
plications [6].
A variety of infectious and non-infectious conditions
may result in severe cardiorespiratory failure, and an in-
fection or sepsis is no longer considered a contraindica-
tion for ECMO [7]. Similarly, patients on ECMO may
develop a variety of ICU-acquired infections that may
necessitate antimicrobial therapy. Optimal antimicrobial
therapy in these patients is a balance between potency,
bacterial susceptibility and exposure [8, 9]. The authors
of a recent review identified 30.1 infections per 1000 days
of ECMO among patients with infections who were ex-
periencing prolonged ICU and hospital lengths of stay
[10]. The authors of another review [11] identified a
total of 2418 infections in 20,741 (12 %) ECMO cases,
with increased morbidity seen in patients with infections.
Antimicrobial therapy is commonly prescribed in ECMO
patients, and optimisation of dosing is central not only to
improving patient outcomes but also to minimising the
emergence of microbial resistance [8].
However, ECMO is known to induce significant phar-
macokinetic (PK) alterations [12] in critically ill patients
who already exhibit significantly altered PK [13], raising
concerns of therapeutic failure or toxicity. Neonatal
studies have shown major variations in antibiotic PK
during ECMO [12, 14–16], and there is an emerging body
of literature to support this in adult patients [17–20]. The
interaction between the drug, the ECMO device and the
disease are complex; hence clinical population PK studies
alone may not be able to advance understanding of mech-
anisms behind altered PK in ECMO patients. This calls
for systematic investigation [21] of each of these factors.
To this end, experimental studies [22, 23] using circuit
components used in adults have shown significant drug
sequestration in ECMO circuits based on physicochemical
properties of the drug, such as drug stability, octanol-
water coefficient (logP, a marker of lipophilicity) and
protein binding (PB).
Ex vivo experimental conditions are quite different
from in vivo scenarios. The addition of an extracorporealcircuit to a critically ill patient may result in profound
PK alterations, and appreciating the relative contribu-
tions of drug, device and disease factors to altered PK is
challenging. Building on the data derived from ex vivo
circuit studies, we aimed to develop PK models for anti-
biotic study drugs that exhibit wide a range of logP and
PB in ambulatory healthy sheep (HS) as well as in
healthy and critically ill sheep on ECMO. We hypothe-
sised that the drug properties logP and PB can be used
to predict PK alterations of antimicrobial drugs during
ECMO.
Methods
Ethical approval was obtained from the Queensland
University of Technology Animal Ethics Committee
(approval number 1100000053) and the University of
Queensland Animal Ethics Committee (approval num-
ber QUT/194/12). All experimentation was done in
accordance with the National Health and Medical Re-
search Council’s Australian Code for the Care and Use of
Animals for Scientific Purposes, Eighth Edition (2013)
(https://www.nhmrc.gov.au/book/australian-code-care-
and-use-animals-scientific-purposes-8th-edition-2013).
Pharmacokinetic sampling
Healthy ambulatory sheep
Seven HS weighing 46–51 kg were housed in a meta-
bolic cart amongst a larger flock, with free access to food
and water. Two three-lumen central venous catheters
were inserted in the left and right internal jugular veins
(IJVs) while the animals were under local anaesthesia for
drug administration and PK sampling. The catheters
were secured with adhesive glue and a sleeve dressing
around the neck. Study drugs were infused for 30 mi-
nutes, and serial blood samples were obtained for drug
assays using validated chromatographic methods and
subsequent PK analysis.
Healthy sheep on ECMO
We performed PK sampling in seven healthy sheep on
extracorporeal membrane oxygenation (E24H). A de-
tailed description of our ovine model of venovenous
ECMO is provided elsewhere [21, 24]. Briefly, a central
venous line was placed in the right IJV while the animals
were under local anaesthesia. Alfaxalone, ketamine and
midazolam were used for induction and maintenance of
anaesthesia. Buprenorphine 0.01 mg/kg was used for
supplemental analgesia. Sheep were intubated and venti-
lated with a Hamilton Galileo ventilator (Hamilton Medical
AG, Bonaduz, Switzerland). The facial artery was cannu-
lated for invasive arterial blood pressure monitoring. A
pulmonary arterial catheter provided continuous measure-
ments of central venous pressure, mixed venous oxygen
saturation and continuous cardiac output (CCO).
Table 1 Lipophilicity and protein binding characteristics of
study drugs
Study drug Lipophilicity (logP) Protein binding (%)
Ceftriaxone −1.7 95
Ciprofloxacin 2.3 20–40
Caspofungin 0.1 97
Fluconazole 0.4 11–12
Gentamicin −3.1 0–30
Meropenem −0.6 2
Doripenem 0.7 8
Vancomycin −3.1 55
A higher numeric value for octanol-water partition coefficient (logP) indicates
greater lipophilicity [29]
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mals in supine position. A 21-French (50 cm) CAR-
MEDA BioActive Surface–coated (CBAS®; Carmeda,
Upplands Väsby, Sweden) venous cannula (Medtronic,
Minneapolis, MN, USA) was inserted into the right IJV
using a Seldinger technique and positioned using intra-
cardiac echocardiography (ICE) [25] in the proximal
inferior vena cava. A 19-French (50 cm) CARMEDA-
coated femoral venous cannula was used for return
blood and was inserted in the right IJV and positioned at
the superior vena cava right atrium using ICE. ECMO
pump speeds were titrated to target flows at least two-
thirds of pre-ECMO CCO (or 60–80 ml/kg). Immedi-
ately upon commencement of ECMO, study drugs were
infused for 30 minutes and serial blood samples were
obtained for drug assays using validated chromatographic
methods and subsequent PK analysis.
Smoke inhalation acute lung injury sheep on ECMO
We performed PK sampling in six sheep with smoke in-
halation acute lung injury on ECMO (SE24H). The an-
aesthesia and ECMO techniques we used are described
in the previous section. Smoke inhalation acute lung in-
jury (S-ALI) was induced using a validated, reproducible
technique previously published [26]. Briefly, a stainless
steel plate was heated to 750 °C and placed on top of 8 g
of cotton in a cup. The smoke resulting from combus-
tion collected in the bellows of the purpose-built
device was delivered to the sheep by manual com-
pression (tidal volume [VT], 10–12 ml/kg) to achieve
a carboxyhaemoglobin content of 45–50 %. The sheep
were ventilated using Acute Respiratory Distress Syn-
drome Network criteria (VT 4–6 ml/kg, positive end-
expiratory pressure 10–15 cm H2O) for lung-protective
ventilation [27]. Once ECMO was established, study drugs
were infused for 30 minutes and serial blood samples were
obtained for drug assays using validated chromatographic
methods and subsequent PK analysis.
Study drugs, drug administration and pharmacokinetic
sampling
Following baseline sampling, study drugs in identical
doses were administered to the HS, E24H and SE24H
groups. The chosen anti-infective study drugs exhibit a
wide range of logP and PB (Table 1). The intravenous (IV)
study drugs (doses, administration techniques) used were
meropenem (500 mg, bolus), ceftriaxone (500 mg, IV
bolus), gentamicin (240 mg, slow IV bolus), vancomycin
(500 mg in 50 ml 0.9 % saline, IV for 30 minutes), flucona-
zole (100 mg in 50 ml of 0.9 % saline, IV for 30 minutes),
caspofungin (50 mg in 100 ml of 0.9 % saline, IV for 30 mi-
nutes), ciprofloxacin (100 mg in 50 ml of 0.9 % saline, IV
for 30 minutes) and doripenem (500 mg in 100 ml of
0.9 % saline, IV for 30 minutes). Serial blood samples(2 ml) were obtained at 15, 30, 45, 60, 90, 180, 360, 480
and 720 minutes after commencement of antibiotic drug
infusions for drug assays and subsequent PK analysis.Antimicrobial drug assays
Meropenem, doripenem, ceftriaxone and vancomycin
analysis was done using high-performance liquid chro-
matography (HPLC) on a Prominence Ultra Fast system
(Shimadzu, Kyoto, Japan) with ultraviolet light detection
at 304 nm (meropenem and doripenem) and 230 nm
(ceftriaxone and vancomycin). Ciprofloxacin was ana-
lysed on a Prominence HPLC system with fluorescence
detection at 278 nm (excitation) and 456 nm (emission).
Caspofungin, gentamicin and fluconazole analysis was
carried out using liquid chromatography–tandem mass
spectrometry on a Shimadzu Nexera-8030+ system with
detection by positive mode multiple reaction monitoring.
Samples were prepared by protein precipitation with
trichloroacetic acid (ciprofloxacin and gentamicin),
acetonitrile (caspofungin and fluconazole) or acetonitrile
with dichloromethane washing (meropenem, ceftriaxone,
vancomycin and doripenem). Chromatography was
carried out using reversed-phase C18 HPLC columns
(meropenem, ceftriaxone, vancomycin, doripenem, cipro-
floxacin), reversed-phase C8 HPLC columns (caspofungin,
fluconazole) or high-performance liquid chromatography
(HPLC) (gentamicin). All methods were validated accord-
ing to the guidelines of the US Food and Drug Adminis-
tration [28]. All samples were assayed with internal
standards, alongside calibration standards and quality con-
trol samples, and met the acceptance criteria.Statistical analysis and pharmacokinetic modelling
Discrete variables were expressed as count (percentage)
and continuous variables as mean ± SD. Demographics and
clinical differences between study groups were assessed
using a χ2 test, Fisher’s exact test or Student’s t test, as ap-
propriate. p < 0.05 was considered statistically significant.
Table 2 Demographic and physiologic data at baseline
after initiation of anaesthesia, mechanical ventilation and
haemodynamic monitoring and before smoke inhalation and
commencement of ECMO
Group Mean SD p Value
Weight, kg E24H 48.5 4.6 0.84
SE24H 49.6 4.4
Heart rate, beats/min E24H 116 13 0.78
SE24H 118 11
Mean arterial BP, mmHg E24H 116.1 6.8 0.91
SE24H 115.7 8.1
Mean PAP, mmHg E24H 24.6 2.8 0.06
SE24H 21.2 3.2
CVP, cmH2O E24H 15.6 2.8 0.06
SE24H 12.2 3.2
CCO, L/min E24H 5.44 0.93 0.33
SE24H 5.03 0.46
SvO2, % E24H 78.8 7.1 0.31
SE24H 82.0 4.1
PEEP, cmH2O E24H 8.1 2.6 0.67
SE24H 7.5 2.7
Respiratory rate, breaths/min E24H 10.9 6.0 0.6
SE24H 12.5 5.2
Fluid balance, ml E24H 681 376 0.11
SE24H 926 68
Haemoglobin, g/L E24H 7.0 1.2 0.47
SE24H 7.6 1.7
pH E24H 7.385 0.031 0.62
SE24H 7.397 0.052
Body temperature, °C E24H 38.26 0.61 0.67
SE24H 38.13 0.50
Lactate, mmol/L E24H 1.34 0.44 0.17
SE24H 1.07 0.24
Midazolam dose, mg/h E24H 14.4 1.2 0.17
SE24H 15.0 0.0
Urine output, ml/h E24H 69 44 0.87
SE24H 74 68
Albumin, g/L E24H 37.16 2.53 0.33
SE24H 38.15 0.86
Alanine aminotransferase (U/L) E24H 11.7 2.1 0.51
SE24H 12.4 1.7
Serum bilirubin, μmol/L E24H 2.16 0.69 0.75
SE24H 2.03 0.74
Serum creatinine, μmol/L E24H 88 15 0.94
SE24H 87 11
Table 2 Demographic and physiologic data at baseline
after initiation of anaesthesia, mechanical ventilation and
haemodynamic monitoring and before smoke inhalation and
commencement of ECMO (Continued)
Total protein, g/L E24H 71.7 6.4 0.78
SE24H 71.0 1.9
Urine creatinine, μmol/L E24H 10,172 3798 0.17
SE24H 15,541 8009
BP blood pressure, PAP pulmonary arterial pressure, CVP central venous
pressure, CCO continuous cardiac output, SvO2 mixed venous oxygen
saturation, PEEP positive end-expiratory pressure
Data presented are derived from comparison of the results between groups:
healthy sheep on extracorporeal membrane oxygenation (E24H) (n = 7), sheep
with smoke inhalation acute lung injury on extracorporeal membrane
oxygenation (SE24H) (n = 6)
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changes in concentration over time whilst controlling
for repeated results from the same sheep. The result ad-
justs for changes over time and repeated results from
the same sheep. The concentration versus time curves
(mean ± SEM) were plotted using GraphPad Prism ver-
sion 5.03 software (GraphPad Software, La Jolla, CA,
USA). PK analysis of antibiotic concentrations was
undertaken using a non-compartmental approach. All
statistical analyses were done using R version 3.1.2 soft-
ware (R Foundation for Statistical Computing, Vienna,
Austria).
We compared the statistical data between the three
groups using a box plot. To look for a difference in the
mean statistics between groups, we used a linear model
with group as the dependent variable. Because the PK
data were strongly positively skewed, we log-transformed
them before building regression models. Regression
models were derived to examine the differences in the
following PK parameters between the three study groups:
area under the curve (AUC), mean resident time, clear-
ance (CL), steady-state volume of distribution (Vss), max-
imum plasma concentration and minimum plasma
concentration. A linear regression analysis was used to
predict PK parameters based on drug properties. logP data
for the individual drugs are available from the University
of Alberta DrugBank website [29].
Results
We observed no complications during the ECMO run.
We found no significant differences between the physio-
logic variables at the baseline (Table 2). Differences in
physiologic variables between the E24H and SE24H
groups are presented in Table 3. We found statistically
significant differences in pH, haemodynamics, fluid bal-
ance and plasma proteins between the E24H and SE24H
groups (p < 0.001).
Sixteen hundred samples were analysed for study drug
concentrations. Concentration versus time curves for
Table 3 Mean differences in Physiologic parameters of E24H and
SE24H groups during the pharmacokinetic sampling interval
Variable Mean Lower Upper p Value
Heart rate 1.41 −9.54 12.36 0.815
Mean arterial BP −23.83 −31.35 −16.25 <0.001
Mean PAP 1.77 −0.83 4.37 0.234
CVP 0.93 −3.00 4.86 0.669
CCO −2.09 −3.30 −0.87 0.01
SvO2 −0.78 −3.31 1.74 0.585
PEEP 2.09 0.66 3.52 0.02
Respiratory rate (sheep) 2.33 0.18 4.48 0.068
Tidal volume −38.24 −135.38 58.87 0.479
FiO2 7.77 −2.04 17.69 0.151
paO2 48.05 0.43 95.67 0.053
paCO2 3.12 −0.28 6.52 0.115
Running fluid balance 4604.14 2779.38 6428.89 <0.001
ctHb 2.00 1.34 2.66 <0.001
pH −0.07 −0.10 −0.03 0.003
Body temperature −0.06 −0.38 0.27 0.754
Lactate 0.71 0.26 1.16 0.013
Midazolam dose per hour −5.97 −21.37 9.42 0.485
Urine output 6.68 −54.88 68.25 0.843
Albumin −14.91 −16.70 −13.10 <0.001
ALT 5.12 −6.25 16.49 0.419
AST 82.87 −23.66 189.39 0.175
Bilirubin (Direct) −0.48 −1.68 0.73 0.476
Bilirubin (Total) −0.12 −0.71 0.50 0.823
Creatinine 0.56 −11.52 12.64 0.933
Total protein −26.60 <0.001
Urea 0.79 −0.47 2.06 0.271
Urine creatinine −4327.47 −9508.52 974.49 0.322
BP blood pressure, PAP pulmonary arterial pressure, CVP central venous
pressure, CCO continuous cardiac output, SvO2 mixed venous oxygen
saturation, PEEP positive end-expiratory pressure, FiO2 fraction of inspired
oxygen, paO2 partial pressure of oxygen, paCO2 partial pressure of carbon
dioxide, ctHb concentration of total blood haemoglobin, ALT alanine
aminotransferase, AST aspartate aminotransferase
The analysis was carried out using a mixed model with a random intercept for
each sample. The results are presented as mean difference and 95 %
confidence intervals, including a linear time trend and using each sheep’s
baseline (time 0) as a covariate
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PK parameters estimated using a non-compartmental
analysis is presented in Table 4. Significant differences in
AUC between groups were found for ciprofloxacin, gen-
tamicin and caspofungin. For ciprofloxacin, the most
lipophilic drug studied, there was a significant difference
in Vss between the E24H and SE24H groups (p = 0.004).
For relatively protein-bound drugs, there was a trend to-
wards increased Vss only in the SE24H group compared
with HS group. However, an increase in CL was seen inboth the E24H and SE24H groups compared with the
HS group for vancomycin (p = 0.02 for both), ceftriaxone
(p = 0008 and p = 0.05, respectively) and caspofungin
(p < 0.001 for both), which are relatively more
protein-bound.
Scatterplots and linear regression of both CL and Vss
against logP and PB are presented in Figs. 2 and 3.
Table 5 shows regression parameters for predicting study
drug PK using logP and PB. PB exhibited a weaker
negative linear relationship with CL (HS, p = 0.01; E24H,
p < 0.001; SE24H, p < 0.001) and with Vss (HS, p = 0.01;
E24H, p = 0.004; SE24H, p =0.05). Despite an increased
CL for more protein-bound study drugs, PB in itself was
a predictor of decreased CL in all study groups (Table 5).
logP had a strong positive linear relationship with Vss in
both E24H and SE24H (p < 0.001) but not in HS (p = 0.9).
There was no significant association of logP with CL (HS,
p = 0.55; E24H, p = 0.74; SE24H, p = 0.24).
Discussion
In this study, we systematically investigated the effects of
the ECMO circuit on PK in HS and the combined effects
of ECMO circuit and critical illness on PK in S-ALI sheep
receiving ECMO. In addition, by using antimicrobials with
a range of logP and PB, we were also able to investigate
the relative contributions of drug, circuit and disease fac-
tors influencing PK during ECMO.
There was some expected variability in PK parameters
between the groups. Overall, the main findings of the
study are that (1) a significant increase in Vss for lipo-
philic drugs that was observed only in the ECMO sheep
and (2) protein-bound drugs exhibited decreased CL
and CL was also more significantly reduced in ECMO
sheep. These findings are significant, as they conform to
PK alterations described in neonates in the clinical
ECMO setting and to emerging PK data in adults, and
they provide further insights into mechanisms behind
these PK alterations.
Although an increase in Vss during ECMO has been
described clinically [12] for many antimicrobial and
sedative drugs, the relative contribution of critical ill-
ness, circuit and drug factors towards this phenomenon
is largely unclear. Systemic inflammation, capillary leak
syndrome and hypoproteinaemia during critical illness
can result in a significantly increased Vss [13]. Similarly,
sequestration of drugs in ECMO circuits may lead to a
further increase in Vss. Equally, a reduction in drug CL
during critical illness may result from renal and hepatic
dysfunction [13]. This study confirms both these find-
ings. An increase in Vss for lipophilic drugs occurred in
both E24H and SE24H but not in HS, clearly highlight-
ing the role of circuit drug sequestration. For all study
drugs except ciprofloxacin, we found no significant dif-
ference in Vss between the E24H and SE24H groups,
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Fig. 1 Concentration versus time curves for study drugs. a Meropenem. b Vancomycin. c Ceftriaxone. d Ciprofloxacin. e Fluconazole. f
Doripenem. g Caspofungin. h Gentamicin. E24H healthy sheep on extracorporeal membrane oxygenation, HS healthy sheep, SE24H sheep with
smoke inhalation acute lung injury on extracorporeal membrane oxygenation
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Table 4 Non-compartmental pharmacokinetic estimates for eight study drugs for all three study groups
Study drug Group Cmax (mg/L) Cmin (mg/L) AUC0–∞ (mg/h/L) Vss (L) Clearance (L/h) MRT (h)
Ceftriaxone HS 71 (14) 0.0 (0.1) 202 (46) 9.0 (1.8) 2.6 (0.6) 3.5 (0.2)
E24H 86 (15) 1.2 (1.4) 135 (74)a 6.3 (1.4)a 4.3 (1.4)a 1.7 (0.8)a
SE24H 85 (18) 1.0 (0.3)b,c 142 (39) 7.4 (1.8) 3.6 (0.8) 2.1 (0.6)b
Vancomycin HS 48 (9) 0.0 (0) 180 (37) 12.4 (2.6) 2.8 (0.7) 4.5 (0.2)
E24H 52 (10) 1.59 (0.9)a 131 (60)a 15.7 (3.9) 4.0 (1.1)a 4.0 (0.6)
SE24H 51 (12) 2.2 (0.4)b 116 (20)b 19.3 (3.3)b 3.9 (0.6)b 4.9 (0.7)c
Gentamicin HS 20 (2) 0.0 (0) 78 (7) 13.0 (1.3) 3.1 (0.3) 4.3 (0.1)
E24H 12 (6)a 0.3 (0.3)a 25 (12)a 34 (23.5)a 12.1 (7.4)a 2.7 (0.5)a
SE24H 16 (2)b 0.6 (0.2)b,c 39 (6.5)b 20.1 (2.9)b 5.9 (1.0)b,c 3.5 (0.7)b,c
Meropenem HS 26 (16) 0.0 (0.1) 71 (45) 91.0 (138) 20.9 (28) 3.9 (0.8)
E24H 27 (13) 0.5 (0.4) 36 (26) 16.5 (3.0) 13.8 (4.9) 1.4 (0.9)a
SE24H 29 (7) 0.3 (0.1) 39 (9.0) 19.9 (3.7) 13.2 (2.4) 1.6 (0.3)b
Doripenem HS 26 (17) 0 (0) 73 (47) 63.8 (83) 17.6 (22) 3.5 (0.2)
E24H 30 (6) 0 (0) 42 (20) 17.1 (2.8) 13.5 (4.6) 1.5 (0.9)a
SE24H 28 (6) 0 (0) 39 (8) 20.2 (3.0) 13.1 (2.4) 1.6 (0.2)b
Ciprofloxacin HS 3.3 (0.5) 0 (0) 13.6 (1.8) 31.9 (4.4) 7.2 (0.9) 4.5 (0.3)
E24H 5.1 (1.1)a 0.1 (0.1)a 8.3 (1.5)a 39.0 (7.6)a 11.8 (2.5)a 3.5 (1.2)a
SE24H 5.8 (1.2)b 0.1 (0.1)b,c 10.2 (1.5)b,c 52.7 (9.1)b,c 8.2 (1.2)c 6.4 (0.5)b,c
Fluconazole HS 7.7 (0.9) 0 (0) 48.2 (6.2) 13.3 (2.2) 1.2 (0.3) 12.0 (5.8)
E24H 9.1 (1.2)a 2.6 (0.8)d 51.0 (5.0) 16.7 (2.8)a 1.0 (0.3) 17.1 (5.5)
SE24H 9.2 (1.4)b 2.9 (0.5)b 52.3 (3.5) 17.7 (3.4)b 0.8 (0.5)b 33.7 (29)b
Caspofungin HS 5.7 (1.0) 0 (0) 33.8 (7.3) 10.0 (2.5) 0.8 (0.1) 12.9 (2.6)
E24H 4.8 (0.8) 0.7 (0.2)a 22.3 (6.6)a 14.4 (5.0)a 1.9 (0.4)a 7.6 (1.9)a
SE24H 4.3 (1.3)b 0.4 (0.2)b,c 15.5 (3.7)b,c 18.8 (8.4)b 2.8 (0.9)b,c 7.9 (6.4)b
HS healthy sheep (n = 7), E24H healthy sheep on extracorporeal membrane oxygenation (n = 7), SE24H sheep with smoke inhalation acute lung injury on
extracorporeal membrane oxygenation (n = 6), AUC area under the curve, MRT mean resident time, Vss steady-state volume of distribution, Cmax maximum plasma
concentration, Cmin minimum plasma concentration
aStatistically significant results for E24H group compared with HS group
bStatistically significant results for SE24H group compared with HS group
cStatistically significant differences between E24H and SE24H groups
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in increasing Vss was less apparent. The reasons behind
a greater Vss seen in the case of ciprofloxacin in the
SE24H group relative to the E24H group is probably a re-
sult of decreased CL in the SE24H group and may indicate
altered hepatic metabolism. It should be noted that there
was no biochemical evidence of any significant hepatic
dysfunction in our model. Clinicians should consider
circuit sequestration and alterations in hepatic function
when prescribing lipophilic antibiotics. In patients with
presumably preserved hepatic function, lipophilic antibi-
otics may have to be prescribed in higher doses. These
findings need further validation in clinical PK studies.
Even though protein-bound drugs have previously
been shown to be sequestered in ECMO circuits under
physiologic conditions [23] with expected increased Vss,
we observed no significant increase in Vss for these
drugs in the present study. However, there was a trendtowards increased Vss for protein-bound drugs in the
SE24H group. This may have resulted from reduced
plasma protein concentrations in the SE24H group. The
difference in blood pH between the SE24H and E24H
groups was significant and may have affected PB [30, 31]
and circuit sequestration. Given that unbound drug con-
centrations were not measured, further interpretation of
these data is not possible. From a general PK perspec-
tive, protein-bound drugs are expected to have a rela-
tively lower Vss, and during critical illness and ECMO
there is a potential for this to increase due to circuit
sequestration and other critical illness–induced PK alter-
ations [13]. The net increase in Vss in a critically ill pa-
tient on ECMO is therefore challenging to predict on
the basis of mechanistic studies alone. Clinical population
PK studies are therefore indicated.
Decreases in CL of antimicrobial and other drugs dur-
ing ECMO have been reported in previous clinical
Fig. 2 Scatterplots and regression of clearance against octanol-water partition coefficient and protein binding by groups. Healthy sheep (HS, n = 7),
healthy sheep on extracorporeal membrane oxygenation (E24H, n = 7), sheep with smoke inhalation acute lung injury on extracorporeal membrane
oxygenation (SE24H, n = 6)
Shekar et al. Critical Care  (2015) 19:437 Page 8 of 11studies [12]. Antimicrobial CL could not be predicted on
the basis of logP in the present study, which suggests
that the CL for lipophilic drugs may depend largely on
critical illness factors and hepatic drug metabolism. Se-
questration of drugs in the ECMO circuit by itself is un-
likely to play any significant role in reducing CL for
lipophilic drugs. However, it should be noted that alter-
ations in hepatic blood flow [32] and hepatic dysfunction
may occur in patients before initiation of ECMO or dur-
ing ECMO (especially during venoarterial ECMO initi-
ated in patients with severe cardiac failure), which may
then adversely affect hepatic metabolism of lipophilic
drugs and result in decreased CL. The degree of bio-
chemical hepatic derangement in the SE24H group that
received venovenous ECMO for predominant respiratory
failure may not have been sufficient to influence metab-
olism of lipophilic drugs significantly.
Even though protein-bound drugs appeared to have
more significantly reduced CL in ECMO sheep in the
final model, we observed increased CL in both healthy
and critically ill sheep on ECMO for relatively moreprotein-bound drugs (55 % for vancomycin, 95 % for
ceftriaxone and 97 % for caspofungin) compared with
HS. Interestingly, these three drugs also demonstrated a
trend towards an increased Vss during ECMO, especially
in the SE24H group. This is an interesting finding, given
that protein-bound drugs have been shown to have a
greater propensity for sequestration in ECMO circuits in
the ex vivo setting. This relative increase in CL and a
trend towards an increased Vss for more protein-bound
drugs in ECMO sheep may indicate circuit sequestra-
tion. Equally, an increase in plasma unbound fraction of
these drugs due to heparin displacement [33] may also
have contributed to increased CL and Vss for these drugs.
Although this increased CL was apparent in our ovine
ECMO models with relatively preserved renal function,
this may be of less significance in critically ill patients with
significant renal dysfunction or those on continuous renal
replacement therapy (CRRT). For example, no significant
impact of ECMO on vancomycin CL was observed in a re-
cent clinical population PK study by Donadello et al. [18].
The sheep had normal renal function, at least
Fig. 3 Scatterplots and regression of steady-state volume of distribution (Vss) against octanol-water partition coefficient and protein binding by
groups. Healthy sheep (HS, n = 7), healthy sheep on extracorporeal membrane oxygenation (E24H, n = 7), sheep with smoke inhalation acute lung
injury on extracorporeal membrane oxygenation (SE24H, n = 6)
Table 5 Linear regression parameters for predicting PK
parameters using drug properties
Group Dependent Independent Mean Lower Upper p Value
HS CL logP −0.54 −2.37 1.29 0.556
E24H CL logP −0.12 −0.86 0.62 0.744
SE24H CL logP −0.41 −1.09 0.28 0.235
HS CL PB −0.13 −0.22 −0.03 0.01
E24H CL PB −0.08 −0.11 −0.04 <0.001
SE24H CL PB −0.07 −0.10 −0.04 <0.001
HS Vss logP −0.48 −8.43 7.46 0.903
E24H Vss logP 2.85 1.73 3.97 <0.001
SE24H Vss logP 3.84 2.18 5.50 <0.001
HS Vss PB −0.50 −0.92 −0.09 0.017
E24H Vss PB −0.10 −0.17 −0.04 0.004
SE24H Vss PB −0.10 −0.21 0.00 0.056
PB protein binding, logP octanol-water partition coefficient (measure of
drug lipophilicity)
Separate results for each group are presented for healthy sheep (HS, n = 7),
healthy sheep on extracorporeal membrane oxygenation (E24H, n = 7), sheep
with smoke inhalation acute lung injury on extracorporeal membrane
oxygenation (SE24H, n = 6) and pharmacokinetic (PK) parameters clearance
(CL) and steady-state volume of distribution (Vss)
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CRRT in the above-mentioned study. This is an important
point to note because kidney injury and relatively lower
CL for vancomycin achieved on CRRT may have negated
an increase in CL during ECMO.
Although ex vivo studies confirm relative stability of
vancomycin in ECMO circuits, they do not replicate the
in vivo situation. A recent ex vivo study showed that,
with drugs with similar PB, lipophilicity becomes the de-
terminant of eventual circuit loss. Vancomycin, although
relatively protein-bound (55 %), is hydrophilic. Hence, it
is possible that, in the in vivo setting, there is a greater
propensity for hydrophilic protein-bound drugs to undergo
circuit sequestration. Appropriately powered clinical popu-
lation PK studies in which investigators compare vanco-
mycin PK in ECMO patients with and without preserved
renal function are needed to address this further, and such
studies are currently underway [34].
In summary, sequestration of lipophilic antibiotics
plays an important role in increasing their Vss during
ECMO. CL of lipophilic drugs is largely dependent on
hepatic drug metabolism, which can be significantly
Shekar et al. Critical Care  (2015) 19:437 Page 10 of 11affected in a subgroup of ECMO patients receiving
venoarterial ECMO for cardiac failure. Although more
protein-bound drugs were found to have relatively higher
CL in this study, PB in isolation may not be a reliable pre-
dictor of CL. Patients on ECMO may have significant
renal dysfunction, which is more likely to influence the
net CL than sequestration alone. Overall, ECMO appears
to decrease antimicrobial CL. These findings need further
validation in clinical studies, and such studies are cur-
rently underway [34].
This animal study has limitations. Apart from inherent
PK variability that is expected in a small sample, the distri-
bution, metabolism and excretion processes in sheep may
differ from those of humans. Despite the SE24H group’s
development of severe cardiorespiratory failure following
S-ALI, the degree of hepatic and renal dysfunction may
not have been sufficient to more fully elucidate the full
impact of critical illness of PK. However, the changes in
PK due to critical illness are very well described, and the
use of a model with no advanced end-organ failures that is
designed to more fully examine the circuit–drug interac-
tions is justified. Also, this study was directed more at ob-
serving relative PK changes between groups and the
effects of drug factors logP and PB on antibiotic PK.
Conclusions
Lipophilic antimicrobial agents are likely to have an
increased Vss and decreased CL during ECMO. Protein-
bound antibiotics are likely to have reductions in both
CL and Vss during ECMO. The strong relationship
between logP and Vss during ECMO indicates circuit
sequestration of lipophilic drugs. These findings high-
light the importance of drug factors in predicting
antibiotic drug PK during ECMO and should be a
consideration when performing and interpreting popula-
tion PK studies.
Key messages
 Sequestration of lipophilic antibiotics results in
increased Vss on ECMO.
 Lipophilic drugs exhibit a larger Vss during
ECMO, and lipophilicity by itself has little impact
on drug CL.
 Protein-bound drugs may have decreased Vss and
CL during ECMO.
 Higher doses of lipophilic antibiotics may
be indicated in patients with intact hepatic
function.
 Lipophilicity and PB are useful drug factors
to use in predicting antibiotic PK during ECMO.
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7.1 THE COMBINED EFFECTS OF EXTRACORPOREAL MEMBRANE OXYGENATION 
AND RENAL REPLACEMENT THERAPY ON MEROPENEM PHARAMCOKINETICS: A 
MATCHED COHORT STUDY. 
 
7.1.1 Introduction to this publication 
This chapter focuses on the translational aspects of the ECMO PK project. Meropenem PK 
data was compared between critically ill patients with and without ECMO in order to 
relatively quantify the clinical magnitude of altered PK. Meropenem was chosen 
deliberately as it is hydrophilic, less protein bound and renally excreted and therefore is 
more likely to be significantly affected by critical illness factors such as systemic 
inflammation and capillary leak. This was also based on published preliminary data that 
showed major alterations in meropenem PK (not included in this thesis) and risks of under 
dosing with use of standard doses (1g q 8h).  However, the population PK results were 
surprising and indicated that even standard dosing of meropenem may provide usually 
targeted meropenem plasma minimum inhibitory concentrations of ≥ 2 mg/L in most 
patients even when renal functions were preserved and whilst on renal replacement 
therapy. Using sophisticated dosing simulations, plasma meropenem concentrations in 
ECMO patients with or without dialysis dependent renal failure were able to be predicted.  
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Extracorporeal membrane oxygenation (ECMO) is being
increasingly used in adult patients with acute severe car-
diorespiratory failure as a supportive therapy [1,2]. Pro-
longed support for bridge to recovery or transplantation is
now possible. While ECMO sustains life, stabilises physi-
ology and allows time for definitive management, little is
known about the independent effects of ECMO on anti-
biotic pharmacokinetics (PK). ECMO is thought to further
complicate the PK alterations seen during critical illness
[3], which appears to manifest as increased volume of dis-
tribution (Vd) and decreased clearance (CL) [4]. Ex vivo,
animal [5,6] and clinical studies [7] are currently underway
to further investigate the PK changes seen during ECMO
and to develop evidence-based dosing guidelines. Simu-
lated ex-vivo studies that utilised adult circuitry [8] have
demonstrated significant antibiotic drug sequestration in
the circuit based on physicochemical properties of individ-
ual drugs. However, the PK data on antibiotics in critically
ill adult patients is limited with available studies indicating
significant PK alterations [3,9,10]. This is concerning as the
risks of suboptimal drug dosing (both under- and overdos-
ing) are profound in this complex group of patients who
have high infection-related mortality.
A significant number of patients receive ECMO for se-
vere cardiac and/or respiratory failure resulting from in-
fectious aetiologies. Patients may develop new infection
during ECMO support. Studies indicate that infections
occur frequently during ECMO and infections/colonisa-
tion with multi-drug-resistant organisms is not uncom-
mon [11-13]. Gram-negative bacteria are responsible for
significant proportions of these infections acquired dur-
ing ECMO [11]. Meropenem is used as an empirical or
targeted broad-spectrum antibiotic in this setting. It is a
minimally protein-bound and hydrophilic drug that under-
goes significant sequestration/degradation in ex vivo ECMO
circuit models [8]. In this setting, one would anticipate pro-
found alterations in meropenem PK in patients on ECMO,
although to date, we are unaware of any studies to guide
meropenem dosing in adults on ECMO.
This open-label, descriptive, matched-cohort PK study
aimed to describe single-dose meropenem PK during
ECMO using critically ill patients with sepsis and not re-
ceiving ECMO as controls.
Materials and methods
Participants and data collection
This study was conducted at a 650-bed university-affiliated
tertiary referral hospital. The ICU is a 27-bed mixed ICU
with a predominantly cardio-thoracic cohort. There is an
antibiotic stewardship programme with twice weekly ward
rounds by an infectious diseases physician. Infection con-
trol practices include review of all healthcare-associated
bacteraemia and multiple-resistant organism screening.Ethics approval was obtained from the Prince Charles Hos-
pital Ethics Committee, Brisbane, QLD, Australia (HREC/
11/QPCH/121). Informed consent was obtained from the
study participants or surrogate decision makers as applic-
able. The study protocol has been published and detailed
methodology, inclusion and exclusion may be found else-
where [7]. Eligible patients ≥18 years of age and receiving
meropenem during their ECMO therapy were recruited.
Known allergy to study drug, pregnancy, serum bilurubin
concentration >150 μmol/L, ongoing massive blood trans-
fusion requirement (>50% blood volume transfused in the
previous 8 hours) and therapeutic plasma exchange in the
preceding 24 hours were exclusion criteria. Data re-
lated to patient demographics, renal and hepatic func-
tion, details of ECMO and renal replacement therapy
(RRT) were collected.
Details of ECMO and RRT support
Patients received either venovenous (VV) or peripheral
venoarterial (VA) ECMO as clinically indicated. The
standardised ECMO circuitry comprised of Bioline tub-
ing, Quadrox D oxygenator and a centrifugal pump (Jostra
Medizintechnik AG, Hirrlingen, Germany). The prime
volume was 668 mL and the circuits were freshly primed
with Plasmalyte 148 (Baxter, Sydney, NSW, Australia)
followed by Albumex 4% (human albumin, 40 g/L; CSL
Bioplasma, Melbourne, VIC, Australia). RRT was provided
as extended daily diafiltration (EDD-f) to ECMO patients
using a Fresenius haemodialysis machine (4008 s ARrT
plus, Fresenius Medical Care, Bad Homburg, Germany)
that was connected to the post-oxygenator site of the
ECMO circuit using Fresenius AV600S filters. The blood
flow (200 to 300 mL/min) and dialysate flow rates (200 mL/
min) and duration were standardised (6 to 8 hours).
Continuous venovenous haemofiltration (CVVHF) was
performed in the control group RRT patients [14] using
the Nephral ST500 (AN69 hollow-fibre) filter with a sur-
face area of 2.15 m2. All patients were initiated on the
CVVHF at least 8 hours prior to the sampling period. The
ultrafiltrate rate was set between 66 and 100 mL/min, with
a target blood flow rate of 250 mL/min.
Controls
Previously published meropenem PK data were used for
the historical controls (n = 10). Five patients with sepsis
and no renal dysfunction receiving intermittent infusions
of meropenem were included [15] from one study. The
remaining five patients were the first five recruited to a
PK study (n = 10) examining meropenem PK in high-
volume continuous RRT [14].
Meropenem dosing and measurements
Meropenem dosing in ECMO patients was at the discre-
tion of the clinician, based on the clinical context and
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administered prior to PK sampling in the ECMO pa-
tients; 1 g intravenous (IV) bolus and 1 g IV q8h (n = 8),
1.5 g IV bolus and 1 g IV q8h (n = 2), 2 g IV bolus and
1 g IV q8h (n = 1). None of the RRT-dependent patients
received an additional dose post RRT. Doses were recon-
stituted in 10 mL of diluent and given as IV bolus infu-
sion in 50 mL over 30 minutes. The control patients
[15] with preserved renal function (n = 5) were given a
1.5 g meropenem first dose (in 10 mL of water-for-
injection infused by central line over 5 minutes) and
then 1 g (in 10 mL of water-for-injection infused by
central line over 3 minutes) every 8 hours. Controls
with impaired renal function on high-volume CVVHF
[14] received meropenem as 1 g (in 20 mL of water-
for-injection infused by central line over 3 minutes)
every 8 hours.
Blood sampling in ECMO patients was undertaken at
predose, 15, 30, 45, 60, 120, 180, 360 and 480 minutes.
In controls with preserved renal function [15], samples
were collected at predose, 3, 5, 7, 10 15, 20, 30, 45, 60,
90, 150, 240, 360 and 480 minutes. In controls on
CVVHF [14], sampling was performed at predose, and
at 15, 30, 45, 60, 120, 240, and 480 minutes. All samples
were immediately refrigerated at 4°C, and plasma was
separated and frozen at 80°C within 24 hours of sample col-
lection. The blood samples were centrifuged at 3,000 rpm
for 10 minutes.
Meropenem analysis was conducted on a Shimadzu
Prominence high-performance liquid chromatography
(HPLC) system (Shimadzu Corp, Kyoto, Japan) with a
Waters XBridge C18 column stationary phase (Waters
Corp, Milford, MA, USA). The mobile phase was 4%
acetonitrile/96% phosphate buffer 50 mM at pH 2.5 and
the eluent was measured by UV at 304 nm. The internal
standard for the HPLC assay was ertapenem. HPLC as-
says had inter- and intra-day reproducibility of 5.6% and
0.6%, respectively. The limit of quantification for mero-
penem was 1.0 mg/L and the coefficient of correlation
for the assay was 1.000.
Population pharmacokinetic analysis
The concentration-time data for meropenem in plasma
were fitted using a non-linear mixed-effects modeling
approach (NONMEM version 7.3, Globomax LLC,
Hanover, MD, USA) [30]. A Digital Fortran compiler was
used and the runs were executed using Wings for NON-
MEM [16]. Data were analysed using the first-order condi-
tional estimation method with interaction (ADVAN3).
Between-subject variability (BSV) was calculated using
an exponential variability model and was assumed to fol-
low a log-normal distribution. Residual unexplained vari-
ability (RUV) was modeled using a combined exponential
and additive random error model. Visual inspection ofdiagnostic scatter plots and the NONMEM objective
function value (OFV) were used to evaluate goodness of
fit. Statistical comparison of nested models was under-
taken in the NONMEM program on the basis of a χ2 test
of the difference in OFV. A decrease in the OFV of 3.84
units (P <0.05) was considered statistically significant. De-
creases in BSV of one of the parameters of at least 10%
were also accepted for inclusion of a more complicated
model. Specifically, we calculated central volume of distri-
bution (Vc), peripheral volume of distribution (Vp), total
indexed volume of distribution (Vd), inter-compartmental
clearance (Q) and meropenem CL using NONMEM.Population pharmacokinetic model diagnostics
Visual inspection of diagnostic scatter plots and the
NONMEM OFV were used to evaluate goodness of fit.
Statistical comparison of nested models was undertaken
in the NONMEM program using log-likelihood ratios,
which are assumed to be chi-square distributed. On the
basis of a χ2 test of the difference in OFV, a decrease in
the OFV of 3.84 units (P <0.05) for one degree of free-
dom was considered statistically significant. Decreases in
BSV of one of the parameters of at least 10% were also
accepted for inclusion of a more complicated model.Population pharmacokinetic covariate screening
Covariate model building was performed in a stepwise fash-
ion with forward inclusion and backward deletion based
upon the aforementioned model selection criteria. Age, sex,
weight, serum creatinine concentration, Cockroft-Gault-
calculated creatinine clearance (CrCL) as well as presence
of ECMO and RRT were evaluated as covariates.Population pharmacokinetic bootstrap
A non-parametric bootstrap method (n = 1,000) was used
to study the uncertainty of the pharmacokinetic parameter
estimates in the final model. From the bootstrap empirical
posterior distribution, we have been able to obtain the
95% confidence interval (2.5 to 97.5% percentile) for the
parameters, as described previously [17].Dosing simulations
We performed Monte Carlo simulations (n = 1,000) to
describe the effect of five different CrCL on meropenem
concentrations in a 50-year-old, 80 kg male receiving
ECMO. The CrCL simulated were at 20, 50, 80, 120 and
180 mL/min. We simulated the following doses 1 g IV
8-hourly, 500 mg IV 8-hourly and 2 g IV 8-hourly.
While interpreting the simulations, a trough meropenem
concentration of 2 mg/L and 8 mg/L was considered op-
timal for treating susceptible and less susceptible patho-
gens, respectively [18].
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Statistical analyses were performed using the SPSS 13.0 for
Windows NT software package (SPSS Inc., Chicago, IL,
USA, 2004). Discrete variables were expressed as counts
(percentage) and continuous variables as means ± standard
deviation (SD) or median (25th to 75th percentiles). Demo-
graphics and clinical differences between study groups
were assessed using a chi-square, Fisher’s exact test, Stu-
dent’s t test, or Mann-Whitney U test, as appropriate. A
P <0.05 was considered to be statistically significant.
Results
Five (two VV, three VA) out of eleven ECMO patients re-
ceived RRT. The other six patients (four VV, two VA) had
no significant impairment in renal and hepatic functions,
based on routine biochemical parameters. The indications
for ECMO included pneumonia, septic shock (n = 7); cardio-
genic shock (n = 2); sickle-cell crisis (n = 1); primary graft
dysfunction post lung transplant (n = 1). The median se-
quential organ failure assessment scores were not signifi-
cantly different between the controls and ECMO patients (7
[3-15] vs. 13 [9-15,17,18], respectively, P= 0.14). The demo-
graphic and clinical data are summarised in Table 1. Median
time to PK sampling in ECMO patients was 2 days (1 to 7).
Meropenem concentrations and PK parameters in
controls and ECMO patients
The median observed peak concentrations (Cmax) and
trough meropenem concentrations (Cmin) in controlsTable 1 Demography and severity of illness data
Controls
No RRT
(n = 5)
Male/Female 3/2
Age (years) 55.0 (48–61)
Total body weight (kg) 80 (75–85)
Mechanical ventilation 5/5
Type of ECMO (VA/VV) 0/0
Day 1 SOFA score 3 (3–4)
Plasma creatinine concentration (μmol/L) 73 (55–101)
Creatinine clearance (mL/min) 106 (98–127)
RRT mode -
Serum bilirubin (μmol/L) 9 (5–23)
Serum albumin (g/L) 22 (18–36)
Serum proteins (g/L) 56 (55–70)
Meropenem daily dose (g) 1 q 8 h
Plasma C max (mg/L) 93 (74–119)
Plasma C min (mg/L) 0 (0–2)
*Patients RRT dependent. The biochemical indices were measured on day of pharm
membrane oxygenation; RRT, renal replacement therapy; VA, venoarterial; VV, veno
venovenous haemofiltration; EDD-f, extended daily diafiltration.were 65.4 (58.7 to 74.4) mg/L and 4.2 (0.0 to 5.7) mg/L
respectively. The ECMO group achieved a median Cmax
of 55.3 (37.8 to 60.4) mg/L and a Cmin of 7.2 (4.0 to
17.2) mg/L; 10 out of 11 ECMO patients maintained a
Cmin >2 mg/L between doses. ECMO patients had a nu-
merically higher, but non-statistically significant volume
of distribution (0.45 ± 0.17 vs. 0.41 ± 0.13 L/kg, P = 0.21)
and lower clearance compared to controls (7.9 ± 5.9 vs.
11.7 ± 6.5 L/h, P = 0.18). In ECMO patients, while trough
meropenem concentrations of >2 mg/L were achieved in
all patients, a more aggressive strategy of >8 mg/L tar-
geting less susceptible microorganisms was maintained
only in eight out of eleven patients, with five of them be-
ing on RRT.
Pharmacokinetic model building
The time course of plasma meropenem concentrations
was best described by a two-compartment linear model
with combined residual error and BSV on Vc, Vp and
CL. This model included zero order input of drug into
the central compartment. The mean parameter esti-
mates from the final covariate model as well as the
95% confidence intervals from all bootstrap runs are
shown in Table 2. The goodness-of-fit plots are shown
in Figure 1.
After screening all relevant biologically plausible co-
variates, the following covariates were included in the
final model. RRT was included for CL with Cockroft-
Gault CrCL for CL in patients not receiving RRT. WhenECMO
RRT No RRT RRT
(n = 5) (n = 6) (n = 5)
3/2 1/5 3/2
56 (46–66) 29 (16–46) 38 (23–56)
70 (60–100) 69 (60–80) 70 (70–76)
5/5 5/5 5/5
0/0 3/3 2/3
15 (14–16) 9 (7–14) 16 (13–17)
na* 75 (44–82) na*
na* 108 (65–183) na*
CVVH - EDD-f
93 (36–115) 23 (9–73) 58 (34–134)
26 (23–36) 31 (27–35) 24 (22–32)
62 (60–65) 49 (46–54) 44 (34–56)
1 q 8 h 1 q 8 h 1q 8 h
58 (52–68) 42 (27–56) 59 (50–86)
7.5 (5–18) 4.9 (2–10) 18 (7–43)
acokinetic sampling. Data are presented as median (IQR). ECMO, extracorporeal
venous; SOFA, sequential organ failure assessment; CVVH, continuous
Table 2 Mean parameter estimates and bootstrap mean
(95% confidence interval) estimates for the final
covariate model
Parameter Model Bootstrap
Mean Mean 95% confidence interval
2.5% 97.5%
Fixed effects
CL (L/h) 5.1 5.4 3.7 7.4
Vc (L) 18.7 18.2 13.0 21.0
Vp (L) 13.2 13.6 11.3 15.9
Q (L/h) 21.0 24.2 12.8 37.0
CLCRCL 1.89 1.85 0.99 2.65
Random effects BSV (% CV)
CL (L/h) 51.6 52.2 37.9 66.6
Vc (L) 45.8 48.4 32.1 69.9
Vp (L) 28.7 16.2 0.2 42.1
Random error
RUV (% CV) 13.7 13.3 10.1 17.6
RUV (SD, mg/L) 2.3 1.87 1.02 2.70
CL, clearance; Vc, volume of distribution of the central compartment; Vp,
volume of distribution of the peripheral compartment; Q, inter-compartmental
clearance; CLCRCL, the fractional effect of CrCL on CL for patients not receiving
RRT; BSV, between-subject variability; RUV, residual unexplained variability.
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Figure 1 Goodness-of-fit plots for the final covariate meropenem
pharmacokinetic model. The top panel presents the population
predicted concentrations versus the observed concentrations. The lower
panel presents the individual predicted concentrations versus the
observed concentrations. For both graphs, the dashed line
represents the lines of best fit that have acceptable correlations
(r2 = 0.96, P <0.0001 for population predicted concentrations and
r2 = 0.64, P <0.0001, for the individual predicted concentrations
using linear regression).
Shekar et al. Critical Care  (2014) 18:565 Page 5 of 9each covariate was sequentially added to the parameters,
the OFV reduced statistically significantly (P <0.05) and
the goodness-of-fit plots improved. Inclusion of ECMO
as a covariate on any parameter did not improve the good-
ness of fit of the model nor was it statistically significant.
The final covariate model for the two-compartment mero-
penem model was represented by the following equation:
TVCL ¼ θ1: CLRRTð Þ þ θ1: CLNORRT  CrCLð Þ
Where TVCL is the typical value of meropenem clear-
ance where CLRRT is 0 for patients not receiving RRT
and CLNORRT is 0 for patients receiving RRT. CrCL is
Cockroft-Gault-calculated creatinine clearance and θ1 is
the typical population value for clearance.
Dosing simulations
Figure 2 (a-c) shows the mean concentration-time curves
for the 1,000 simulated patients for each dose and CrCL
and highlights the importance of CrCL in meropenem
dosing. Table 3 reports the mean and 10th percentile
trough concentrations for the simulated regimens. This
table demonstrates the wide PK variability present in the
studied patients as evidenced by the profound difference
in the values described. From this data, patients with the
following CrCL should receive the corresponding doses to
ensure 90% of patients maintain concentrations above
2 mg/L throughout the entire dosing interval, 20 to50 mL/min - 500 mg 8-hourly, 80 to 180 mL/min - 1 g
8-hourly, >180 mL/min - 2 g 8-hourly.
Discussion
This study provides preliminary evidence that standard
meropenem dosing (1 g IV 8-hourly) as an intermittent
bolus infusion in ECMO patients is likely to result in
drug concentrations sufficient to treat highly susceptible
Gram-negative pathogens. Conventional-dose meropenem
should achieve a time over minimal inhibitory concentra-
tion (T>MIC) of 100%, assuming a minimum inhibitory
concentration (MIC) of 2 mg/L (the European Committee
on Antimicrobial Susceptibility Testing (EUCAST) for
Figure 2 Simulated mean meropenem logarithmic concentrations
in a critically ill patient on ECMO with CrCL of 20, 50, 80, 120 and
180 mL/min for (a) 500 mg IV 8-hourly, (b) 1 g IV 8-hourly and
(c) 2 g IV 8-hourly. CrCL, creatinine clearance; ECMO, extracorporeal
membrane oxygenation.
Table 3 The effect of changing creatinine clearance on
mean (50th percentile) and 10th percentile trough
concentrations from the simulated ECMO patients
(n = 1,000) receiving various meropenem doses
Dose
Creatinine
clearance
Concentration
percentile
500 mg
8-hrly
1 g
8-hrly
2 g
8-hrly
20 50th 18.9 26.4 76.4
10th 3.6 16.2 14.6
50 50th 14.5 19.7 58.8
10th 2.6 9.8 10.5
80 50th 10.0 14.8 39.7
10th 1.3 4.8 5.1
120 50th 7.6 11.1 30.0
10th 0.7 2.5 2.7
180 50th 5.6 7.9 21.7
10th 0.4 0.7 0.9
These simulations assume that no significant accumulation of meropenem
occurred in study population. ECMO, extracorporeal membrane oxygenation.
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susceptible P. aeruginosa (MIC90 8 mg/L) and Acineto-
bacter species (MIC90 16 mg/L) higher meropenem
doses would have to be considered especially in pa-
tients with elevated CrCL. Given that, patients on
ECMO have decreased CL in most cases [3], standard
dosing is likely to achieve target plasma concentrations
in most patients. This is important considering the po-
tential clinical and bacteriological benefits of maintain-
ing 100% T>MIC in critically ill patients [19].
This study uses meropenem plasma concentration data
from four different patient populations to perform ro-
bust dosing simulations and to provide preliminary in-
sights into the incremental effects of critical illness,
ECMO and RRT on meropenem PK. The plasma con-
centrations observed in ECMO patients reflect a balancebetween the independent alterations in Vd and CL that
occur in the presence of critical illness [20], organ fail-
ures and ECMO [3]. Interestingly in this study, routinely
targeted meropenem plasma concentrations (>2 mg/L)
were maintained with standard dosing, both in ECMO
patients on RRT and those with preserved renal func-
tion. However, plasma meropenem concentrations were
significantly higher in the RRT group when compared to
patients with preserved renal function. This is important
as standard dose adjustments for renal impairment (for
example IV 500 mg 8-hourly or 1 g 12-hourly) in these
patients receiving RRT may potentially result in under
dosing. Equally, use of higher than standard doses may
precipitate the risk of toxicity. Therapeutic drug moni-
toring where available may further improve the safety
and efficacy of meropenem dosing during ECMO [4,21].
ECMO patients demonstrated reduced meropenem CL
and an increased Vd when compared with controls, but
these changes were not statistically significant. This
trend is consistent with the PK changes expected during
ECMO based on available literature [3]. An increase in
Vd resulting from critical illness [20] and sequestration
in the ECMO circuit [8] can significantly affect plasma
concentrations probably of meropenem, a hydrophilic
with limited protein binding and predominant renal CL.
Equally, AKI is common in patients on ECMO, with
incidence as high as 70% to 85% in single-centre stud-
ies [22]. The Extracorporeal Life Support Organisation
(ELSO) Registry data [23] suggests that up to 46% of
patients on VV ECMO and 44% on VA ECMO may re-
quire some form of RRT during the ECMO run. There
is significant variability in mode of RRT used in ECMO
patients and this may appear to limit the generalisability
Shekar et al. Critical Care  (2014) 18:565 Page 7 of 9of our results. This to an extent has been overcome with
our dosing simulations that account for a range (20 to
180 mL/min) of net CrCL (native and RRT) achieved in
ECMO patients However, dosing may not be entirely
based on CL achieved during RRT and possible residual
renal CL or extra renal CL may have to be considered.
This is of high relevance during ECMO as meropenem
can undergo significant degradation/sequestration during
their transit through the ECMO circuit. Although upregu-
lated non-renal elimination is possible for ciprofloxacin in
renally impaired patients [24], there is no data to support
this in the case of meropenem.
In this study the estimated median meropenem CL
seen in controls on CVVHF was 3.5 (3 to 4) L/h. There
is no reliable data on meropenem CL during EDD-f even
in non-ECMO patients and it is highly likely that this
will be greater than seen with high-volume CVVHF.
Despite RRT partially compensating for decreased drug
CL in patients with ECMO and acute kidney injury
(AKI), they maintained significantly higher meropenem
concentrations during the entire dosing interval with
standard dosing when compared with patients without
RRT and the controls. Our simulations confirm that a
meropenem dose of 500 mg - 1 g 8-hourly will provide a
plasma concentration >2 mg/mL in 90% of the patients
with CrCL ranging from 20 to 180 mL/min. Given the
relatively wide therapeutic index of meropenem, highly
variable CrCL between ECMO patients based on modal-
ity and intensity of RRT used, loss in the ECMO circuit
and preponderance of less susceptible organisms in this
population especially with prolonged ECMO support, a
dose of 1 g 8-hourly may be considered appropriate till
more PK data becomes available. Meropenem accumula-
tion and under dosing are still potential concerns in pa-
tients with extremes of CL and these high-risk groups
need to be specifically addressed in future PK studies in
this population.
The findings of this study contradict the available
sparse data pertaining to meropenem PK during ECMO.
To our knowledge, there are no previously published PK
studies in neonatal or adult patients on ECMO. A recent
case report [9] indicated heightened meropenem CL
(20.8 L/h) and Vd (0.56 L/kg) during ECMO and RRT
and a high-dose meropenem infusion was utilised to
maintain optimal concentrations. However, the CL for
meropenem in the current study was significantly
lower (7.3 ± 5.6 L/h) and the Vd was highly comparable
(0.53 ± 0.17 L/kg). However, it should be noted that
meropenem is unstable at 37°C and ongoing exterio-
rization of blood during ECMO may lead to a degree of
spontaneous degradation, which can be erroneously inter-
preted as increased CL. While it is challenging to arrive at
any strong conclusions based on these data, it appears that
eventual success of meropenem regimens during ECMOmay rely more on the CL that occurs in an individual
patient.
There is emerging data to suggest that the commonly
used dose of meropenem (1 g 8-hourly) may be suffi-
cient to treat an unselected population of septic critically
ill patients not receiving ECMO or RRT [25]. In this set-
ting, the risk of under dosing with 1 g 8-hourly dosing
in critically ill patients on ECMO and with preserved
renal function appears small and augmented renal clear-
ance [26] has not yet been described in this population.
However, patients on peripheral VA ECMO in whom ox-
ygenated blood is being returned into iliac artery or dis-
tal aorta may experience very high non-pulsatile renal
blood flows and whether this result in heightened CL in
patients with preserved renal function needs further
evaluation.
The current study has limitations. Characterizing al-
tered PK in patients receiving RRT while on ECMO can
be complex. Variability in the techniques used for RRT
and ECMO is a significant limitation in the generalis-
ability of our results. Future studies should further inves-
tigate the effects of type and intensity of RRT chosen on
meropenem PK during ECMO. Despite the ECMO
population being small and heterogeneous, our model
could accurately predict drug concentrations in ECMO
patients and controls and discriminated well for RRT.
This study does not address the pharmacodynamic as-
pects of meropenem therapy and no meaningful clinical
outcome measures can be generated from the small
sample. The non-ECMO patients selected were consid-
ered to be optimal controls for patients on ECMO who
exhibited systemic inflammatory syndrome with or with-
out clear evidence of infection. Systemic inflammation is
known to significantly affect volume of distribution of
the hydrophilic and renally excreted drugs such as mero-
penem [20]. Hepatic and renal function, however, were
not matched as a clear separation between controls and
ECMO patients who had preserved renal function and
ECMO patients who were dialysis dependent, desirable
in the context of this study, which sought to highlight
the influence of inflammation and illness, ECMO and
RRT.
Conclusions
In patients receiving meropenem on ECMO, standard
dosing (1 g 8-hourly) should achieve routinely targeted
plasma concentrations. However, an increase in dose
may be necessary when targeting higher plasma concen-
trations (>4x MIC and 100% T>MIC) and or in patients
with elevated creatinine clearance. Future PK studies
should validate these findings especially in ECMO pa-
tients with extremes of CrCL (<20 or >150 mL/min).
Therapeutic drug monitoring where possible is recom-
mended until robust dosing guidelines become available.
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 ECMO patients exhibit high PK variability.
 Standard meropenem dosing (1 g IV 8-hourly) during
ECMO achieved usual target trough concentrations
of >2 mg/L both in patients with preserved renal
function and in those on RRT.
 Standard meropenem dosing (1 g IV 8-hourly)
during ECMO may not achieve higher target MICs
(>8 mg/L), especially in patients with preserved
renal function.
 Clinicians need to consider the presence of ECMO,
renal function or RRT and microbiological
characteristics when choosing doses for patients
 Therapeutic drug monitoring (TDM) is
recommended where possible
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CHAPTER 8 
CONCLUDING DISCUSSION AND 
FUTURE RESEARCH 
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8.1. KEY FINDINGS 
- Significant PK alterations may occur during ECMO in adult patients even when 
modern technology is used as evidenced by suboptimal plasma antibiotic 
concentrations and increased sedative requirements in adult patients on ECMO. 
- Escalating sedative doses in ECMO patients are associated with decrements in 
plasma sedative drug concentrations and an increase in BIS. 
- An incremental research plan as utilised in this research constitutes a rational, 
holistic research approach to a complex problem. 
- Drug factors stability, lipophilicty and protein binding are the key determinants of 
drug loss in ECMO circuits. 
- When multiple drugs with similar degrees of protein binding are administered, circuit 
drug loss is determined by degree of lipophilicity and vice versa. 
- For the relatively lipophilic, protein bound drugs such as midazolam; the effects of 
ECMO on PK may be more significant than those induced by critical illness 
depending on the extent of organ failure present in the patient. 
- Drug properties lipophilicty and protein binding can be used to predict antimicrobial 
PK during ECMO. 
- For hydrophilic and less protein bound drugs such as meropenem, an increase in 
Vd appears to be offset by a decreased CL in the presence of ECMO resulting in 
usual target minimum inhibitory concentrations (≥ 2 mg/L) aimed at less resistant 
organisms.  
- Given that lipophilic and protein bound drugs are most likely to be affected by both 
the presence of ECMO circuit and critical illness itself, clinical population PK studies 
should prioritise these drugs to obtain vital PK data and inform dosing. 
- Future antibiotic and sedative dosing approaches in ECMO patients should 
consider drug factors, circuit–drug interactions, disease factors and available data 
from early clinical population PK studies until robust dosing guidelines become 
available. 
- Population PK studies and dosing simulations will remain a vital tool until TDM is 
readily available 
- ECMO is also likely to alter host pathophysiology significantly and the PD 
consequences of which are poorly understood and remain a subject for future 
research. 
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8.2 IMPLICATIONS OF THIS PROJECT ON CLINICAL PRACTICE 
This research originated at the patient bedside and the findings are imminently translatable 
as and when clinical population PK data becomes available for the study drugs. The 
clinical data will be further complimented by the mechanistic data and will facilitate the 
development of dosing guidelines for antibiotic and sedative drugs during ECMO.  The 
guideline development process and possible recommendations are outlined in the 
subsequent sections. Optimal dosing of the study drugs in ECMO patients has the 
potential to improve patient outcomes both in terms of survival and long term quality of life. 
Optimal sedation and development of sedation protocols can minimise sedative use and 
reduce short and long term morbidity. Optimal antibiotic dosing will not only improve 
outcomes in patients but may also reduce the burden of antimicrobial resistance and 
benefit society in general. The dosing recommendations will need further prospective 
validation in future clinical studies. Most importantly, clinicians will now know what they are 
dealing with when it comes to altered PK during ECMO in adult patients.  
 
8.3 CONCLUDING SUMMARY 
This research originated from a real world clinical problem. Given the complex interactions 
between drug, device and disease factors that may affect PK during ECMO, a 
comprehensive research plan outlined in the thesis was the only logical way to deconstruct 
the key determinants of altered PK. Based on this research, the ability to predict PK based 
on lipophilicity and protein binding characteristics of drugs can be a significant step 
forward. This will help identifying drugs that are most affected by ECMO and prioritise 
them for future population PK studies. Until robust dosing guidelines become available, 
clinicians may use the physicochemical profile of antibiotic and sedative drugs and 
available data on antibiotic drug dosing in critically ill as a guide when dosing patients on 
ECMO. 
 
8.4 FUTURE DIRECTIONS 
 
8.4.1 Completion of clinical PK study 
The multi-centre study ASAP ECMO is currently recruiting patients and recruitment is 
nearing completion for some study drugs such as ceftriaxone, vancomycin. The samples 
will be analysed for plasma drug concentrations sin batches and PK data upon analysis 
will be published prospectively. More ECMO centres have expressed interest in this study, 
which will further assist with patient recruitment. 
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8.4.1 Development of dosing guidelines 
Although necessary collaborations are in place to ensure robust dosing guidelines for 
antibiotic and sedative drug dosing in adults patients on ECMO are developed in a timely 
manner, population PK data for all drugs will only be available at the end of the clinical 
study. In the meantime clinicians will be guided by ongoing publication of PK data for 
individual drugs. A systems approach outlined by the NHMRC will serve as a useful 
template for guideline development. A schematic presentation of guideline development 
process is provided in Figure 9.  
The members of this research team are ECMO and PK experts and play key roles within 
International ECMO Network (www.internationalecmonetwork.org), Extracorporeal Life 
Support Organisation, Australia New Zealand Intensive Care Society, European Society of 
Intensive Care Medicine and European Society of Clinical Microbiology and Infectious 
Diseases. This will further facilitate guideline development and translation process.  
It is anticipated the recommendations will pertain to:  
Clinical problem 
Identified and 
defined
Engage ECMO,
PK experts
Stake holders
Exclude COI
Data analysis
Data interpretation
Publish data
Collaboration
Preclinical /clinical
translational
Research
Clinical problem
resolved?
Follow up 
Review evidence
Public consultation
External review
Clear actionable 
Recommendations
Industry consult
(if needed)
Dissemination
Publications
ELSO Red Book
Implementation
Developing evidence based 
guidelines for prescription of 
antibiotic sedative and analgesic 
drugs during ECMO
Fig 9. Guideline development process.
 
Figure 3. Guideline development process 
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8.4.1.1 Choice of drug:  
Physicochemical properties of drugs along with patient and microbiological factors are key 
factors when prescribing for patients on ECMO. For example, midazolam and fentanyl may 
not be ideal for ECMO patients as they are highly sequestered in the circuit.  
8.4.1.2 Dose, mode of administration (bolus vs. infusions) and dosing intervals: 
 Adjusting the method of administration can minimise the effect of PK variability and hence 
will be considered during our guideline development. For example, preliminary data8 
shows that in a patient supported with venovenous ECMO and RRT, meropenem 
administered as a continuous infusion resulted in  target concentrations (~8 mg/L). 
However, subsequent population study (Chapter 7) found that meropenem in standard 
doses should achieve usual target MIC. Thus population PK data, dosing simulations and 
Bayesian dosing approaches (including adaptive feedback control algorithms) will increase 
the likelihood of successful drug therapy.  
8.4.1.3 Dose adjustments for RRT during ECMO: 
No drug dosing guidelines during RRT and ECMO exist. As described in (Chapter 7) 
Standard doses of meropenem achieved acceptable plasma meropenem concentrations 
even in ECMO patients receiving RRT and dose adjustments during RRT are probably not 
required. These findings can be further substantiated when population Pk data becomes 
available fro all study antibiotics. 
8.4.1.4 Development of ECMO specific sedation protocols:  
Preliminary data9,11(Fig 2) highlights that the sedation protocols designed for general 
critically ill patients are not ideal for patients on ECMO due to significantly altered PK of 
sedative and analgesic drugs. The knowledge gained from future research will assist 
development of specific sedation protocols for patients on ECMO 
 
8.4.2 Refinements in ECMO circuitry 
ECMO circuits have evolved significantly; however they continue to sequester vital drugs.  
It is important to acknowledge that drug sequestration is not the predominant issue with 
circuits. Bleeding and thrombosis remain major circuit related complications and optimising 
anticoagulation in these patients can be a difficult balancing act. Technological 
advancements should be more directed at these aspects first. Exteriorisation of blood onto 
foreign surfaces comes at a physiologic cost and it may be nearly impossible to completely 
overcome this. However, research into engineering aspects of circuit design such as 
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choice of materials used, coating, flow dynamics etc are areas where there is potential to 
minimise drug sequestration in ECMO circuit.  
 
8.4.3 Drug development 
Altering drug physicochemistry just to minimise circuit sequestration is not without 
challenges. Even minor modifications to physicochemical properties of drugs can result in 
major alterations in safety and efficacy of that drug. For example, a less Lipophilic and 
protein –bound sedative drug may be ideal for ECMO patients based on the findings in this 
thesis. However, a hydrophilic drug may not penetrate the blood-brain barrier as effectively 
as a lipophilic drug and most available sedative agents are lipophilic and protein-bound. 
Thus, it appears that altering chemistry of currently available drugs in order to minimise 
circuit sequestration is probably not practical. However, as newer drugs become available, 
the findings of this research can be applied to those drugs to determine their suitability for 
use during ECMO.  
 
8.4.4 Investigating PD during ECMO 
This research focuses predominantly on the PK of antibiotic and sedative drugs. However, 
these Pk alterations do not fully explain the clinical findings. For example, ECMO patients 
often need higher sedative doses compared with critically ill patients not on ECMO despite 
the degree of other organ failures being similar. While circuit sequestration may partly 
explain this, it is possible that ECMO may also alter the PD responses to sedative drugs. 
The probable mechanisms may include alterations to the blood-brain barrier, hepatic and 
renal perfusion and hepatic metabolism.  The effects of a non–pulsatile circulation that 
may result from venoarterial ECMO on pathophysiology and PD responses remain largely 
unclear. A deeper understanding altered PD may help further optimise drug dosing during 
ECMO. Building such PD models is challenging and a comprehensive research plan 
similar to the one used in this thesis may have to be utilised to study the interactions 
between the drug, devise and the disease that result in altered PD.  
 
8.4.5 More detailed understanding of pathophysiology of ECMO 
ECMO can independently alter pathophysiology in a critically ill Advancements in circuit 
technology may have minimised these alterations to an extent, but it is highly likely that the 
bio-synthetic interface created during ECMO may significantly influence inflammation, 
regional blood flows, the microcirculation and hence end organ function. Despite 
significant advances in our understanding of critical illness and related PK alterations, 
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there is a paucity of knowledge when it comes to pathophysiology of ECMO. Preclinical 
and clinical research aimed at understanding the altered pathophysiology has significant 
implications for the field of extracorporeal life support and is necessary to refine the ECMO 
technology and its clinical application further. Such research will allow any significant 
ECMO induced physiologic covariates to be included in PK/PD models and will further 
compliment the findings of this research. 
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APPENDIX 6: STATISTICAL AND PK MODELING APPROACH 
Linear and non-linear mixed effects modeling, non-compartmental and compartmental PK 
model building techniques were effectively used during data analysis in this research. In 
addition, regression analysis was used to estimate the relationships among a dependent 
variable and one or more independent variables. The statistical software used for these 
analyses have been described in the relevant chapters. These published, validated 
techniques have been extensively used in previous research. However a brief overview of 
these techniques is provided below.  
 
6.1. Mixed effects modelling 
PK studies invariably involve repeated measurements on each subject over time or space 
and mixed model analysis provides a general, flexible approach in these situations, 
because it allows a wide variety of correlation patterns (or variance-covariance structures) 
to be explicitly modeled. The term mixed model refers to the use of both fixed and random 
effects in the same analysis. Fixed effects have levels that are of primary interest and 
would be used again if the experiment were repeated. Random effects have levels that are 
not of primary interest, but rather are thought of as a random selection from a much larger 
set of levels. Subject effects are almost always random effects, while treatment levels are 
almost always fixed effects. Mixed effects models flexibly give correct estimates of 
treatment and other fixed effects in the presence of the correlated errors that arise from a 
data hierarchy70.  
 
6.2. Pharmacokinetic modeling 
 
6.2.1. Non-compartmental models 
PK data can be analysed by either model fitting using nonlinear regression analysis or 
non-compartmental analysis techniques (NCA). The method applied usually depends on 
what is required from the analysis. If the primary requirement is to determine the degree of 
exposure following administration of a drug (such as AUC), and other PK parameters, 
such as CL, elimination half-life, T (max), C (max), etc., then NCA is the preferred method 
because it requires fewer assumptions than model-based approaches. In this research, 
the NCA methods used applied the trapezoidal rule for measurements of the area under 
the plasma concentration-time curve72.  
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6.2.2. Compartmental models  
A compartmental analysis is based on development of PK models. A PK model is a 
mathematical representation of the passage and fate of the drug through the body and 
contains variables (e.g. dose, times of doses and times at which blood samples are taken) 
and constants called parameters (e.g. clearance and volume of distribution) that quantify 
the drug disposition. This approach assumes that there are some underlying physiological 
processes that underpin the PK of the drug73. In this approach the body is divided into a 
series of linked homogenous compartments that represent the disposition of the drug.  For 
example, the models built during this research factored the physiologic perturbations that 
may arise in the presence of critical illness and ECMO. The mechanistic PK data from 
simulated ECMO circuit experiments and ovine models further assisted the choice of 
covariates to be included in those models.  Compartmental approaches reliable predictive 
properties and are generally independent of the size of the drug dose and dosing interval 
and allow extrapolation to a similar patient population that may receive the drug in the 
future. Bootstrapping refers to a method to obtain a measure of reliability of predictions 
made in part from fits of individual drug level data with a PK model, and to help clarify 
parameter identifiability for such models71,74. This is important because this translational 
research aims to develop evidence based guidelines based on the PK data generated 
through the clinical population PK study (ASAP ECMO). 
 
6.3. Population PK analysis 
Population PK is the study of PK at the population level, in which data from all individuals 
in a population are evaluated simultaneously using a nonlinear mixed-effects model. 
“Nonlinear” refers to the fact that the dependent variable (e.g., drug concentration) is 
nonlinearly related to the model parameters and independent variable(s). “Mixed-effects” 
refers to the parameterization: parameters that do not vary across individuals are referred 
to as “fixed effects,” parameters that vary across individuals are called “random effects.” 
The five key aspects to developing a population PK model are, (i) data, (ii) structural 
model, (iii) statistical model, (iv) covariate models, and (v) modeling software. Structural 
models describe the typical concentration time course within the population. Statistical 
models account for “unexplainable” (random) variability in concentration within the 
population (e.g., between-subject, between-occasion, residual, etc.). Covariate models 
explain variability predicted by subject characteristics (covariates). Nonlinear mixed effects 
modeling software brings data and models together, implementing an estimation method 
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for finding parameters for the structural, statistical, and covariate models that describe the 
data71. 
  
6.4. Dosing simulations 
The practical and financial difficulties of performing PK studies in critically ill patients mean 
that analyses to maximize data such as Monte Carlo simulation (MCS) are highly valuable. 
MCS uses computer software to perform virtual clinical trials. The building blocks for MCS 
are: firstly, a robust population PK model from the patient population of interest; secondly, 
descriptors of the effect of covariates that influence the PK parameters; thirdly, description 
of the susceptibility of bacteria to the antibiotic and finally a PK/PD target associated with 
antibiotic efficacy. Such analyses can then inform dosing requirements, which can be used 
to have a high likelihood of achieving PK/PD targets for organisms with a range of MICs75. 
For example, MCS was effectively used in Chapter 7 where in plasma meropenem 
concentrations were simulated at various CrCL and meropenem doses. Dosing 
simulations will be invaluable tools for development of drug dosing guidelines through this 
research. 
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APPENDIX 8: ERRATA 
 
Chapter 4.1 
i. Page 46: The phrase ‘multi-centre’ in the article abstract to be read as 
‘multicentre’  
ii. Page 52, Figure 6. The label insert ‘oxygentor’ to be read as ‘oxygenator’. 
 
 
 
 
 
 
 
